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Abstract 
A third of epilepsy patients are resistant to currently available medication, 
highlighting a need to identify new antiepileptic drugs. To identify new drugs, 
researchers often explore new chemical structures with a common mechanism of 
action, but surprisingly the direct cellular target for many drugs remains unclear. 
One such drug is valproic acid (VPA), commonly used in the treatment of both 
epilepsy and bipolar disorder (BD). Previous research using the single celled 
amoeba Dictyostelium discoideum identified phosphoinositide recycling as a 
potential therapeutic mechanism for VPA and this has been validated in animal 
seizure models, however, the molecular target for this mechanism is unclear. To 
identify this target, research in this thesis initially focuses on assessing the role of 
several key enzymes involved in phosphoinositide signalling as potential VPA 
targets. Loss of these proteins did not confer resistance to VPA in this model, 
suggesting that VPA may function through targeting proteins in the 
phosphatidylinositol (PI) salvage pathway. In this pathway three key enzymes, 
cytidine-diphosphate-diacylglycerol synthase (CDS), cytidine-diphosphate- 
diacylglycerol-inositol-3-phosphatidyltransferase (CDIPT) and diacylglycerol kinase 
(DGK) were investigated, with phylogenetic analysis establishing evolutionary 
conservation. Attempts to ablate the single D. discoideum Cds (CdsA) and Cdipt 
encoding genes were unsuccessful, suggesting a vital role for these proteins. In 
contrast, overexpressing both proteins showed that cells with elevated expression 
of CDIPT, but not CDSA, were resistant to therapeutic VPA concentrations. 
Furthermore, deletion of the single D. discoideum DGK (DGKA) gene was successful, 
with the mutant resistant to VPA during both acute and chronic treatment, that 
was restored on reintroduction of DGKA. To investigate whether loss of DGKA is 
related to epilepsy and BD, a range of related compounds were investigated for an 
effect on cell development. These experiments suggest that in D. discoideum, DGKA 
may provide a common target for both epilepsy and BD treatments, supporting 
data provided from preclinical and clinical studies in both disorders. Together this 
  
work suggests that DGK may provide a new therapeutic target for the treatment of 
both epilepsy and BD.   
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1. Introduction 
1.1 VPA 
1.1.1 VPA as a Therapeutic Treatment 
Valproic acid (2-propylpentanoic acid, VPA) is an 8-carbon molecule with a 
carboxylic acid side chain (Figure 1.1). The role of VPA as an anti-epileptic was 
discovered accidentally in 1963, where the drug protected rodents against 
pentylenetetrazol (PTZ)- induced convulsions (Meunier, et al., 1963). VPA was then 
studied in animal models as a therapeutic treatment for epilepsy (a disease 
characterized by recurrent seizures) and was first licensed as an anti-epileptic drug 
(AED) in France, 1967 (Carraz, et al., 1964; Mutani, et al., 1968; Tulloch, et al., 
1982). Following the license of VPA as an AED, a small patient study (22 patients) 
conducted in 1980 found a 75 % improvement when treated with VPA for 1 year, 
where the drug protected patients experiencing a range of seizure types, from 
states of unconsciousness (absences) to muscles stiffening and jerking (tonic- 
clonic) (Bruni, et al., 1980). VPA today is marketed under the brand names 
Depakote, Depakene, Divalproex and Epilim. 
 
 
 
Figure 1.1. Chemical structure of valproic acid. Valproic acid (VPA) is a branched chain 
fatty acid with a 5-carbon backbone and a 3-carbon side chain branched at the second 
carbon.  
 
In addition to treating epileptic seizures, VPA is also a therapeutic option for bipolar 
disorder (BD) (characterized by manic and depressive states) (Pope, et al., 1991) 
Chapter 1  Introduction 
 20 
and migraine (characterized by a severe headache) (Hering and Kuritzky, 1992; 
Yurekli, et al., 2008) and is currently being studied as a treatment option for cancer 
(Göttlicher, et al., 2001; Tang, et al., 2004; Witt, et al., 2013). VPA could be used to 
treat a range of cancer types, including leukaemia (Göttlicher, et al., 2001; Tang, et 
al., 2004) and prostate cancer (Witt, et al., 2013), due to its role as a histone 
deacetylase inhibitor (Phiel, et al., 2001). VPA has been listed by the World Health 
Organisation as an essential medicine, which is defined as a drug which improves 
health for the majority of patients within a population (World Health Organisation, 
2017).  
 
1.1.1.1 Epilepsy 
Epilepsy is a neurological disease characterized by recurrent seizures. To date, 
approximately 50 million people worldwide have epilepsy, with around 130,000 
children in Europe diagnosed with the disease each year (Forsgren, et al., 2005; 
World Health Organisation, 2018). Epilepsy, therefore, accounts as a worldwide 
disease burden of approximately 0.7 % (Wilmshurst, et al., 2014). As 10% of the 
general population will encounter a one-off seizure before the age of 85, epilepsy is 
diagnosed after a patient has experienced 2 or more unprovoked seizures (Wilden 
and Cohen-Gadol, 2012). Epilepsy affects both children and adults, with the risk of 
developing the disease lessening with increasing age (Lee, et al., 2014). For 
example, the incidence of epilepsy diagnosis before the age of 1 is 90-212 per 
100,000 people, which drops considerably for those patients identified in 
adolescence (20-70 per 100,000 people) (Wilmshurst, et al., 2014). However, the 
risk of developing epilepsy increases in the elderly and is higher in children with 
intellectual (learning) difficulties (Illingworth, Watson and Ring, 2014; Wilmshurst, 
et al., 2014). 
 
There are 3 classifications of epilepsy- symptomatic or provoked, cryptogenic and 
idiopathic (Shorvon, 2011). Symptomatic or provoked epilepsy occurs as a result of 
neurological damage from disease or trauma (e.g. meningitis, stroke or head 
trauma), a genetic cause or birth defects (such as cerebral palsy, autism, significant 
developmental delay and cognitive impairment). Cryptogenic epilepsy occurs when 
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symptoms, such as learning difficulties, suggests brain damage has occurred. 
Idiopathic epilepsy is when no known cause is found. Independent of the disease 
classification, all patients will experience recurrent seizures. Epileptic seizures arise 
through calcium- dependent pathways where inositol-1,4,5-trisphosphate (IP3) 
initiates calcium release (Alswied and Parekh, 2015). One theory suggests seizures 
are maintained through attenuating N-methyl-D-aspartate (NMDA) receptor 
activation (Slater, Stelzer and Galvan, 1985; Holmes, et al., 1990). At the onset of a 
seizure, there is a rapid increase in diacylglycerol (DAG) levels, followed by the 
accumulation of almost 2-fold free fatty acids (Bazán, 1970; Bazán and Rakowski, 
1970; Bazán, Morelli de Liberti and Rodriguez de Turco, 1982; Rodriguez de Turco, 
Morelli de Liberti and Bazán, 1983). This is accompanied with a decrease in 
phosphatidylinositol (PI) levels with free fatty acids being converted into 
triglycerides (Yoshida, et al., 1987). During seizures, there is no change in 
phosphatidylethanolamine (PE) (Marku, et al., 1987), however phosphatidylcholine 
(PC) levels decrease 6 minutes after seizure induction (Corazzi, et al., 1986). 
Following 6 minutes of seizure induction, the levels of the water-soluble precursors 
cytidine-diphosphate (CDP)- ethanolamine, phosphoethanolamine (Marku, et al., 
1987), CDP-choline and phosphocholine double (Corazzi, et al., 1986). It is the 
excitation of NMDA receptors which causes the characteristic neuronal damage of 
repeated seizures (Zeise, Kasparow and Zieglgänsberger, 1991).  
 
There are two main categories of seizures, focal and generalized (Berg, et al., 2010). 
Focal seizures occur in one hemisphere of the brain within a single or few neuronal 
networks and have a repeated site of onset within subcortical structures (e.g. 
thalamus, brainstem and cerebellum). In comparison, generalised seizures spread 
rapidly and bilaterally throughout the brain, affecting cortical (e.g. frontal or 
temporal lobes) and subcortical structures and originate in different locations 
depending on seizure type (Berg, et al., 2010). Generalized seizures range from 
absences to tonic- clonic. Seizures can be triggered by a number of factors, 
including sleep deprivation, stress, time of day and menstrual status (Illingworth, 
Watson and Ring, 2014).  
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All epilepsy treatments aim at reducing seizures. These include the medium chain 
triglyceride diet (MCT, also known as the ketogenic diet), a high fat- low 
carbohydrate diet administered to children, which causes an accumulation of 
decanoic acid (DA) and octanoic acid (OA) (Haidukewych, Forsythe and Sills, 1982; 
Augustin, et al., 2018). This diet was originally thought to work through ketone 
production, however, recent studies suggest that neuroprotection arises through a 
direct role of fatty acids (Chang, et al., 2016). Surgery is offered to patients with 
medical refractory epilepsy as it can reduce or completely prevent seizure 
recurrence (Kelly and Chung, 2011). Surgery is only offered when the seizure focus 
is known at a confident level and when removal of the area will not result in 
neurological problems. The primary treatment for epilepsy is AED, including VPA, 
gabapentin, lacosamide, lamotrigine and vigabatrin (Becerra, et al., 2011; Brodie 
and Sills, 2011; Ramgopal, et al., 2014). AEDs are administrated either as a single 
drug (monotherapy), or as is the case for approximately 40 % of patients, as a 
combination of two or more treatments (polytherapy) (Tan, et al., 2012). 
Polytherapy is given when monotherapy fails at preventing seizures. However, 
despite treatment, if a seizure has a duration of over 5 minutes, rescue medications 
such as benzodiazepines, need to be administered (Arzimanoglou, et al., 2014). 
Even when a patient becomes seizure free there is a risk of relapse e.g. when taking 
medications, during periods of stress, tiredness, changes in daily routines and 
medication compliance. This is because AEDs need to be taken long-term and can 
have undesirable side effects (Ferrari, de Sousa and Castro, 2013). After a patient 
has been seizure free for 2 years, medication is gradually withdrawn, where the risk 
of a breakout seizure is between 20-40 % in children (Bouma, et al., 1987; Olmez, et 
al., 2008). An uncommon consequence of epilepsy, affecting 9 % of patients, is 
sudden unexpected death in epilepsy, which is confirmed after a patient has 
undergone a 30 minute seizure and has died within an hour (Sillanpää and Shinnar, 
2010). The total cost of epilepsy in Europe in 2010 was estimated at € 13.8 million 
(Gustavsson, et al., 2011).  
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1.1.1.2 Bipolar Disorder 
BD is a chronic disabling condition characterised by recurrent episodes of 
depression, mania and hypomania. Mania and hypomania are similar in that they 
both involve abnormally elevated irritability or mood. Mania and hypomania differ 
by severe psychotic symptoms or functional impairment with a duration of over 7 
days in mania, compared with hypomania where function is either increased or 
decreased and lasts for a minimum of 4 days (Morriss, 2015). Worldwide, 2.4 % of 
the population have BD (Merikangas, et al., 2011), of which there are two types- 
BD-I and -II, which differ in the degree of mania symptoms. BD-I involves excessive 
mania and depression, whereas BD-II is less severe with hypomania and depression 
(Pini, et al., 2005). The disease prevalence for BD-I in adults is approximately 1 % 
and for BD-II 0.4 % (Morriss, 2015). BD is difficult to diagnose as the symptoms of 
combined disorders such as attention deficit hyperactivity disorder, substance 
misuse, personality disorders and anxiety prevent initial identification of the 
disorder. BD commonly develops during adolescence (15-19 year olds) and early 
adulthood and very rarely in children under the age of 12. Diagnosis of BD is 
confirmed once a patient has undergone at least one mixed or manic episode (Pini, 
et al., 2005). The hereditary risk of offspring developing BD is approximately 85 % 
(McGuffin, et al., 2003). Studies have linked BD to a range of pathways including 
hormonal regulation and the signalling of calcium, phospholipase C (PLC) and 
glutamate (Nurnberger, et al., 2014). 
 
BD is treated with drugs which aim to rapidly stabilize and maintain a constant state 
within the patient, i.e. especially aimed at treating mania (e.g. lithium and VPA) or 
depression (Geddes and Miklowitz, 2013). Problems with treatment occur as the 
aim of each medication is to reduce either the manic or depressive state and can 
result in a rise in the second state. In addition, a third of BD patients are resistant to 
currently available medication (Perlis, et al., 2006). VPA was first investigated as a 
therapeutic treatment option for acute mania in a small pilot study of 5 patients, 
which had a success rate of 80 % (Emrich, et al., 1980). This pilot study was 
followed with 7 further patients who were unresponsive to lithium treatment alone 
(Emrich, et al., 1980). All 7 patients were administered a combined treatment of 
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VPA and low-dose lithium and showed improvement with no relapse after 1.5-3 
years of observation (Emrich, et al., 1980). VPA was then further investigated in 3 
studies for use as an alternative treatment for BD in the 1990s (Calabrese and 
Delucchi, 1990; Pope, et al., 1991; Freeman, et al., 1992). The results from all of 
these studies confirmed VPA treatment improved manic symptoms when treated 
with VPA alone or as a combination with lithium. In 1986, the VPA amide derivative 
valpromide (VPD, Depamide), was also investigated as a treatment option for acute 
psychotic states for BD and schizophrenic patients (Altamura, et al., 1986). In this 
study, it was found that VPD reduced patient agitation.  
 
BD affects patients’ health status and quality of life. The disease is associated with 
irresponsible behaviour, sleep loss and extreme talking due to excess energy. Half 
of BD patients will attempt suicide at least once in their lifetime, with 15-19 % of 
patients going through with it (Nabuco de Abreu, et al., 2009). In addition, the 
disease is associated with high medical costs, both directly and indirectly. In the 
United States, the estimated direct cost of BD in 2009 was $ 30.7 billion and the 
indirect cost was $ 120.3 billion (Dilsaver, 2010).  
 
1.1.1.3 Migraine 
Migraine is characterised by a severe headache positioned in a unilateral location at 
the front of the head, with pain occurring in a pulsating manor for 4-72 hours 
(Headache Classification Committee of the International Headache Society, 2013). 
Migraine is associated with photophobia, phonophobia, vomiting, nausea and aura. 
In 2000, the World Health Organisation estimated migraine to reduce life 
expectancy by 1.4 % years in both men and women of all ages. For women aged 15-
44 years, life expectancy was estimated to be reduced by 2.1 % years and was 
ranked 14th in the leading cause of disease for women in this age range (World 
Health Organization, 2001). Women (18.2 %) are more susceptible to developing 
migraine compared with men (6.5 %) (Lipton, et al., 2001). 
 
The primary treatment of migraine is to write a headache diary to identify initiation 
triggers (Pryse-Phillips, et al., 1997). If migraines continue, prophylactic (drug) 
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treatment is given. Prophylactic treatment is thought successful if migraine attacks 
are reduced by 50 %, and include - blockers (Propranolol hydrochloride), calcium 
channel blockers (Verapamil), serotonin receptor agonists (Pizotifen) and AEDs/ 
tricyclic antidepressants (VPA) (BNF, 2018). Migraines arise from an increase in 
calcium signalling, where familial hemiplegic migraine is caused by missense 
mutations in sodium/ potassium pump (Maurizio De Fusco, et al., 2003), calcium 
(Ophoff, et al., 1996) or sodium voltage gated channels (Dichgans, et al., 2005). 
 
VPA was shown to be an effective treatment for migraine in 1992, where the drug 
either prevented or reduced the frequency, duration and severity of migraines in 
86.2 % of patients (Hering and Kuritzky, 1992). The estimated total cost of migraine 
in Europe in 2010 was € 43.5 million (Gustavsson, et al., 2011). 
 
1.1.2 Problems Associated with VPA Treatment  
Epilepsy, BD and migraine are all associated with calcium signalling and can be 
treated with VPA. Interestingly, both VPA and lithium treatment cause a rise in 
cytidine diphosphate- diacylglycerol (CDP-DAG) (Watson, Shipman and Godfrey, 
1990; Stubbs Jr., et al., 1992; Stubbs Jr. and Agranoff, 1993; Ju and Greenberg, 
2003), DAG (Drummond and Raeburn, 1984; Brami, Leli and Hauser, 1993) and the 
phosphorylated extracellular signal-regulated kinase (pERK) (Ludtmann, Boeckeler 
and Williams, 2011) levels. pERK is activated by DAG activated protein kinase C 
(PKC) and is responsible for protein phosphorylation. VPA and lithium alter PI levels 
(Allison, et al., 1976) and inhibit PKC (Wang and Friedman, 1989; Bitran, et al., 
1990; Chen, et al., 1994). As with all medications, VPA has side effects. The most 
common of these include heartburn, nausea and vomiting. Under 10 % of patients 
taking VPA can develop rashes, alopecia, drowsiness, ataxia, irritability or dose-
related tremors (Davis, Peters and McTavish, 1994; Zarate, et al., 1999). The most 
severe and rare side effects of VPA are hepatoxicity (liver damage) and 
teratogenicity (defects of a developing embryo) (Hauck and Nau, 1989), which are 
believed to be caused by - oxidation (Coudé, et al., 1983; Kesterson, Granneman 
and Machinist, 1984; Granneman, et al., 1984) and histone deacetylase inhibition 
(Phiel, et al., 2001) respectively. Teratogenicity is also a side effect for the VPA 
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amide analogue, VPD, which has been used as an epilepsy and BD treatment (Favel, 
et al., 1973; Pacifici, et al., 1985).  
 
Hepatoxicity from VPA results in increased activation of reactive oxygen species, 
which causes tissue and organ damage (Tong, et al., 2005). Teratogenicity caused 
by VPA arises through the activation of the peroxisome proliferator- activated 
receptor  (Lampen, et al., 1999; Werling, et al., 2001). Teratogenic compounds 
contain a free carboxyl group, an - hydrogen atom (present on the carbon atom 
also containing the carboxyl group) and has branching on carbon 2 (Figure 1.2) 
(Nau, Hauck and Ehlers, 1991).  
 
 
 
Figure 1.2. Chemical structure of valproic acid identifying the regions responsible for the 
teratogenic effects. The chemical structure of valproic acid. Carbon atoms 1 and 2 are 
labelled in blue with the location of the - hydrogen shown in green. Teratogenic 
compounds contain an - hydrogen atom, branching on carbon 2 and a free carboxyl 
group.   
 
1.1.3 Studies Investigating the Mechanism of Action of VPA 
Despite the side effects, VPA is one of the most highly prescribed AEDs (37.8 %) 
(Haroon, et al., 2012). For this reason, many studies have been conducted to 
determine the mechanism of action of VPA. These studies have shown VPA to work 
through enhancing brain -amino butyrate levels (Godin, et al., 1969); NMDA 
excitation (Slater, Stelzer and Galvan, 1985; Holmes, et al., 1990; Zeise, Kasparow 
and Zieglgänsberger, 1991); inhibiting voltage gated potassium, sodium and calcium 
channels (VanDongen, VanErp and Voskuyl, 1986; Kelly, Gross and Macdonald, 
1990); histone deacetylase (Göttlicher, et al., 2001); and reducing inositol 
Chapter 1  Introduction 
 27 
phosphate and phosphoinositide levels (Williams, et al., 2002; Eickholt, et al., 2005; 
Chang, et al., 2012; Chang, Walker and Williams, 2014). VPA reduces 
phosphoinositide levels in both a time and dose-dependent manner, independent 
of PI-3-kinase (PI3K) activity, inositol recycling, de novo inositol production and de 
novo inositol biosynthesis (Chang, et al., 2012; Frej, et al., 2016). This leaves the PI 
salvage pathway as potentially containing the molecular target of VPA.  
1.2 Phosphatidylinositol Salvage Pathway 
1.2.1 Phosphoinositides 
Phosphoinositides are minor lipid molecules belonging to the acidic phospholipid 
family of proteins, with cellular membranes comprising of 2-12 % PI (Flint, et al., 
1986; Falkenburger, et al., 2010). Phosphoinositides consists of 2 fatty acid tails 
attached to a glycerol backbone through ester linkages. To the glycerol backbone, 
an inositol head in the myo- conformation is attached via a phosphate group which 
extends into the cytoplasm (Figure 1.3). The inositol used in the synthesis of 
phosphoinositides comes from either the diet, the de novo pathway or from the PI 
salvage pathway (Saul, et al., 2004). Phosphorylation events occur by cytoplasmic 
lipid kinases which utilize the free oxygen atoms on the myo-inositol group 
(Falkenburger, et al., 2010).  
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Figure 1.3. Schematic of the generalized chemical structure of phosphoinositides. 
Schematic of the generalized chemical structure of phosphoinositides showing the fatty 
acid groups (black) with the “R” groups indicating the locations of the fatty acid chains, the 
glycerol group (green), the phosphate groups (blue) and the inositol ring (pink).  
 
Both the de novo PI pathway and the PI salvage pathway cross over in the  
utilization of phosphatidic acid (PA), which is synthesized within the plasma 
membrane (Nuwayhid, et al., 2006). The de novo pathway utilizes glucose to 
produce PA via the production of the intermediates dihydroxyacetone phosphate 
and glycerol phosphate (Paulus and Kennedy, 1960; Katz and Wood, 1960; Prottey 
and Hawthorne, 1967). The PI salvage pathway regulates the long-term supply of 
the signalling molecule PI-4,5-bisphosphate (PIP2) through its synthesis and 
hydrolysis (Paulus and Kennedy, 1960; Prottey and Hawthorne, 1967; Whatmore, et 
al., 1999). 
 
1.2.2 Phosphatidylinositol Salvage Pathway 
The PI salvage pathway involves the hydrolysis of PIP2 into IP3 and DAG by PLC 
within the plasma membrane (Figure 1.4). This creates a branch point in the salvage 
pathway, whereby IP3 is dephosphorylated into inositol-1,4-bisphosphate (IP2), 
inositol-4-phosphate (IP) and then myo-inositol (I) by the enzymes 5-phosphatase 
(type 1) (5’P), inositol polyphosphatase (IPPase) and inositol monophosphatase 
(IMPase), respectively. Meanwhile, DAG is phosphorylated into PA by DAG kinase 
(DGK). PA then moves across the cytosol from the plasma membrane to the 
endoplasmic reticulum where it is involved in a condensation reaction with cytidine 
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triphosphate (CTP) to form CDP-DAG, catalysed by the enzyme CDP-DAG synthase 
(CDS). CDP-DAG and myo-inositol are converted into PI by CDP-DAG-inositol 3 
phosphatidyltransferase (CDIPT). PI is then transferred to the plasma membrane by 
a PI-transfer protein (PIPT) where it is phosphorylated into PI-4-phosphate (PIP) and 
PIP2 by PI kinase and PIP kinase respectively, thereby restarting the cycle (Paulus 
and Kennedy, 1960; Prottey and Hawthorne, 1967; Whatmore, et al., 1999). A rate-
limiting step in this pathway is the conversion of PA into CDP-DAG as the PA pool is 
larger than that of the intermediate CDP-DAG (Raetz and Kennedy, 1973).  
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Figure 1.4. Schematic of the phosphatidylinositol salvage pathway and 
interlinking pathways. Schematic of the phosphatidylinositol (PI) salvage pathway 
(black arrows), inositol recycling (grey arrows) and interlinking pathways. The 
locations of each reaction step within the plasma membrane (green) and 
endoplasmic reticulum (yellow) with the names of the reaction product (black) 
and enzymes (yellow) given. The chemical structures of each component of the 
pathway are shown above or below the product name with the “R” groups 
indicating the fatty acid chains. Phosphatidylinositol-4,5-bisphosphate (PIP2) is 
dephosphorylated by phospholipase C (PLC) into diacylglycerol (DAG) and inositol-
1,4,5-triphosphate (IP3). IP3 is then dephosphorylated into inositol-1,4-
bisphosphate (IP2) by 5-phosphatase (type 1) (5’P), inositol-4-phosphate by 
inositol polyphosphatase (IPPase) and myo-inositol by inositol monophosphatase 
(IMPase). Meanwhile, DAG is phosphorylated into phosphatidic acid (PA) by DAG 
kinase (DGK). PA is then converted into cytidine diphosphate-DAG (CDP-DAG) by 
CDP-DAG synthase in a rate-limiting step before being converted into phosphatidylinositol (PI) by CDP-diacylglycerol-inositol 3 phosphatidyltransferase 
(CDIPT). PI is then phosphorylated into phosphatidylinositol-4-phosphate (PIP) by phosphatidylinositol kinase (PIK) and into PIP2 by phosphatidylinositol-4-
phosphate kinase (PIPK). Interlinking with the salvage pathway is a redox reaction between the phosphorylation of PIP2 into PIP3 by PI-3-kinase (PI3K) and 
the dephosphorylation of PIP3 into PIP2 by phosphatase and tensin homolog (PTEN). Phosphatidate phosphatase LPIN2 (LPIN2) dephosphorylates PA into 
DAG, which is a substrate for triacylglycerol (TAG) synthesis and the Kennedy pathway. CDP-DAG is utilized during the PI salvage pathway and the CDP-DAG 
pathway. 
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1.3 Proteins of Interest 
1.3.1 Interacting Signalling Pathways 
A number of pathways interact with the PI salvage pathway, including PI3K 
signalling, the Kennedy pathway and the CDP-DAG pathway. From these pathways, 
PKC activity is regulated through components of the PI salvage pathway (DAG) and 
CDP-DAG pathway (cardiolipin). Of the PI salvage pathway and interacting 
pathways, there are 7 key enzymes involved in regulating phosphoinositide levels. 
These are PI3K, phosphatase and tensin homolog (PTEN), PLC, phosphatidate 
phosphatase LPIN2 (LPIN2), CDS, CDIPT and DGK. All of these proteins have been 
associated with epilepsy and AED research. Seizure generation and development 
has been linked to both the PI3K/PI-3,4,5-trisphosphate(PIP3)/Akt (Akt is also 
known as serine -threonine protein kinase and the protein kinase B) (Backman, et 
al., 2001; Shinoda, et al., 2004) and mammalian target of rapamycin (mTOR) 
pathways (Takei, et al., 2004; Ehninger, et al., 2008; Zeng, et al., 2008; van Vliet, et 
al., 2012), which are regulated through PI3K/ PTEN and LPIN2 signalling respectively 
(Jaworski, et al., 2005; Kumar, et al., 2005; Meikle, et al., 2008).  
 
PI salvage pathway proteins have also been linked with epilepsy, BD and VPA 
treatment of these two disorders. Mutations within PLC (Kurian, et al., 2010) and a 
number of DGK isoforms (DGK-,- and -) have been linked with epilepsy 
(Rodriguez de Turco, et al., 2001; Leach, et al., 2007; Tokuoka, Saiardi and Nurrish, 
2008; Ishisaka, et al., 2013), with DGK- and - also being associated with BD   
(Baum, et al., 2008;  Squassina, et al., 2009; Kakefuda, et al., 2010). Additionally, 
during VPA treatment, the levels of CDP-DAG and phosphatidylglycerol (PG) are 
significantly increased, suggesting a role of the enzyme CDS in the mechanism of 
action of the drug (Ju and Greenberg, 2003). These proteins are important due to 
the range of signalling pathways the reaction products regulate.  
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1.3.1.1 PI3K Signalling  
Levels of the signalling molecule PIP2 can be maintained through the PI salvage 
pathway via the phosphorylation of PIP2 and by the dephosphorylation of PIP3. PIP2 
is phosphorylated into PIP3 by PI3K to activate a number of pathways including actin 
reorganisation (Arcaro and Wymann, 1993), chemotaxis (Wennstroem, et al., 
1994), glucose uptake (Hara, et al., 1994), mitosis and cell growth and survival 
through Akt (Fantl, et al., 1992; Burgering and Coffer, 1995; Franke, et al., 1995). 
PIP3 signalling is reduced by dephosphorylation into PIP2 by PTEN.  
 
1.3.1.2 DAG Signalling 
DAG regulates a number of signalling pathways including PKC (van Baal, et al., 
2005), synaptic plasticity (Lee, Kim and Tanaka-Yamamoto, 2016) and the synthesis 
of triglycerides, PC and PE (Kennedy and Weiss, 1956; Gibellini and Smith, 2010). PC 
and PE are synthesised through the Kennedy pathway (Kennedy and Weiss, 1956; 
Gibellini and Smith, 2010). The Kennedy pathway begins as a branch point of the PI 
salvage pathway, bypassing the formation of PA from DAG catalysed by DGK. In this 
pathway, PA is dephosphorylated into DAG by the enzyme LPIN2. DAG is then 
converted directly into PC by the enzyme choline phosphotransferase or indirectly 
into PE via ethanolamine phosphotransferase and then into PC. Phospholipase D 
(PLD) then catalyses the formation of PA from PC (Kennedy and Weiss, 1956; 
Henneberry and McMaster, 1999). The Kennedy pathway is essential for neuronal 
function and mammalian development (Ahmed, et al., 2017).  
 
1.3.1.3 PA Signalling  
PA is an important signalling molecule involved in cell proliferation (Banfić, et al., 
1993; Cerbón, et al., 2005), lipid metabolism (Milne, et al., 2008) and calcium 
signalling (Carpio and Dziak, 1998). In addition, PA is a precursor of DAG via PLD and 
therefore a regulator of PKC. The involvement of PA in cell proliferation is via the 
platelet derived growth factor and epidermal growth factor (Fukami and Takenawa, 
1992; Kaszkin, Richards and Kinzel, 1992). A rise in PA is correlated with 
accumulation of calcium which activates PLC and PLD (Kawase and Suzuki, 1990; 
Bourgoin, Harbour and Poubelle, 1996). PA accumulation has also been associated 
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with high levels of glucose (Farese, et al., 1986) and insulin secretion (Ma, Park and 
Han, 2010) via PLD.  
 
1.3.1.4 CDP-DAG Signalling 
CDP-DAG is an intermediate molecule used to synthesise PI within the PI salvage 
pathway and PG and phosphatidylserine (PS) within the CDP-DAG pathway (Paulus 
and Kennedy, 1960; Kiyasu, et al., 1963; Kanfer and Kenendy, 1964). PG is used to 
synthesise cardiolipin (Lecocq and Ballou, 1964), which has a role in mitochondria 
morphology (Xu, et al., 2006), thereby effecting the electron transport chain (Fry 
and Green, 1981) and the respiratory burst (Paradies, et al., 2004); and calcium 
(Kamer, Grabarek and Mootha, 2017) and PKC (Nobori, et al., 1987) signalling.  
 
1.3.2 Potential Novel Targets of VPA 
Proteins which have not previously been investigated as potential targets of VPA 
are the PI salvage pathway components CDS, CDIPT and DGK. 
 
1.3.2.1 CDS 
CDS is an integral membrane protein whose activity occurs at the cytoplasmic side 
of the endoplasmic reticulum for the synthesis of PI and at the inner mitochondrial 
matrix for PG and cardiolipin (Thompson and MacDonald, 1975; Kuchler, Daum and 
Paltauf, 1986; Shen, et al., 1996; Henry, Kohlwein and Carman, 2012; Lilley, et al., 
2014). CDS is activated by potassium ions, with enzyme activity dependent on 
magnesium (Nigou and Besra, 2002). Higher organisms contain multiple isoforms of 
CDS which differ in their substrates, i.e. CDS1 has no isomeric preference for its 
lipid target, whereas CDS2 targets lipids with acyl groups at positions sn1 and sn2 of 
the glycerol molecule (D'Souza, et al., 2014).   
 
1.3.2.2 CDIPT 
CDIPT is the protein responsible for the synthesis of PI within the endoplasmic 
reticulum plasma membrane and whose activity depends on magnesium ions 
(Agranoff, Bradley and Brady, 1958; Paulus and Kennedy, 1960). CDIPT was first 
discovered in the late 1950s and has since been found to be highly conserved 
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among many organisms (Agranoff, Bradley and Brady, 1958; Paulus and Kennedy, 
1960; Lykidis, et al., 1997; Lilley, et al., 2014).  
 
1.3.2.3 DGK 
DGKs are a family of enzymes which resides in the cytosol until activation is 
required at the plasma membrane. There are 5 types of DGK isoenzymes, divided 
according to the presence of specific protein domains. All DGKs contain 2 or 3 
phorbol-ester/ DAG type 1 binding domains which is followed with the catalytic 
site. Type 1 DGKs (DGK-, - and -) have a recoverin homology domain and EF 
hand motifs, whereas type 2 (DGK-, -, -) have pleckstrin homology domains. 
Type 3 DGKs (DGK-) contain arachidonate- DAG domains, whereas type 4 (DGK- 
and -) have PDZ and ankyrin repeat (ANK) domains and type 5 (DGK-) contain 3 
phorbol-ester/ DAG type 1 binding domains and Ras associating domains. The DGK 
isoenzymes are tissue specific, with DGK-, -, -, -, -, -, - and - being 
predominantly found within the central nervous system (Tu-Sekine and Raben, 
2011).  
1.4 D. discoideum as an Alternative Model 
Dictyostelium discoideum is a well-established non-animal model, listed by the 
National Institute of Health (Drayer, et al., 1994; Abu-Elneel, Karchi and Ravid, 
1996; Keizer-Gunnink, Kortholt and van Haastert, 2007; Couto, et al., 2011;  
Cunliffe, et al., 2014; Rakhimova, et al., 2017; National Institute of Health, 2017). D. 
discoideum, like the model organism zebrafish, can be used to screen potential 
therapeutic treatments and identify the mechanism of action of drugs, including 
AEDs (Terbach, et al., 2011; Chang, et al., 2012; Mahmood, et al., 2013).   
 
D. discoideum belongs to the Dictyostelia class of Mycetozoa phylum. D. discoideum 
is an excellent model for biomedical research as isogenic (from a single cell) cell 
lines can be cultured with ease and the effects of drugs can be visualised by 
changes in cell behaviour, e.g. in studying cell motility, signalling and differentiation 
and the mechanism of action of epilepsy and BD treatments (Williams, et al., 2002; 
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Eickholt, et al., 2005; Williams, 2005; Elphick, et al., 2012; Chang, et al., 2012). The 
haploid eukaryote D. discoideum consists of a single cell with a genome of 
approximately 11,000 genes, of which, 33 % are found in humans (Williams, 2005). 
D. discoideum contains six chromosomes which accounts for a genome size of 34 
Mb and a mitochondria genome of 54 Kb (Cole and Williams, 1994; Kuspa and 
Loomis, 1996). There are a high number of adenine and thymine base pairs 
(average of 60-70 % adenine and thymine in protein coding and 80-95 % in non- 
coding regions) (Escalante and Vicente, 2000). D. discoideum is a monophyletic 
organism whose genes are further away from plants and fungi and closer to 
vertebrates (Figure 1.5).  
 
 
Figure 1.5. Schematic tree of life showing the relationship of different biological 
kingdoms. Schematic tree of life showing the evolution from bacteria, archaea, social 
amoeba, animals, fungi and plants.  
 
1.4.1 Developmental Cycle 
D. discoideum was discovered in 1935 and is naturally found within soil where it 
survives on micro-organisms by phagocytosis, or, as in the laboratory, on liquid 
media by micropinocytosis (Raper, 1935; Williams, et al., 2006). D. discoideum 
replicates every 8-10 hours by binary fission, which stops during times of starvation 
and switches to the start of the multicellular developmental cycle (Figure 1.6). The 
development cycle can be divided into two stages- the aggregation phase and the 
post-aggregation phase. The developmental cycle involves programmed gene 
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expression and morphogenesis and is initiated when cyclic-adenosine-3,5-cyclic 
monophosphate (cAMP) is released in pulses from the amoeba 4 hours after the 
onset of starvation (Parent and Devreotes, 1996; Williams, 2005). cAMP is 
produced at 6 minute intervals and is degraded between pulses by extracellular 
phosphodiesterase. Individual D. discoideum cells migrate towards the site of cAMP 
by chemotaxis where they group together to form a mound of approximately 105 
cells at a single point, 10 hours after starvation. Chemotaxis occurs as cAMP binds 
to G- protein coupled receptors (primarily cAR1) which initiates F-actin 
polymerization (increased by 80 % within 2 seconds of cAMP exposure) and 
pseudopodium extension towards the highest cAMP concentration at the front of 
the cell (Wessels, et al., 1989). At the back end of the cell, myosin filaments are 
formed. These cellular changes occur through the release of the second messages 
cAMP, cyclic guanosine monophosphate, phospholipid methylation and calcium 
(Mato, et al., 1977; Mato and Marin-Cao, 1979). Within the mound, cell-to-cell 
interactions are initiated by cell adhesion molecules (Xu, et al., 2014). This signal is 
relayed to the more distant cells, initiating their movement towards the mound. As 
the mound forms, the cells become more compact until multicellular differentiation 
occurs by cAMP induced transcription factor activation. At this stage, the cells 
differentiate into either a pre-stalk and pre-spore cell, before forming either a stalk 
or spore cell, which together form the multicellular fruiting body. Differentiation 
into one of the two cellular subtypes depends on what stage of the cell cycle 
individual cells were at on the onset of starvation and through the action of 
ammonia, adenosine and the differentiation-inducing growth factor. Once a tight 
mound has formed, the different cell types reorganise so that the spore cells are at 
the tip of the structure, causing elongation into a finger-like shape. The top 20 % of 
the finger-structure contains pre-stalk cells and consists of a subpopulation of pre-
stalk A at the anterior end, extracellular matrix protein B in the middle and pre-stalk 
O at the posterior end (Escalante and Vicente, 2000). Throughout the finger-like 
structure anterior-like cells (ALC) are present. ALCs either express no markers, or 
one or both extracellular matrix protein A and extracellular matrix protein B 
expression. ALCs move both up and down the finger-like structure to form the 
upper cup or lower cup that surrounds the sporus/ spore head respectively, and the 
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basal disc. Pre-spores are located at the posterior end of the finger. Once in the 
finger structure, cells either form a slug or differentiate further into a fruiting body. 
 
Under unfavourable conditions (absence of heat or light), partially differentiated 
stalk (15 %), spore (75 %) and ALCs (10 %) located in the pre-spore region undergo 
an extra step in the developmental cycle where they form a multicellular migratory 
organism called a slug (Smith and Williams, 1981; Wilkins and Williams, 1995). The 
slug has a dense epithelium-like layer, at a thickness of a few cells, which is able to 
migrate through the continuous synthesis of an extracellular protein and cellulose 
matrix, termed a slime sheath. During movement to a more advantageous spot for 
spore formation and dispersal, this slime sheath is lost (Newell, Telser and Sussman, 
1969). Once migration stops, these partially differentiated cells fully develop into 
stalk or spore cells and then form a fruiting body. If a slug is not formed, the finger-
like structure continues culmination and forms a Mexican hat and mid culminant 
structures before forming a fruiting body. 
 
The formation of a 1 mm high fruiting body marks the end of the developmental 
cycle and arises after cell differentiation and morphogenetic cell movement. The 
fruiting body consists of a cellulose covered basal disc, a stem of 20,000 vacuolated 
dead stalk cells on which 80,000 spore cells are supported. Once conditions become 
favourable again, the spores can germinate and survive as unicellular cells.  
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Figure 1.6. Schematic of the D. discoideum developmental cycle. Schematic of the D. 
discoideum developmental cycle whereby unicellular vegetative cells migrate together to 
form a multicellular fruiting body over 24 hours. The intermediate structures formed are 
shown and labelled in the figure. 
 
It is the ability of D. discoideum to exist as a single cell and form a multicellular fruiting 
body which makes the amoeba a suitable non-mammalian model for biomedical 
research. At the unicellular stage the amoeba can be transformed, whereby specific 
genes of interest can be manipulated and grown rapidly. The formation of the 
homologous cell fruiting body requires a number of signalling events which are 
common to those found in vertebrates (Williams, 2005). For this reason, the effect 
of drugs on individual pathways can be investigated using D. discoideum as a model 
organism.  
 
1.4.2 Methodology 
Previous studies using D. discoideum as a model to determine the molecular action 
of therapeutic drugs has involved the ablation and overexpression of specific genes 
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of interest (Terbach, et al., 2011; Chang, et al., 2012; Frej, et al., 2016). These 
mutant cell lines are then phenotypically characterized in both the absence and 
presence of a drug of interest during cell growth, acute cell behaviour (random cell 
movement) and development. If the null cell line shows resistance to the drug, i.e. 
the calculated value of 50 % inhibition (IC50) is approximately double that of wild 
type (WT) cells, the gene ablated is then reintroduced, creating rescue cells. 
Phenotypic characterization is then repeated to ensure drug resistance is due to the 
ablated gene by drug-sensitivity being restored in the rescue cell line. 
 
1.4.2.1 Gene manipulation  
 
To identify a target of VPA, genes of interest within the PI salvage pathway were 
first identified (Figure 1.7A and Figure 1.8A). These genes were then ablated or 
overexpressed by creating recombinant plasmids (Figure 1.7B and Figure 1.8B). To 
ablate a gene, two open reading frame regions of the gene of interest are 
polymerase chain reaction (PCR) amplified from genomic DNA and cloned into a 
vector on either side of an antibiotic resistance gene, creating a knockout cassette. 
This knockout cassette contains the two PCR gene fragments and the antibiotic 
resistance gene. The plasmid is then sequenced to ensure that there are no errors 
in the two gene fragments. This knockout cassette is then digested out from the 
recombinant plasmid using restriction enzymes and electroporated into WT D. 
discoideum cells. Transformant cells are then selected by growth in the presence of 
an antibiotic determined by the resistance gene. PCR screening is then conducted 
on surviving cell colonies to determine homologous recombinant cells which 
contain a correctly inserted knockout cassette, as this results in a truncated protein, 
interrupted by the presence of the antibiotic resistance gene and loss of part of the 
coding sequence. PCR screening is then conducted and involves 3 sets of primers 
for the 5’- and 3’- terminus of the gene of interest (Figure 1.7C). The first primer set 
are genomic control (G) primers which confirm the presence of the 2 PCR gene 
fragments and is present in both WT and transformant cells. The second primer set 
are vector control (V) primers which confirm the gene fragment is adjacent to the 
antibiotic resistance gene and so is only present in transformant cells. The third 
primer set is the knockout diagnostic (K) which confirms the gene of interest is 
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interrupted by the antibiotic resistance gene at the 5’ and 3’ gene terminus and has 
a portion of the amino acid sequence removed. A PCR band for the knockout 
diagnostic is only present in homologous recombinant cells. When a knockout 
diagnostic band is identified at both the 5’ and 3’ gene terminus, isogenic 
homologous recombinant cell lines are then produced and confirmed as a knockout 
cell line by PCR amplifying a region of the deleted gene by reverse transcriptase 
(RT)-PCR. Isogenic knockout cells are then used for phenotypic characterization in 
both the absence and presence of VPA (Figure 1.7D). 
 
 
 
 
 
 
Chapter 1  Introduction 
 41 
 
 
Figure 1.7. Schematic of the gene ablation protocol resulting in the characterization of 
mutant cells. Schematic of gene ablation procedure where (A) genes of interest are 
identified within the phosphoinositide salvage pathway. Genes are then cloned into (B) 
knockout vector and electroporated into WT cells. Resulting isogenic transformant cell lines 
are confirmed by (C) RT-PCR screening using primers for genomic (G) and vector (V) control 
and knockout diagnostic (K). Confirmed transformant cells are then (D) phenotypically 
characterized in both the absence and presence of VPA during cell growth, acute cell 
behaviour and development. Each step is shown to the far left of the figure.   
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To overexpress or reintroduce an identified gene of interest in D. discoideum, the 
entire gene sequence is PCR amplified from coding DNA (cDNA) (Figure 1.8A). The 
cDNA PCR product is then cloned into a plasmid adjacent to a fluorescent tag, e.g. 
green or red fluorescent protein (GFP or RFP respectively) (Figure 1.8B). The 
overexpression plasmid is then sequenced to ensure there are no errors in the PCR 
gene fragment. The overexpression plasmid is then electroporated into WT or null 
cells and selected by growth in the presence of an antibiotic determined by the 
resistance gene present on the plasmid. Expression of the fluorescently-tagged 
protein of interest is then confirmed by Western blot and fluorescence microscopy 
(Figure 1.8C). Once confirmed, the overexpressing cells are used for phenotypic 
characterization in both the absence and presence of VPA (Figure 1.8D). 
 
 
 
 
Chapter 1  Introduction 
 43 
 
 
Figure 1.8. Schematic of the gene overexpression protocol resulting in the 
characterization of mutant cells.  Schematic of the gene overexpression procedure where 
(A) genes of interest are identified within the phosphoinositide salvage pathway. Genes are 
then cloned into an (B) overexpression vector containing a fluorescent tag and 
electroporated into WT cells. Resulting transformant cells are then confirmed by (C) 
Western blot and fluorescence microscopy. Confirmed cells are then (D) phenotypically 
characterized in both the absence and presence of VPA during cell growth, acute cell 
behaviour and development. Each step is shown to the far left of the figure.   
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1.4.3 Identifying the Target of VPA 
Potential molecular targets of VPA can be identified by the phenotypic 
characterization of mutant cells in both the absence and presence of VPA. 
Characterization involves comparing the effects of VPA on cell growth (Terbach, et 
al., 2011), acute cell behaviour (Xu, et al., 2007) and development (Williams, et al., 
2002), as VPA has previously been shown to inhibit these processes. If mutant cells 
are resistant to VPA during cell growth, cells will proliferate at a similar rate to that 
of control conditions when exposed to the drug. However, if cells proliferate at a 
slower rate when exposed to VPA compared with control conditions, when cells are 
not exposed to the drug, then the cells are drug- sensitive. VPA resistance and 
sensitivity will be illustrated in a secondary plot which compares the rate of cell 
growth between WT and mutant cells in the presence of increasing VPA 
concentrations. The secondary plot is used to calculate an IC50 value for each cell 
line.  
 
During acute cell behaviour, cell displacement, circularity, membrane protrusions 
and motility are measured (Figure 1.9). Cell displacement is the shortest distance a 
cell travels from point A to point B (Figure 1.9A). Circularity is a measure of cell 
shape (Figure 1.9B). Membrane protrusions are extensions of the cell membrane 
which enables a cell to elongate and move forward (Figure 1.9C). Motility is the 
speed at which a cell has travelled (Figure 1.9D). If mutant cells are resistant to 
VPA, the overall calculated distance travelled by each individual cell and the 
average value for circularity, number of membrane protrusions and motility will be 
similar to control conditions when no drug was added. However, if cells are drug- 
sensitive, cell displacement will be lower than control conditions and there will be a 
decrease in the average number of membrane protrusions and speed, correlated 
with an increased value for circularity, which is a measure of cell rounding. VPA 
sensitivity or resistance will be shown in the secondary plots, which will compare 
either total displacement or average circuity, membrane protrusions and motility 
within the final 300 seconds of the assay with increasing VPA concentrations. An 
IC50 value will be calculated for each cell line for displacement, average membrane 
protrusions and motility. 
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Figure 1.9. Schematic of measurable acute cell behaviour criteria. Schematic of the 
measurable acute cell behaviour criteria displacement (shortest distance a cell travels 
between two points), circularity (a measure of cell shape, with round cells given a value of 
“1”), membrane protrusions (number of cell membrane extensions) and motility (speed).  
 
VPA treatment has previously been shown to inhibit D. discoideum development at 
the mound stage (Williams, et al., 2002). Therefore, if a mutant cell line is resistant 
to VPA, multicellular fruiting bodies resembling control conditions will develop 
when exposed to the drug. If cells are VPA-sensitive, cell development will mimic 
that of WT cells and not develop into mature fruiting bodies containing a basal disc, 
stalk and spore head.  
1.5 Aims and Specific Objectives  
The aim of this PhD thesis, therefore, is to investigate whether the PI salvage 
pathway contains the molecular target(s) of VPA using D. discoideum as a model 
organism. If successful, new AEDs can be developed around this target which have 
a similar potency to VPA but without the side effects of teratogenicity and 
hepatoxicity, by altering the drugs chemical structure. Identifying molecular targets 
of VPA will be achieved by investigating the interlinking pathways and individual 
components of the PI salvage pathway.  
 
Previous studies investigating PLC and all 5 D. discoideum PI3K and PTEN            
(pi3k1-5-/pten-) in response to VPA did not characterize the effect of the drug on 
acute cell behaviour and development (Chang, et al., 2012). For this reason, D. 
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discoideum pi3k1-5-/pten- of the PI3K pathway and plc- and lpin2- of the PI salvage 
pathway were initially investigated as potential targets of VPA, along with other 
anti-seizure compounds and the bipolar disorder treatment lithium chloride (LiCl). 
Conservation of CDS, CDIPT and DGK proteins from D. discoideum and a range of 
other organisms was then investigated. D. discoideum PI salvage pathway proteins 
CDSA, CDIPT and DGKA were then either ablated or overexpressed. The resulting 
mutant cells were phenotypically characterized in both the absence and presence 
of VPA and the other anti-seizure compounds and the BD treatment LiCl.  
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2. Materials and Methods 
2.1 Materials 
2.1.1 General Reagents 
2.1.1.1 Reagents from Sigma-Aldrich (Gillingham, Dorset, U.K.) 
1,2-Dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt , 2-
mercaptoethanol, 4-ethyloctanoic acid (4-EOA), acetic acid, ammonium persulfate 
(APS), bacteriological agar, bovine serum albumin (BSA), cyclic adenosine 
monophosphate (cAMP), ethylenediaminetetraacetic acid (EDTA), HEPES, horse 
serum, L-α-PI from Glycine max (soybean), LiCl (8 mM), Immobilon-FL 
polyvinylidene fluoride (PDVF) transfer membrane, Lurina broth (LB) tablets, 
magnesium chloride, magnesium sulphate, N’N’N’N’- tetramethylethylenediamine 
(TEMED), phosphatase inhibitors, potassium acetate, potassium chloride, sodium 
acetate, sodium chloride, sodium dihydrogen phosphate, sodium dodecyl sulphate 
polyacrylamide (SDS), sodium hydroxide, Tris base, Tris buffered saline with tween 
(TBS-T), Tween-20, VPA and water came from Sigma-Aldrich (Gillingham, Dorset).  
 
2.1.1.2 Reagents from Other Suppliers 
2-methylhexanoic acid (2-MHA), DA and OA (Alfa Aesar, Heysham, U.K.). 
2-(propan-2-yl)pentanoic acid (propylisopropylacetic acid, PIA) and VPD (Meir 
Bialer, The Hebrew University of Jerusalem, Israel).  
Ethidium bromide and 2X Laemeli sample buffer (Bio-Rad, Hemel Hempstead, U.K.). 
5x loading dye, agarose, ammonia buffer, deoxynucleotides (dNTPs) and 
magnesium chloride (MgCl2) (Bioline, London, U.K). 
Axenic media, LoFlo medium and SM medium (Formedium, Norfolk, U.K.). 
SM agar (Gibco, Paisley, U.K.). 
Protogel 30 % solution (National Diagnostics, Nottingham, U.K.). 
Tris-borate-EDTA (TBE) buffer (Severn Biotech Ltd, Kidderminster, U.K.). 
Fluoromount-G, glycine, TBS-T, Tris pH 6.8 and Tris pH 8.0 (Thermo Fisher Scientific, 
Hemel Hempstead, U.K.). 
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Acetic acid, bromophenol blue, ethanol, dimethyl sulfoxide (DMSO), glucose, 
glycerol, hydrochloric acid, methanol, paraformaldehyde and propan-2-ol (VWR, 
Lutterworth, U.K.). 
 
2.1.1.3 Antibiotics 
Penicillin- streptomycin (PenStrip) (Gibco, Paisley, U.K.).  
Blasticidin (PAA Laboratories Ltd, Somerset, U.K.). 
Ampicillin (Sigma Aldrich, Gillingham, Dorset, U.K.). 
Geneticin and hygromycin (Thermo Fisher Scientific, Hemel Hempstead, U.K.). 
 
 2.1.1.4 Molecular Weight Standards 
Hyperladder 1 kb (Bioline, London, U.K). 
PageRuler Plus Pre-stained Protein Ladder (Thermo Fisher Scientific, Hemel 
Hempstead, U.K.). 
 
2.1.1.5 Enzymes and Corresponding Buffers 
BioTAQ Polymerase (Bioline, London, U.K.). 
HindIII and thermosensitive alkaline phosphatase (TSAP) (Promega, Southampton, 
U.K.). 
Q5 DNA polymerase (New England Biolabs, Hitchin, U.K.). 
BamHI, DNase, EcoRI, KpnI, NcoI, Proteinase K, PstI and T4 DNA ligase (Thermo 
Fisher Scientific, Hemel Hempstead, U.K.). 
RNase A (Sigma- Aldrich, Gillingham, U.K.).  
 
2.1.1.6 Antibodies 
3H9-GFP and 6G6-RFP (ChromoTek, Planegg, Germany). 
Calreticulin and myosin II heavy chain (MHC) primary antibody (Developmental 
Studies Hybridoma Bank, Iowa, U.S.). 
IRDye 800 Goat Anti-Mouse and IRDye 800 Goat Anti-Rat (LI-COR Bioscience, 
Nebraska, U.S.).  
Streptavidin (MccA/ MCCR1) (Thermo Fisher Scientific, Hemel Hempstead, U.K.).  
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2.1.1.7 Kits 
General Diacyl Glycerol, DAG/ DG enzyme linked immunosorbent assay (ELISA) Kit 
(Amsbio, Abingdon, U.K.). 
DNeasy Blood and Tissue kit, HiSpeed Plasmid Purification kit, QIAquick Gel 
Extraction kit, QIAquick PCR Purification kit and RNeasy Mini kit (Qiagen, West 
Sussex, U.K.). 
DNase Treatment Removal kit and First Strand cDNA Synthesis kit (Thermo Fisher 
Scientific, Hemel Hempstead, U.K.).  
 
2.1.1.8 Escherichia coli Strain 
Chemically competent Escherichia coli (E. coli) JM107 cells (Invitrogen, Gröningen, 
Netherlands). 
 
2.1.1.9 Primers 
All primers were custom made and purchased from Sigma-Aldrich (Gillingham, 
Dorset, U.K.) (Supplementary Table S1).  
 
2.1.1.10 Equipment 
Bio-Rad gel casting system, Bio-Rad gel doc 2000, Bio-Rad GenePulser Xcell 
electroporator, Bio-Rad Power Pack 300, Bio-Rad wide mini-sub cell electrophoresis 
system and BioRad Mini-PROTEIN Tetra Cell (Bio-Rad, Hemel Hempstead, U.K). 
Airstream ESCO class II biological safety cabinet (ESCO, Barnsley, U.K.). 
Lab-Tek Chambered Coverglass 8 well (Lab-Tek, Thermo Fisher Scientific, Hemel 
Hempstead, U.K.). 
Odyssey CLx (LI-COR Biosciences, Nebraska, U.S.). 
MCE MF-Millipore hydrophobic plain edge 0.45 µm pore size 47 mm membrane 
filter and MCE MF-Millipore plain black 0.45 µm pore size 47 mm diameter 
membrane filter (Milipore, Oxfordshire, U.K.).  
Plate reader spectra Mac 190 (Molecular Devices, Wokingham, U.K.). 
Neubauer Improved haemocytometer (Neubauer Improved, Hawksley, Sussex, 
U.K.). 
Excella E25 incubator shaker series (New Brunswick Scientific, St Albans, U.K.).  
Light Microscope (Nikon, Kingston Upon Thames, U.K.). 
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Olympus IX71 (microscope), Olympus TH4-200 (halogen lamp power supply unit) 
and Olympus U-RFL-T (fluorescent lamp) (Olympus, Southend- On-Sea, U.K.). 
0.2 mm electroporation cuvettes (PEQLAB Ltd, Portsmouth, U.K.) 
2X Gradient PCR machine (Peqstar, Southampton, U.K.). 
QImaging RetigaExi Fast 1394 digital camera (QImaging, British Columbia, Canada). 
Spectra Mac 190 Plate Reader (Molecular devices, Wokingham, U.K.). 
Sartorius certomat RM rotatory platform (Satorius, Epsom, U.K.). 
Magnetic Heat Stir CB/62 (Stuart, Stone, Staffordshire). 
GeneFlash gel system (Syngene, Cambridge, U.K.).  
Dri- block DB-2D (Techne, Stone, U.K.) 
Heraeus Fresco 21 centrifuge and nanodrop (Thermo Fisher Scientific, Hemel 
Hempstead, U.K.). 
Galaxy Mini Star and MEGA STAR 1.6 centrifuge (VWR, Leighton Buzzard, U.K.). 
 
2.1.1.11 Plasmids and D. discoideum Cell Lines 
N-terminal RFP tagged mRFPmars in pDEXH (338-19) (Annette Müller-
Taubenberger, Ludwig- Maximilians- University, Munich, Germany).  
LB150B (F-actin GFP) and pBIGGFPmyo (GFP-myosin II heavy chain (MHC)) (Arjan 
Kortholt, University of Groningen, Groningen, Netherlands).  
D. discoideum Ax2, Ax3, plc- Ax3 and pikA-/pikB-/pikC-/pikF-/pikG-/pten- Ax2 (pi3k1-
5/pten-) cells (Dicty Stock Centre, Chicago, U.S.). 
pLPBLP plasmid (Dictybase, www.dictybase.org). 
D. discoideum lpin2- Ax2 cells and Ax2 parental cells used to make this mutant 
(Markus Maniak, University of Kassel, Hesse, Germany).  
pTX-DGK1 (Tomas Egelhoff, Case Western Reserve University, Cleveland, U.S.).  
2.2 Methods 
2.2.1 Bioinformatic Analysis 
2.2.1.1 BLAST 
Homologs of D. discoideum proteins in other organisms were identified using the 
position-specific iterative (PSI)- basic local alignment tool (BLAST) database 
provided by the National Centre for Biotechnology Information (NCBI). This search 
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was conducted using the non-redundant protein sequence (nr) database. The 
protein-protein- BLAST database provided by NCBI was used to compare D. 
discoideum protein sequences with specific H. sapiens protein isoforms.  
 
2.2.1.2 Phylogenetic Tree 
Evolutionary conservation of proteins across a range of organisms was determined 
by phylogenetic analysis. This involved using the Molecular Evolutionary Genetic 
Analysis (MEGA) 7 software to input protein sequences from the website 
UniProt.org. Protein sequences were aligned in order to produce a phylogenetic 
tree using the neighbour- joining method with bootstrap replicates (500), corrected 
using the Poisson correction method.  
 
2.2.1.3 Protein Sequence Alignment 
Protein sequences were obtained from the website UniProt.org and aligned using 
the Clustal Omega webpage. Once aligned, amino acids conserved in D. discoideum 
and other organisms were highlighted in blue using the website bioinformatics.org.  
 
2.2.1.4 Domain Analysis  
Key protein domains were determined using the UniProt.org website. These 
domains were then plotted in a schematic to illustrate homology of key sites 
between D. discoideum and H. sapiens proteins. Where the catalytic site was not 
stated on the UniProt.org website, this domain was predicted from areas of high 
homology from the protein sequence alignment.  
 
2.2.2 D. discoideum Protocols 
2.2.2.1 Cell Culture 
D. discoideum stocks were stored at -80 °C in freezing medium (7 % DMSO and 
horse serum). Every 4 weeks, cells from frozen stocks were scraped onto SM agar 
plates streaked with 350 l Raoutella planticola. Plates were incubated at 22 °C for 
4-5 days to enable colonies to form. Cells within a single colony growth zone were 
inoculated into liquid axenic media containing PenStrep (100 g/ml) to obtain 
isogenic cell lines. Cells were maintained in the log phase (1-4x106 cells/ml) and cell 
number was determined using a haemocytometer.  
Chapter 2  Materials and Methods 
 53 
2.2.2.2 Live Cell Imaging 
For live cell imaging, D. discoideum cells containing fluorescent tags were grown to 
the log phase prior to washing and being placed into low fluorescing media. Cells 
were then grown for 16 hours at 22 °C. Cells were then transferred to the top of a 
large round glass coverslip and allowed to adhere for 10 minutes. This was followed 
by placing a square of 1 % agar diluted in phosphate buffer (16.2 mM potassium 
phosphate monobasic and 4 mM potassium phosphate dibasic in double distilled 
water) above the cells and allowing cells to adhere for a further 5 minutes. Protein 
localization was determined using fluorescence microscopy at x 60 objective.  
 
2.2.2.3 Fixed Cell Imaging 
D. discoideum cells (1x107) were transferred to a 6-well plate to which glass cover 
slips were added and allowed to adhere for 16 hours at 22 °C. Cells were fixed to 
the glass cover slips using paraformaldehyde. This was followed by 
immunofluorescent staining whereby fixed cells were incubated in the presence of 
a calreticulin (diluted 1:4) (control) or MHC (diluted 1:3) primary antibody for 1 
hour. Both antibodies were diluted in 2 % BSA in TBS-T. Cells were then washed in  
2 % BSA in TBS-T before being incubated for a further hour in a relevant secondary 
antibody diluted 1:1000 in 2 % BSA in TBS-T. Cells were again washed in 2 % BSA in 
TBS-T, followed by attaching the cell fixed cover slips to a glass slide using 
Fluoromount-G. The slides were then incubated in the dark for 16 hours as 
fluorescent antibodies are light sensitive. Fluorescing cells were visualised at x 60 
objective using a fluorescence microscope.  
 
2.2.2.4 Live Cell Imaging of MHC Localization  
Shaking D. discoideum cells containing a plasmid driving the expression of a GFP 
fluorescently tagged F-actin (LB15-B) or MHC (pBIGGFPmyo) (1x107) were washed 
and resuspended in 6 ml phosphate buffer. Cells were shaken (120 rpm) and pulsed 
every 6 minutes with cAMP (30 nM) for 5 hours. This was followed by washing and 
resuspending cells in 4 ml phosphate buffer. Cells were then diluted 1:10 times in 
phosphate buffer before 250 l of cells were transferred to a Nunc Lab-Tek 8-well 
glass chamber. Cells were allowed to adhere to the chamber for 15 minutes at        
22 °C. This was followed by fluorescence microscopy using the x 40 objective where 
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images of cells were taken at 0, 10, 20, 30, 60 and 120 seconds following 
stimulation by cAMP (100 M).  
 
2.2.2.4 Growth Curve Assay 
A 24-well plate was used to grow 2x104 D. discoideum cells per experimental 
sample. Cells were diluted in axenic media (giving a final volume of 495 l per well) 
prior to being added to the 24- well plate and allowed to adhere for 15 minutes at 
22 °C. This was followed by the addition of 100 X VPA dissolved in double distilled 
water to give final concentrations ranging between 0.01 mM-2 mM. Cells were 
incubated for 168 hours at 22 °C with cell density calculated every 24 hours 
between 72-168 hours. Growth within the exponential phase was used to calculate 
the concentration of VPA which inhibited growth by 50 % (IC50) using a 
haemocytometer and light microscope. 
 
2.2.2.5 Acute Cell Behaviour Assays 
D. discoideum cells (1x107) were harvested from shaking culture mid-log phase and 
washed in phosphate buffer. Cells were resuspended in 6 ml phosphate buffer and 
pulsed with cAMP (30 nM) every 6 minutes for 5 hours shaking at 120 rpm. Cells 
were then washed and resuspended in 4 ml phosphate buffer prior to being diluted 
1:10 times in phosphate buffer. Cells (250 l) were then transferred to a Nunc Lab-
Tek 8-well glass chamber and incubated at 22 °C for 15 minutes to allow cells to 
adhere. Cell movement was then recorded by time-lapse microscopy for 900 
seconds at x 40 objective using the Image-Pro 6.3 software. During the recording, 
there was a control period of 225 seconds which was followed by the addition of 
250 l 2 X VPA to give a final concentration ranging between 0.01 mM-0.7 mM for 
the remaining 675 seconds. Cell behaviour in both the absence and presence of 
VPA was monitored using 30 cells per condition in a minimum of 3 independent 
replicates.  
 
From the time-lapse recordings, acute cell behaviour was analysed using the 
software ImageJ 1.48 g software package where individual cells were segmented. 
This was followed by MATLAB R2011b analysis of the accompanying scripts, 
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enabling the quantification of individual cell displacement, circularity, membrane 
protrusions and motility between all video frames.  
 
2.2.2.6 Development Assay 
D. discoideum cells (1x107) were harvested from a shaking culture, washed and 
resuspended in 10 ml and 1 ml phosphate buffer respectively. Cells were evenly 
distributed across a Millipore membrane filter which was added on top of a 
Millipore hydrophobic membrane filter soaked in either phosphate buffer (control) 
or relevant compound. Cells were incubated for 24 hours at 22 °C before being 
analysed under a light microscope at x 1.25 objective for an overhead view or x 6.3 
for a single fruiting body. 
 
2.2.2.7 DAG ELISA Assay 
D. discoideum cells (5x106) were harvested from a shaking culture, washed and 
resuspended in 6 ml phosphate buffer. Cells were then shaken with pulsatile cAMP 
for 5 hours prior to being washed with phosphate buffer. Cells were then treated 
with VPA (0.3 mM-0.5 mM), LiCl (8 mM), VPD (6.5 mM), PIA (1.4 mM), DA (1.65 
mM), OA (0.22 mM) or 4-EOA (0.5 mM) for 10 minutes in shaking suspension. 
Following treatment, cells were then washed and the cell wall fraction was 
obtained following 6 rounds of freeze-thaw (3 minutes each) and centrifuged 
(10,000 g, 10 minutes, 4 C). The cell pellet was then resuspended in 100 l Sample 
Dilutent provided in the Amsbio General Diacyl glycerol DAG/DG ELISA kit. Samples 
were stored at -20 C prior to the ELISA assay. The ELISA assay was conducted 
following the instructions provided from the supplier.  
 
2.2.3 Molecular Biology Protocols 
2.2.3.1 Polymerase Chain Reaction  
Genomic DNA was amplified using PCR under the conditions: 2 μl DNA, 0.8 μl 50 
mM MgCl2, 2 μl 10 % BIOTAQ ammonia buffer, 2 μl 2 mM dNTPS, 0.1 μl BIOTAQ 
DNA polymerase (5 Uμl-1), 1 μl 10 pmol 5’ primer, 1 μl 10 pmol 3’ primer and      
11.1 μl double distilled water to make a total volume of 20 μl.  
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The PCR reaction was carried out under the following conditions: denaturation at 
95 °C for 1 minute followed with 32 cycles of denaturation at 95 °C for 15 seconds, 
annealing at 50 °C for 30 seconds (temperature dependent on primer annealing 
points) and extension at 72 °C where length was dependent on the product length 
being amplified (1 minute per 1000 bp). This cycle was followed with a final 
extension of 5 minutes at 72 °C prior to samples being stored at 8 °C.  
2.2.3.2 Agarose Gel Electrophoresis 
DNA was separated and visualised on 1 % agarose gels spiked with ethidium 
bromide in 1 X TBE buffer. 5 X DNA loading dye was added to DNA. DNA fragment 
sizes were determined using a 1 kb hyperladder. Gels were run for 30-40 minutes at 
100 V in a gel electrophoresis tank and visualised by UV light on a GeneFlash gel 
system (Syngene Bio Imaging).  
 
2.2.3.3 Restriction Digest 
Qiagen AAMP Gel Extraction kit and the Qiagen QIAquick PCR Purification kit were 
used according to the manufacturer’s instructions to purify the pLPBLP plasmid and 
genomic PCR fragments respectively.  
Restriction digests were carried out in the following conditions: 10 μl DNA,            
0.2-0.5 μl each of the relevant restriction enzyme (100 U/L-1) (volume dependent 
on the restriction enzymes being used and their effectiveness in the buffer), 2 μl 
appropriate buffer (according to the manufacturer’s instructions) made up to a 
total volume of 20 μl with double distilled water. Samples were incubated for 2-4 
hours at 37 °C, depending on the purpose of the reaction (2 hours for creating a 
recombinant plasmid, 4 hours for obtaining the knockout cassette).  
For creating knockout plasmids, TSAP was added after 1 hour to the pLPBLP sample 
only to remove any 5’ phosphate groups to prevent re-ligation or recircularization 
of the plasmid. After a further hour incubation, TSAP was inactivated by incubating 
the sample at 74 °C (15 minutes).  
Enzyme efficiency for all digests was determined by 1 % agarose gel electrophoresis 
(30-40 minutes, 100 V).  
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2.2.3.4 Knockout Vector Construction 
Knockout constructs were created using the pLPBLP plasmid. Two fragments of the 
open reading frame of the gene of interests were PCR amplified from Ax2 cell 
genomic DNA. Primers used for PCR amplification contained restriction sites to 
enable cloning into the pLPBLP vector. PCR products were purified using the Qiagen 
QIAquick PCR Purification kit. This was followed by digesting the pLPBLP vector and 
gene fragments with the appropriate restriction enzymes. A sample (5 l)) of the 
digested PCR fragments were analysed by gel electrophoresis with the remaining 
sample being purified using the Qiagen QIAquick PCR Purification kit. The whole 
pLPBLP digested sample was analysed by gel electrophoresis and the digested band 
at the correct size was excised from the gel and purified using the Qiagen QIAquick 
Gel Extraction kit. The PCR gene fragments were then ligated into the purified 
pLPBLP vector at a ratio of 2:1 using 1 l T4 DNA ligase (1 U/l-1), the corresponding 
T4 DNA ligase buffer (2 l) provided with the enzyme with the total volume of the 
ligation reaction being made up to 20 l with double distilled water. Ligation 
reactions were incubated at 16 °C for 16 hours. This was followed by denaturing T4 
ligase at 65 °C for 20 minutes. The ligation reaction was transformed into 
chemically competent E. coli cells (30 l) by incubating the sample on ice for 2 
minutes, followed by heat- shock treatment for 1 minute at 42 °C and then 
returning the sample to ice for a further 2 minutes. LB media (100 μl) was then 
added to the samples which were then incubated for 1 hour at 37 °C, 200 rpm. Cells 
were streaked onto a spiked LB plate with 1 μl/ml ampicillin and incubated at 37 °C 
overnight. Transformant colonies selected by ampicillin were added to LB liquid 
broth spiked with 2 μl/ml ampicillin and incubated at 37 °C for 16 hours.  
 
Plasmid cultures were then purified. Plasmid cultures to be used for sequencing or 
electroporating into D. discoideum cells were purified using the Qiagen HiSpeed 
Plasmid Purification kit according to the manufacturer’s instructions. Plasmid 
preparations which were not purified with the commercial kit and used for further 
cloning, were extracted from E. coil using verified a using an in- house protocol. This 
involved centrifuging 2 ml E. coli culture, aspirating the supernatant and 
resuspending the cell pellet in 200 μl P1 buffer (1 M glucose, 0.5 M EDTA, 2 M Tris 
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pH 8 and water). Cell lysis occurred by the addition of 200 μl P2 buffer (5 M sodium 
hydroxide in 10 % SDS and water) and was followed with neutralization of the lysis 
mixture by the addition of 200 μl P3 buffer (3 M potassium acetate and 2 M glacial 
acetic acid in water). Samples were centrifuged at 17,000 g for 15 minutes, after 
which the supernatant was added to 420 μl 100 % propan-2-ol and further 
centrifuged (17,000 g, 15 minutes). DNA precipitation occurred by the addition of 
500 μl 80 % ethanol, after which samples were centrifuged at 13,000 rpm for 5 
minutes. The DNA pellet was then air dried for 10 minutes to remove any residual 
ethanol. DNA was resuspended in 30 μl double distilled water.  
 
The concentration of the purified plasmid was then determined using a nanodrop. 
This was followed by single and double restriction digests to confirm the insertion 
of the fragment of interest. The whole cloning process was then repeated for the 
insertion of the second gene fragment. Once both fragments were inserted into the 
pLPBLP vector, the purified plasmid was sequenced by MWG-Biotech to ensure no 
mutations were present.   
 
2.2.3.7 D. discoideum Knockout Transformation by Electroporation 
For each knockout construct, the knockout cassette (2 PCR gene fragments flanking 
either side of a blasticidin resistance cassette) was excised from the pLPBLP plasmid 
via a 4-hour restriction digest. This was achieved by digesting the knockout 
construct (20 μg) at 37 °C in the relevant enzyme buffer using the two restriction 
enzymes whose cut sites were present at either end of the knockout cassette. Gel 
electrophoresis was then used to confirm efficiency of the digest. DNA was then 
precipitated by the addition of 10 μl 3 M sodium acetate and 330 μl 100 % ethanol. 
Samples were centrifuged at 17,000 g for 15 minutes and the resulting DNA pellet 
was washed in 80 % ethanol (750 μl) and spun under the same conditions. The DNA 
pellet was then air dried for 10 minutes before being resuspended in 20 μl double 
distilled water.  
The knockout cassette was then electroporated into D. discoideum cells. D. 
discoideum cells (1x107) were incubated on ice for 10 minutes and then centrifuged 
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at 1500 g for 3 minutes. Cells were washed twice in phosphate buffer and sterile 
filtered electroporation buffer (20 mM HEPES, 50 mM potassium chloride, 10 mM 
sodium chloride, 1 mM magnesium sulphate, 5 mM sodium bicarbonate and 1 mM 
monosodium phosphate). The cell pellet was resuspended in 20 μl of the 20 μg 
digested knockout construct and transferred into a 0.2 cm electroporation cuvette 
and incubated on ice for 10 minutes. D. discoideum cells were then electroporated 
with a Bio-Rad GenePulser Xcell electroporator using 2 pulses with 15 seconds rest 
in between, 25 μF and 850 V. Cells were then allowed to recover by incubating on 
ice for a further 10 minutes before being transferred to 10 ml axenic media spiked 
with 0.1 % PenStrep. Cells were then transferred to a 96-well plate with 100 μl 
added to each well. After 24 hours incubation at 22 °C, 100 μl of axenic media 
containing 0.1 % PenStrep and 20 μg/ml blasticidin was added to each well, giving a 
final blasticidin concentration of 10 μg/ml. Where stated, cells were also grown in 
the presence of 100 M PI and/or 100 M PG liposomes, produced from 
sonication. Cell were then incubated at 22 °C for 2 weeks for wells to become 
confluent.  
2.2.3.8 DNA Extraction of Transformed Cells 
Once transformant cells became confluent after selection in blasticidin, 200 μl of 
cells were spun in a microfuge and the cell pellet was washed in 100 μl phosphate 
buffer. The cell pellet was in lysed in 2 μl Proteinase K (20 mg/mL) and 48 μl lysis 
buffer (50 mM potassium chloride, 10 mM Tris pH 8.3, 2.5 mM MgCl2, 0.45 % NP-40 
detergent, 0.45 % Tween-20 and water) following a 5 minute incubation at room 
temperature. Proteinase K was inhibited by an incubation at 95 °C for 1 minute. The 
extracted DNA was then used for PCR screening reactions to identify colonies 
where homologous recombination of the knockout cassette had occurred at the 
correct location.  
 
2.2.3.9 PCR Screening of Transformed D. discoideum Cells 
Screening primers were designed for determining correctly transformed D. 
discoideum cells. Homologous recombinant cells would have the blasticidin 
resistance cassette located within the gene of interest at a site where part of the 
coding sequence had been deleted, thereby preventing the synthesis of a functional 
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protein. Three primer pairs were used to screen for homologous integration of the 
knockout cassette: genomic control, vector control and knockout conformation 
(Figure 2.1). PCR analysis was conducted on freshly extracted genomic DNA based 
upon these 3 sets of primers designed for both the 5’ and 3’ fragments of each gene 
of interest. The genomic control confirmed the non-deleted region of the gene; the 
vector control confirmed the presence of the blasticidin resistance gene adjacent to 
the genomic DNA fragment and the knockout diagnostic confirmed homologous 
integration of the knockout cassette at the correct location. 
 
 
Figure 2.1. Schematic illustrating the locations of the PCR screening primers. Schematic 
representation of a gene knockout construct containing the 5’ and 3’ PCR gene fragments 
(purple) and the blasticidin resistance gene (Bsr, red). The locations of the screening 
primers (arrows) and the corresponding PCR product (dotted line) used for determining 
homologous integration are shown for the genomic control (pink), vector control (blue) and 
knockout diagnostic (yellow) primers.  
 
2.2.3.10 Creation of Isogenic Transformant D. discoideum Cells 
Once PCR confirmed the correct insertion of the resistance gene within 
transformant cells, colonies were plated on sterile SM agar plates with 200 μl R. 
planticola. Plates were incubated for 3-4 days at 22 °C, after which individual cell 
colonies appeared. Cells were obtained from these colonies and grown and 
selected in axenic media containing 0.1 % PenStrep and 10 μg/ml blasticidin.  
 
2.2.3.11 Confirmation of Gene Disruption By Reverse Transcription-PCR 
Isogenic homologous intergrants determined by PCR screening were confirmed as 
knockout cell lines by RT-PCR. This involved harvesting and washing D. discoideum 
cells (1x107) in phosphate buffer. RNA was extracted using the RNeasy Mini kit 
following the manufacturer’s protocol. RNA extraction was followed by the removal 
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of DNA using a DNase Treatment Removal Kit following the manufacturer’s 
instructions. cDNA was then created from 1 g of treated RNA using the First Strand 
cDNA Synthesis kit according to the manufacturer’s protocol. This was then 
followed by RT-PCR using 2 l of cDNA with Q5 DNA polymerase following the 
manufacturer’s instructions and the description of PCR given in section 2.2.3.1.  
 
2.2.3.12 Fluorescently Tagged Overexpression Vector Construction 
D. discoideum overexpressing cells were created using the N-terminal RFP tagged 
mRFPmars in pDEXH (338-19) kindly provided by Annette Müller-Taubenberger. For 
each overexpressing construct, RNA was extracted from WT cells, treated with 
DNase and used to synthesise cDNA as described in section 2.2.3.12. RT-PCR was 
then conducted using primers targeting the start and end of the coding sequence of 
the gene of interest. To these primers, restriction sites were added which 
corresponded to sites present in the N-terminal RFP tagged mRFPmars in pDEXH 
vector, to enable cloning. These primers were used to amplify the gene of interest 
using 2 l of cDNA and the Q5 DNA polymerase following the manufacturer’s 
protocol and as described in section 2.2.3.1. Gel electrophoresis was conducted on 
a portion of the sample to confirm PCR efficiency. PCR products were then purified 
using the Qiagen QIAquick PCR Purification kit. The overexpressing vector and gene 
fragments were then digested in the presence of the two relevant restriction 
enzymes whose cut sites were present in the cDNA PCR product. Gel 
electrophoresis was conducted on a portion of the sample to confirm efficiency of 
the digest. This was followed by ligating the PCR fragment into the overexpressing 
vector and transforming the ligated recombinant plasmid into chemically competed 
E. coli cells as described in section 2.2.3.4. The recombinant plasmid was then 
purified from E. coli cells using the Qiagen HiSpeed Plasmid Purification kit 
according the manufacturer’s instructions. The concentration of the purified 
plasmid was determined using a nanodrop. The purified plasmid was then 
sequenced by MWG-Biotech to ensure no errors were present in the gene 
sequence.  
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2.2.3.13 D. discoideum Overexpression Vector Transformation by Electroporation 
The overexpressing construct was then electroporated into Ax2 WT cells to create 
overexpressing cells or into dgkA- cells to produce a rescue cell line. D. discoideum 
cells (1x107) were incubated for 10 minutes on ice prior to being centrifuged    
(1500 g for 3 minutes). Cells were then washed twice in phosphate buffer followed 
by washing in sterile filtered electroporation buffer (20 mM HEPES, 50 mM 
potassium chloride, 10 mM sodium chloride, 1 mM magnesium sulphate, 5 mM 
sodium bicarbonate and 1 mM monosodium phosphate). The resulting cell pellet 
was resuspended in 20 g overexpressing plasmid prior to being transferred to a 
0.2 cm electroporation cuvette and incubated on ice for 10 minutes. D. discoideum 
cells were then electroporated using a Bio-Rad GenePulser Xcell electroporator 
using 2 pulses with 15 seconds rest in between, 25 μF and 850 V. This was followed 
by a further incubation in ice (10 minutes) before the cells were transferred to      
10 ml axenic media spiked with 0.1 % PenStrep. Cells were then incubated at 22 °C 
for 24 hours. This was followed by the addition of 10 μg/ml G418 (geneticin) or 
hygromycin to select for transformant cells and incubated at 22 °C for 2 weeks. 
Transformant cell lines were analysed using fluorescence microscopy. 
 
2.2.4 Proteomic Protocols 
2.2.4.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis  
Each SDS gel was produced using the following: resolving gel (12.5 %) containing: 2 
ml Protogel 30 % solution, 1.25 ml 1.5 M Tris pH 8.8, 50 l 10 % SDS, 50 l 10 % APS 
and 2 l TEMED made up to 5 ml with double distilled water; and stacking gel 
containing: 167.5 l Protogel 30 % solution, 250 l 0.5 M Tris pH 6.8, 10 l 10 % 
SDS, 10 l 10 % APS, 1 l TEMED and 925 l double distilled water. Sample loading 
dye (5 X) contained 0.001 g bromophenol blue, 30 ml 2 X Laemeli sample buffer, 3 
ml 2-mercaptoethanol, 6 ml 100 % glycerol, 7.5 ml Tris-HCl pH 7.5 and 12 ml 10 % 
SDS made up to 30 ml with double distilled water. 
 
Protein samples to be run on the SDS gel were prepared by pelleting 1.5x106 cells 
per sample by centrifugation (1500 g, 3 minutes). The cell pellet was resuspended 
in protein loading dye (20 l per sample) and boiled at 98 °C for 6.5 minutes. The 
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protein ladder PageRuler Plus Pre-stained Protein Ladder and protein samples were 
loaded into the stacking gel and run in the presence of 1 X running buffer diluted in 
double distilled water (stock 10 X running buffer contained 144 g glycine, 30 g Tris 
base, 100 ml SDS made up to a total volume of 1000 ml with double distilled water) 
at 69 V for 30 minutes, followed by 100 V for 1 hour.  
 
2.2.4.2 Western Blotting 
Once the proteins were separated, the SDS gel was blotted onto a methanol 
activated PDVF membrane. Both PDVF membrane, blotting paper (3 mm) and 
sponges were incubated in transfer buffer. The transfer buffer comprised of 10 % 
methanol and 10 X ETB buffer (10 X ETB buffer contained: 360 g glycine, 75 g Tris 
base and 10 % SDS) and 800 ml double distilled water. Protein transfer occurred by 
placing the transfer blot into a tank containing a magnetic stirring bar and ice-cold 
transfer buffer and running the transfer on a magnetic stirrer at 15 V for 16 hours.  
 
Proteins were visualised by immunostaining the membrane for 16 hours at 4 °C 
with appropriate antibodies (Streptavidin (MccA), 6G6-RFP and 3H9-GFP) at a 
1:1000 dilution. The membrane was then washed with TBS-T prior to an hour 
shaking incubation in the dark in the relevant secondary antibody (anti-rat or anti-
mouse) diluted 1:10000. The secondary antibody was then washed away with TBS-
T. Proteins on the membrane were visualized using the Odyssey CLx (LI-COR 
Biosciences).  
2.3 Statistics 
Growth assays and acute cell behaviour assays were analysed using the Kruskal- 
Wallis test and Dunn’s post hoc test which compared the differences between WT 
and mutant cell lines at each VPA concentration. This test was used as all sample 
sets compared are independent of each other and the data was not normally 
distributed. 
 
DAG ELISA assay was analysed using the Mann-Whitney test which compared 
differences between cell lines in the presence of each drug. This test was used as 
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the samples compared are independent of each other and the data is not normally 
distributed.  
2.4 Software 
Development assay results were analysed using QCapture Pro 6.0 (QImaging). 
ELISA plates were analysed using SoftMax Pro 5.4.1 (Molecular Devices). 
Graphical images and statistical analysis was conducted using Prism 7 (GraphPad).  
Phylogenetic trees were created using Molecular Evolutionary Genetic Analysis 
(MEGA) 7 (Mega Software).  
Acute cell behaviour assays were recorded using Image-Pro 6.3 (Media Cybernetics) 
and analysed using ImageJ 1.48 g (National Institute of Health) using the QiumP    
11 b software (University of Warwick) and MATLAB R2011 b (Mathworks).  
Western blot membranes images were obtained using Image Studio Version 5.2 (LI-
COR Biosciences). 
2.5 Websites 
2.5.1 Information of D. discoideum Gene and Protein 
www.dictybase.org 
www.uniprot.org 
https://dictyexpress.research.bcm.edu  
 
2.5.2 Basic Local Alignment Tool (BLAST) 
http://blast.ncbi.nlm.nih.gov/Blast.cgi  
www.dictybase.org/tools/blast 
   
2.5.3 Alignment of Protein Sequences 
www.ebi.ac.uk/Tools/msa/clustalo/  
https://bioinformatics.org/sms/multi_align.html  
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2.5.4 Gene and Protein Information of Organisms 
www.uniprot.org 
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3. Analysis of PI3K1-5/PTEN, PLC and 
LPIN2 as a Target of VPA 
Studies have shown VPA lowers phosphoinositide levels (Chang, et al., 2012; Chang, 
Walker and Williams, 2014). This mechanism of action is of interest as seizure 
generation has been linked with PTEN and the PI3K/PIP3/Akt pathway (Backman, et 
al., 2001; Shinoda, 2004). To investigate this further, 4 potential VPA targets (PI3K, 
PTEN, PLC and LPIN2) were examined using knockout mutants to test for reduced 
VPA sensitivity, with all 4 proteins having roles in phosphoinositide regulation 
(Figures 1.4 and 3.1). Within this chapter, D. discoideum knockout mutants of all 5 
PI3K and PTEN (PIKA, PIKB, PIKC, PIKF, PIKG, PTEN, pi31-5-/pten-), PLC (plc-) and 
LPIN2 (lpin2-) have been investigated as potential targets of VPA. This begun with 
investigating pi3k1-5-/pten- cells. PIP2 can be phosphorylated into PIP3 by PI3K, with 
the reverse reaction catalysed by PTEN (Figures 3.1 and 3.2). Both the forward and 
reverse reactions of the conversion of PIP2 and PIP3 are essential due to the range 
of pathways regulated. PIP3 activates a range of cellular responses including mitosis 
(Fantl, et al., 1992), chemotaxis (Wennstroem, et al., 1994), actin reorganisation 
(Arcaro and Wymann, 1993), oxidative stress, glucose uptake (Hara, et al., 1994; 
Okada, et al., 1994) and cell growth and survival through Akt (Burgering and Coffer, 
1995; Franke, et al., 1995).  
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Figure 3.1. The role of PI3K, PTEN and LPIN2 in phosphoinositide regulation. Schematic of 
the phosphatidylinositol (PI) salvage pathway (black arrows) and interlinking enzymes (red). 
Within the PI salvage pathway, diacylglycerol (DAG) phosphorylated into phosphatidic acid 
(PA) by DAG kinase (DGK). Cytidine diphosphate- diacylglycerol (CDP-DAG) is produced 
from PA using the enzyme CDP-DAG synthase (CDS). PI is then synthesized from CDP-DAG 
and myo-inositol. PI then undergoes a 2-step phosphorylation reaction to produce 
phosphatidylinositol-4,5-bisphosphate (PIP2). From this pathway, PI-3-kinase (PI3K) 
phosphorylates PIP2 to produce PI-3,4,5-triphosphate (PIP3). PIP3 is dephosphorylated into 
PIP2 by phosphatase and tensin homolog (PTEN). PA can be dephosphorylated into DAG by 
phosphatidate phosphatase LPIN2 (LPIN2). 
 
 
Figure 3.2. The catalytic activity of phosphatidylinositol-4,5-bisphosphate-3-kinase and 
phosphatase and tensin homolog. Phosphorylation of phosphatidylinositol-4,5-
bisphosphate (PIP2) by phosphatidylinositol-4,5-bisphosphate-3-kinase (PI3K) results in the 
generation of phosphatidylinositol-3,4-,5-triphosphate (PIP3). This reaction is reversed by 
the phosphatase and tensin homolog (PTEN). 
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PLC is a protein of interest as VPA has been shown to reduce PIP2 levels (Chang, et 
al., 2012). PLC has the role of diminishing PIP2 signalling by hydrolysis into IP3 and 
DAG (Figures 3.1 and 3.3). Both reaction products, IP3 and DAG, are important 
signalling molecules involved in a range of biological pathways. IP3 stimulates a rise 
in intracellular calcium concentration, which has been linked with epileptogenesis 
(Berridge, 1983; Streb, et al., 1983; Alswied and Parekh, 2015). DAG is involved in 
the signalling of PKC (van Baal, et al., 2005), synaptic plasticity (Lee, Kim and 
Tanaka-Yamamoto, 2016) and triglyceride synthesis (Dahlqvist, et al., 2000). Both 
IP3 and DAG have been implicated in epilepsy (Yoshida, et al., 1987;  Carmant, et al., 
1995; Tokuoka, Saiardi and Nurrish, 2008) and BD (Drummond and Raeburn, 1984;  
Brami, Leli and Hauser, 1993; Sade, et al., 2016). A loss-of-function point mutation 
in PLC has been identified in an epilepsy patient (Kurian, et al., 2010). Therefore, 
PLC was investigated as a potential target of VPA. 
 
 
Figure 3.3. The catalytic activity of phospholipase C. Phospholipase C (PLC) is responsible 
for the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) into inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). 
 
LPIN2 is a protein of interest due to its role in catalysing the formation of DAG from 
the dephosphorylation of PA (Figure 3.1 and 3.4), thereby being a key regulator in 
lipid homeostasis. PA is an important signalling molecule with a range of roles 
including cell growth and signalling (Banfić, et al., 1993; Cerbón, et al., 2005), 
glucose metabolism and lipid regulation (Milne, et al., 2008). The role of PA in 
regulating lipids and therefore potentially PIP2, means LPIN2 may be a target of 
VPA.  
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Figure 3.4. The catalytic activity of lpin2. Lpin2 (also referred to as phosphatidate 
phosphatase lpin2, lipin-2) is responsible for the dephosphorylation of phosphatidic acid 
(PA) into diacylglycerol (DAG). 
 
This chapter, therefore, describes the phenotypic characterization of pi3k1-5-/pten-, 
plc- and lpin2- cells in both the absence and presence of VPA during acute cell 
behaviour and development. In addition, other anti-seizure compounds and the BD 
treatment LiCl have been investigated during development to determine whether 
the mechanism of action of these drugs is similar to that of VPA.  
3.1 pi3k1-5-/pten- Cells 
D. discoideum has 5 PI3K gene isoforms, PikA (DDB_G0278727), PikB 
(DDB_G0283081), PikC (DDB_G0275011), PikF (DDB_G0268548) and PikG 
(DDB_G0282625) and one Pten gene. Both PI3K and PTEN in D. discoideum are 
expressed during the developmental phase (Hoeller and Kay, 2007; Parikh, et al., 
2010; Stajdohar, et al., 2015). The 5 D. discoideum PI3K enzymes have similar 
identity to the H. sapiens proteins (Supplementary Table S2). PI3K are divided into 
3 classes, where class-I synthesise PI-3-phosphate and are either catalytic or 
regulatory proteins, class-II produce PI-3,4-bisphosphate and class-III catalyse PIP3 
production (Jean and Kiger, 2014). PikA has highest identity to H. sapiens class-II 
Pik3c2b (40 %, E-value 5e-135), PikB to class-I catalytic Pik3cg (43 %, E-value 5e-138), 
PikC to class-I catalytic Pik3cb (37 %, E-value 1e-129), PikF to class-II Pik3c2b (40 %, E-
value 1e-136) and PikG to class-III Pik3c2g (48 %, E-value 2e-88). There was also 
similar identity (55 %) between the D. discoideum and H. sapiens PTEN proteins (E-
value 9e-81), suggesting a similar catalytic role for both of these enzymes in the two 
organisms.  
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In 2007 Hoeller and Kay deleted all 5 PI3K and PTEN from Ax2 D. discoideum 
parental cells, thereby blocking the reversible reaction of PIP2 to PIP3. This resulted 
in pi3k1-5-/pten- cells. The pi3k1-5-/pten- cells have been phenotypically 
characterized through a series of experiments and compared with WT cells in both 
the absence and presence of VPA during acute cell behaviour and to a range of anti-
seizure compounds and a BD drug during development.  
 
3.1.1 Analysis of pi3k1-5-/pten- Acute Cell Behaviour in the Presence of VPA 
Since the genes encoding PI3K and PTEN are expressed during early development, 
acute cell behaviour was investigated. VPA is known to inhibit D. discoideum acute 
cell behaviour (Xu, et al., 2007) and therefore, the effects of VPA on pi3k1-5-/pten- 
cells was investigated. For this assay, cells were pulsed with cAMP for 5 hours to 
enable them to enter early development. Time-lapse microscopy was then 
conducted where computer-generated cell outlines detected variations in 
displacement (the shortest distance a cell travel between 2 points), circularity (cell 
shape, with an arbitrary value of “1” given to round cells), membrane protrusions 
and motility (speed) (Figure 3.5A). Initial differences in cell behaviour was 
determined by a control period of 225 seconds prior to VPA treatment (ranging 
from 0.01 mM-0.7 mM) for 525 seconds (Table 3.1 and Figures 3.5B- 3.5E). Under 
control conditions with no VPA added, no significant differences were identified 
between WT and pi3k1-5-/pten- cells, which behaved in a similar manner for 
displacement at 750 seconds and average circularity, membrane protrusions and 
motility within the final 300 seconds of the assay. In the presence of VPA, both cell 
lines had a dose-dependent reduction in acute cell behaviour. However, significant 
differences were detected between WT and pi3k1-5-/pten- cells when exposed to 
0.3 mM (P value 0.0059) and 0.5 mM (P value <0.0001) VPA for displacement and 
when exposed to 0.5 mM VPA only for circularity (P value 0.001) and membrane 
protrusions (P value 0.0016).  
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Cell 
Line 
[VPA] (mM) VPA 
IC50 
Value 
(mM) 
Control 0.01 0.1 0.3 0.5 0.7 
Displacement (m)  
WT 67.2  
 4.2 
70.9 
 3.2 
58.7 
 4.3 
47.3 
 3.3 
40.0 
 3.5 
46.5 
 2.9 
0.4 
 0.08 
pi3k1-5-
/pten- 
85.1 
 4.7 
84.3 
 3.7 
60.8 
 2.9 
59.9 
 2.3 
62.3 
 3.8 
54.1 
 3.1 
0.8  
 0.18 
Circularity  
WT 0.71 
 0.004 
0.67 
 0.004 
0.73 
 0.004 
0.85 
 0.004 
0.90 
 0.001 
0.88 
 0.004 
- 
pi3k1-5-
/pten- 
0.58 
 0.004 
0.55 
 0.004 
0.66 
 0.003 
0.86 
 0.002 
0.83 
 0.003 
0.89  
 0.002 
- 
Protrusions  
WT 8.7 
 0.13 
9.0 
 0.07 
5.8 
 0.17 
3.6 
 0.05 
1.5  
 0.06 
1.7 
 0.07 
0.2  
 0.05 
pi3k1-5-
/pten- 
7.7 
 0.07  
10.0 
 0.04 
7.4 
 0.08 
5.1 
 0.06 
5.1 
 0.03 
3.6 
 0.07 
0.4  
 0.06 
Motility (m/sec)  
WT 0.013 
 0.0009 
0.016 
 0.0009 
0.010 
 
0.0005 
0.004 
 
0.0006 
0.003 
 
0.0002 
0.002 
 
0.0003 
0.1 
 0.01 
pi3k1-5-
/pten- 
0.018 
 
 0.0007 
0.022 
  
0.0006 
0.012 
 
0.0006 
0.004 
 
0.0007 
0.004 
 
0.0006 
0.003 
 
0.0005 
0.1 
 0.06 
 
Table 3.1. WT and pi3k1-5-/pten- changes in acute cell behaviour in both the absence and 
presence of VPA. Comparison of WT (Ax2) and pi3k1-5-/pten- acute cell behaviour values of 
total displacement during the assay and average circularity, protrusions and motility within 
the final 300 seconds. The calculated IC50 values are shown to the right of the table for each 
cell line for displacement, number of protrusions and motility. Data presented as mean (+/- 
SEM). n = 30.  
 
The response of WT and pi3k1-5-/pten- cells to increasing VPA concentrations is also 
shown in the secondary plots for displacement (Figure 3.5F), circularity (Figure 
3.5G), membrane protrusions (Figure 3.5H) and motility (Figure 3.5I). Both cell lines 
had a reduction in displacement, membrane protrusions and motility with 
increasing VPA concentration, which was correlated with an increase in circularity, 
although the extent of VPA sensitivity on pi3k1-5-/pten- cells was not as potent as 
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WT. As the pi3k1-5-/pten- cells are more resistant to VPA during displacement and 
protrusion formation compared with WT cells, these results suggest a role for PI3K 
and PTEN in the mechanism of action of VPA during acute cell behaviour.  
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 Figure 3.5. WT and pi3k1-5-/pten- acute 
cell behaviour in both the absence and 
presence of VPA. (A) Schematic of the 
quantitative measurements taken 
during the assay where the black dashed 
arrows represent the measurement 
being taken for the primary data (B) 
displacement, (C) circularity, (D) 
normalized percentage of membrane 
protrusions and (E) motility for WT (Ax2) 
(left) and pi3k1-5-/pten- (middle) cells. 
Secondary plot data for (F) 
displacement, (G) circularity, (H) 
membrane protrusions and (I) motility 
with WT shown in black circles and 
pi3k1-5-/pten- shown in blue squares 
(right). P value: * P value =  0.05, ** P 
value =  0.01 and **** P value =   
 0.0001. Data presented as mean (+/- 
SEM) n =30 cells
Chapter 3   Analysis of PI3K1-5/PTEN, PLC and LPIN2 as a Target of VPA 
 75 
3.1.2 Analysis of pi3k1-5-/pten- Cell Development in the Presence of VPA 
VPA is known to inhibit the D. discoideum developmental cycle, a process whereby 
starved cells migrate together to form multicellular fruiting bodies over 24 hours 
(Williams, et al., 2002). To examine if VPA functions through a PI3K/PTEN 
dependent mechanism, cell development was investigated using WT and  
pi3k1-5-/pten- cells in the absence (control) and presence of VPA (0.3 mM-1 mM) 
(Figure 3.6). Under control conditions, both WT and pi3k1-5-/pten- cells were able 
to develop into multicellular fruiting bodies containing a basal disc, stalk and spore 
head of similar sizes. In the presence of 0.3 mM and 0.5 mM VPA, both cell lines 
developed into finger structures. When exposed to 1 mM VPA, both cell lines 
developed into mounds. These results suggest that neither of the 5 D. discoideum 
PI3K nor PTEN are targets of VPA during development.  
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Figure 3.6. WT and pi3k1-5-/pten- development in both the absence and presence of VPA.  
WT (Ax2) (left) and pi3k1-5-/pten- (right) cells were developed on nitrocellulose membranes 
for 24 hours in both the absence (top row) and presence (descending rows) of 0.3 mM, 0.5 
mM and 1 mM VPA. Images were taken of an overhead view (left) of the whole membrane 
and of a single fruiting body (right). Fruiting bodies developed in both cell lines in the 
absence of VPA and developed into fingers in the presence of 0.3 mM and 0.5 mM and into 
mounds in the presence of 1 mM VPA. n = 3. Scale bar of the overhead view represents 0.5 
mm and of the side view 0.1 mm. 
 
Chapter 3   Analysis of PI3K1-5/PTEN, PLC and LPIN2 as a Target of VPA 
 77 
3.1.3 Analysis of pi3k1-5-/pten- Cell Development in the Presence of Anti-Seizure 
Compounds and LiCl 
The pi3k1-5-/pten- cells were then investigated as a potential target of other anti-
seizure compounds and the BD treatment LiCl. The compounds tested have 
previously been shown to effect D. discoideum and in vivo epilepsy model growth, 
development and phosphoinositide and inositol phosphate signalling (Williams, et 
al., 1999; Williams, et al., 2002; Ludtmann, Boeckeler and Williams, 2011; Chang, et 
al., 2012; Chang, et al., 2013; Chang, Walker and Williams, 2014; Chang, et al., 
2015; Chang, et al., 2016). In these experiments, cells were starved for 24 hours on 
nitrocellulose filters to induce development in the absence (control) and presence 
of a range of compounds at concentrations which blocked fruiting body 
development in WT cells (Figure 3.7). VPA structurally related epilepsy compounds 
VPD (6.5 mM) and PIA (1.4 mM) (Eickholt, et al., 2005; Ludtmann, Boeckeler and 
Williams 2011; Elphick, et al., 2012) were tested, as well as key components of the 
MCT diet DA (1.65 mM) and OA (0.22 mM) (Chang, et al., 2012; Chang, et al., 2013; 
Chang, et al., 2016). A branched chain compound, 4-EOA (0.5 mM), with known 
seizure control and neuroprotective effects was also tested (Chang, et al., 2013; 
Chang, et al., 2015). As a negative control, a compound which does not control 
seizures, 2-MHA (0.5 mM), was tested (Chang, et al., 2012). Under control 
conditions with no drug added, both WT and pi3k1-5-/pten- were able to develop 
into mature fruiting bodies after 24 hours of starvation. In the presence of all 
compounds tested, including LiCl, both WT and pi3k1-5-/pten- cells developed into 
fingers, slug or mounds. These results suggest that the mechanism of action of 
these compounds in D. discoideum does not involve the 5 PI3K or PTEN.  
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Figure 3.7. WT and pi3k1-5-/pten- development in both the absence and presence of a 
range of other compounds.  WT (Ax2) (left) and pi3k1-5-/pten- (right) cells were developed 
on nitrocellulose membranes for 24 hours in both the absence (top row) and presence 
(descending rows) of VPD, PIA, DA, OA, 4-EOA, 2-MHA and LiCl at the stated concentrations 
to the left of the development images. Images were taken of an overhead view of the 
whole membrane (left) and of a single fruiting body (right). Both cell lines developed into 
fruiting bodies in the absence of any compound. In the presence of VPD, PIA, DA, OA, 4-
EOA, 4-MOA and LiCl both WT and pi3k1-5-/pten- cells developed to the mound stage.          
n = 3. Scale bar of the overhead view represents 0.5 mm and of the side view 0.1 mm. 
Chapter 3   Analysis of PI3K1-5/PTEN, PLC and LPIN2 as a Target of VPA 
 79 
3.2 plc- Cells 
D. discoideum has one Plc isoform (DDB_G0292736), with peak expression during 
the developmental cycle (Drayer, et al., 1994; Parikh, et al., 2010; Stajdohar, et al., 
2015). Of the 11 H. sapiens PLC isoforms, D. discoideum PLC has highest identity to 
PLC1 (45 %, E-value 4e-43) (Supplementary Table S3), suggesting both the D. 
discoideum and H. sapiens PLC enzymes have a similar catalytic role. In 1994 Drayer 
et al deleted PLC from Ax3 parental cells, thereby blocking the hydrolysis of PIP2 
into IP3 and DAG, resulting in plc- cells. Through a series of experiments, plc- cells 
have been phenotypically characterized and compared with WT in both the 
absence and presence of VPA during acute cell behaviour and to a range of anti-
seizure compounds and the BD drug LiCl during D. discoideum development.  
 
3.2.1 Analysis of plc- Acute Cell Behaviour in the Presence of VPA 
As peak PLC expression is during the developmental cycle, acute cell behaviour of 
starved plc- cells in both the absence and presence of VPA was investigated. This is 
because VPA is known to inhibit D. discoideum cell movement (Xu, et al., 2007). In 
this assay, cells were pulsed for 5 hours with cAMP to stimulate cells to enter early 
development. Time lapse microscopy was then employed in which computer-
generated cell outlines detected changes in cell displacement (the shortest distance 
a cell travels between 2 points), circularity (cell shape, with an arbitrary value of “1” 
given to round cells), membrane protrusions and motility (speed) (Figure 3.8A). A 
control period of 225 seconds prior to VPA treatment (ranging from 0.01 mM-0.7 
mM) for 525 seconds was used to determine any initial differences in cell behaviour 
(Table 3.2 and Figures 3.8B- 3.8E). No significant differences (P values over 0.05) 
were identified between WT and plc- cells in the absence of VPA for displacement, 
circularity, membrane protrusions and motility. In the presence of VPA, both cell 
lines had a dose-dependent reduction in acute cell behaviour (displacement, 
circularity, membrane protrusions and motility) with no significant differences 
being identified.  
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Cell 
Line 
[VPA] (mM) VPA 
IC50 
Value 
(mM) 
Control 0.01 0.1 0.3 0.5 0.7 
Displacement (m)  
WT 115.4  
 5.7  
116.3  
 7.1  
70.8  
 4.1  
62.9 
 3.1 
65.1  
 3.0  
62.1  
 3.6  
0.4  
 0.12 
plc- 112.2 
 8.8  
114.3  
 8.3  
84.0 
 5.2  
74.7 
 3.6  
68.9 
 4.0 
62.1 
 3.2  
0.4 
 0.07 
Circularity  
WT 0.76 
 0.005  
0.70  
 0.003 
0.74 
 0.005 
0.89 
 0.005 
0.89 
 0.002 
0.86 
 0.005 
- 
plc- 0.65  
 0.005  
0.64 
 0.006 
0.78 
 0.006 
0.88 
 0.003 
0.87 
 0.004 
0.86 
 0.005 
- 
Protrusions  
WT 7.5  
 0.07  
8.8  
 0.07  
8.4  
 0.03  
5.0  
 0.08  
3.9  
 0.05  
2.6  
 0.06  
0.4 
 0.03 
plc- 7.2  
 0.09  
7.8  
 0.10  
8.4  
 0.08  
5.0  
 0.09 
3.1 
 0.13  
2.6  
 0.06 
0.4 
 0.04 
Motility (m/sec)  
WT 0.021 
  
0.0016 
0.021  
 
0.0013 
0.012 
  
0.0008 
0.007 
  
0.0007 
0.006 
  
0.0006 
0.003 
  
0.0005 
0.2 
 0.06 
plc- 0.030 
  
0.0015 
0.030 
  
0.0018 
0.019 
  
0.0016 
0.008 
 
0.0008  
0.004 
  
0.0006 
0.003 
  
0.0005 
0.1 
 0.01 
 
Table 3.2. WT and plc- changes in acute cell behaviour in both the absence and presence 
of VPA. Comparison of WT (Ax3) and plc- acute cell behaviour values of total displacement 
during the assay and average circularity, protrusions and motility within the final 300 
seconds. The calculated IC50 values are shown to the right of the table for each cell line for 
displacement, number of protrusions and motility. Data presented as mean (+/- SEM). n = 
30.  
 
The similarity in response to VPA of WT and plc- cells to displacement (Figure 3.8F), 
circularity (Figure 3.8G), membrane protrusions (Figure 3.8H) and motility (Figure 
3.8I) is shown in the secondary plots, where the curves for the two cell lines 
overlap. The similarity in response to VPA for the two cell lines is also shown by the 
calculated IC50 values for WT and plc- cells (Table 3.2).  
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 Figure 3.8. WT and plc- acute cell 
behaviour in both the absence and 
presence of VPA. (A) Schematic of 
the quantitative measurements 
taken during the assay where the 
black dashed arrows represent the 
measurement being taken for the 
primary data (B) displacement, (C) 
circularity, (D) membrane 
protrusions and (E) motility for WT 
(Ax3) (left) and plc- (middle) cells. 
Secondary plot data for (F) 
displacement, (G) circularity, (H) 
membrane protrusions and (I) 
motility with WT shown in black 
circles and plc- shown in blue 
squares (right). Data presented as 
mean (+/- SEM) n =30 cells. 
 
Chapter 3   Analysis of PI3K1-5/PTEN, PLC and LPIN2 as a Target of VPA 
 82 
3.2.2 Analysis of plc- Cell Development in the Presence of VPA 
As VPA is known to inhibit the development of multicellular fruiting bodies within 
24 hours (Williams, et al., 2002), D. discoideum development was investigated using 
WT and plc- cells in the absence (control) and presence of VPA (0.3 mM-1 mM) 
(Figure 3.9). In the absence of VPA, both WT and plc- cells were able to develop into 
similar sized multicellular fruiting bodies containing a basal disc, stalk and spore 
head. In the presence of 0.3 mM and 0.5 mM VPA, WT cells developed into finger 
structures, whereas plc- cells developed into mounds. In the presence of 1 mM VPA, 
both cell lines developed into mounds, suggesting plc- cells are more sensitive to 
VPA compared with WT cells during development.  
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Figure 3.9. WT and plc- development in both the absence and presence of VPA. WT (Ax3) 
(left)) and plc- (right) cells were developed on nitrocellulose membranes for 24 hours in 
both the absence (top row) and presence (descending rows) of 0.3 mM, 0.5 mM and 1 mM 
VPA. Images were taken of an overhead view (left) of the whole membrane and of a single 
fruiting body (right). Fruiting bodies developed in both cell lines in the absence of VPA and 
developed into either fingers or mounds in the presence of 0.3 mM, 0.5 mM and 1 mM 
VPA. n = 3. Scale bar of the overhead view represents 0.5 mm and of the side view 0.1 mm. 
 
3.2.3 Analysis of plc- Cell Development in the Presence of Anti-Seizure Compounds 
and LiCl 
PLC was then investigated as a potential target of other anti-seizure compounds 
and the BD treatment LiCl. These compounds were investigated during 
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development, which was induced by starving cells for 24 hours on nitrocellulose 
filters in both the absence (control) and presence of a range of treatments at 
concentrations which blocked fruiting body development in WT cells (Figure 3.10). 
The anti-seizure compounds tested were VPD (6.5 mM), PIA (1.4 mM), DA (1.65 
mM), OA (0.22 mM), 4-EOA (0.5 mM) and 2-MHA (0.5 mM) (Eickholt, et al., 2005; 
Ludtmann, Boeckeler and Williams 2011; Elphick, et al., 2012; Chang, et al., 2012; 
Chang, et al., 2013; Chang, et al., 2015; Chang, et al., 2016). Both WT and plc- cells 
developed into mature fruiting bodies after 24 hours of starvation under control 
conditions. In the presence of all compounds tested, both WT and plc- cells 
developed into finger or mound structures respectively, suggesting that the 
mechanism of action of these compounds does not involve PLC in D. discoideum. 
These results suggest that plc- cells are more sensitive to the anti-seizure 
compounds tested here and LiCl, compared with WT. 
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Figure 3.10. WT and plc- development in both the absence and presence of a range of 
other compounds.  WT (Ax3) (left)) and plc- (right) cells were developed for 24 hours on 
nitrocellulose membranes both in the absence (top row) and presence (descending rows) 
of VPD, PIA, DA, OA, 4-EOA, 2-MHA and LiCl at the stated concentrations to the left of the 
development images. Images were taken of an overhead view of the whole membrane 
(left) and of a single fruiting body (right). Both cell lines developed into fruiting bodies in 
the absence of any compound. In the presence of VPD, PIA, DA, OA, 4-EOA, 4-MOA and LiCl 
both WT and plc- cells developed to the finger or mound stage. n = 3. Scale bar of the 
overhead view represents 0.5 mm and of the side view 0.1 mm. 
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3.3 lpin2- Cells 
There is one Lipin isoform in D. discoideum, Lpin2 (DDB_G0271730), which has peak 
expression during the vegetative phase and at the latter stages of the 
developmental cycle (Parikh, et al., 2010; Stajdohar, et al., 2015). D. discoideum 
LPIN2 has 33 % identity (E-value 4e-86) to the LPIN2 H. sapiens isoform 
(Supplementary Table S4), suggesting a similar catalytic role for this enzyme in 
both organisms. LPIN2 was ablated in Ax2 cells by Markus Maniak, thereby blocking 
the dephosphorylation of PA into DAG, resulting in lpin2- cells. The lpin2- cells have 
been phenotypically characterized and compared with WT in both the absence and 
presence of VPA during acute cell behaviour and to a range of anti-seizure 
compounds and a BD drug during D. discoideum development.  
 
3.3.1 Analysis of lpin2- Acute Cell Behaviour in the Presence of VPA 
Acute cell behaviour of lpin2- cells was investigated due to high protein expression 
during the developmental cycle. This is because VPA is known to inhibit D. 
discoideum cell movement (Xu, et al., 2007). In this assay, cells were pulsed for 5 
hours with cAMP to stimulate cells to enter early development, which was followed 
by time-lapse microscopy. Changes in cell displacement (the shortest distance a cell 
travels from point A to B), circularity (cell shape, with an arbitrary value of “1” given 
to round cells), membrane protrusions and motility (speed) were then determined 
in both the absence and presence of VPA (Figure 3.11A). A control period of 225 
seconds prior to VPA treatment (ranging from 0.01 mM-0.7 mM) for 525 seconds 
was used to determine any initial differences in cell behaviour (Table 3.3 and 
Figures 3.11B- 3.11E). No significant differences (P value above 0.05) were 
identified between WT and lpin2- cells under control conditions with no VPA 
treatment, for displacement, circularity and membrane protrusions. However, 
there was a significant difference in motility (P value 0.01) between the two cell 
lines in the absence of VPA. This result suggests that LPIN2 has a role in cell 
motility. In the presence of VPA, both cell lines had a dose-dependent reduction in 
acute cell behaviour (displacement, circularity, membrane protrusions and 
motility), with a significant difference identified for displacement in the presence of 
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0.1 mM VPA (P value 0.027). These results suggest that LPIN2 is not a target of VPA 
during acute cell behaviour.   
 
Cell 
Line 
[VPA] (mM) VPA 
IC50 
Value 
(mM) 
Control 0.01 0.1 0.3 0.5 0.7 
Displacement (m)  
WT 75.6  
 5.2  
71.2  
 4.0 
60.7 
 3.2  
55.6 
 3.0 
42.5  
 2.1  
38.5 
 1.8  
0.6 
 0.03 
lpin2- 68.0  
 3.2  
73.8 
 5.2  
49.0 
 3.6  
52.1 
 1.8  
50.8 
 3.7 
48.2 
 2.2  
1.3 
 0.3 
Circularity  
WT 0.67 
 0.004 
0.71 
 0.003 
0.81 
 0.004 
0.86 
 0.003 
0.91 
 0.002 
0.92 
 0.002 
- 
lpin2- 0.70 
 0.003  
0.62 
 0.003 
0.73 
 0.003 
0.79 
 0.003 
0.84 
 0.003 
0.89 
 0.001 
- 
Protrusions  
WT 7.6  
 0.04  
6.9  
 0.09 
4.4 
  0.07 
4.3 
 0.06 
2.4 
 0.03 
1.4 
 0.06 
0.3 
 0.11 
lpin2- 8.4 
 0.10 
9.0 
 0.08  
6.6 
 0.05 
5.7 
 0.06 
4.5 
 0.05 
3.9 
 0.12 
0.5 
 0.06 
Motility (m/sec)  
WT 0.019 
  
0.0004 
0.016 
  
0.0007 
0.007 
  
0.0007 
0.005 
  
0.0006 
0.003 
 
0.0003  
0.002 
 
0.0003  
0.1 
 0.09 
lpin2- 0.009 
  
0.0006 
0.016 
  
0.0009 
0.008 
  
0.0006 
0.008 
  
0.0004 
0.006 
  
0.0007 
0.004 
 
0.0005  
0.2 
 0.15 
 
Table 3.3. WT and lpin2- changes in acute cell behaviour in both the absence and 
presence of VPA. Comparison of WT (Ax2) and lpin2- acute cell behaviour values of total 
displacement during the assay and average circularity, protrusions and motility within the 
final 300 seconds. The calculated IC50 values are shown to the right of the table for each cell 
line for displacement, number of protrusions and motility. Data presented as mean (+/- 
SEM). n = 30.  
 
The similarity in response to VPA between WT and lpin2- cells to displacement 
(Figure 3.11F), circularity (Figure 3.11G), membrane protrusions (Figure 3.11H) and 
motility (Figure 3.11I) is shown in the secondary plots. The extent of VPA inhibition 
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on lpin2- cells displacement, membrane protrusions and motility was not as potent 
as that on WT cells as shown in the calculated IC50 values for the two cell lines 
(Table 3.3). These results suggest that the potency of VPA on D. discoideum acute 
cell behaviour is independent of LPIN2 activity.   
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 Figure 3.11. WT and lpin2- acute cell 
behaviour in both the absence and 
presence of VPA. (A) Schematic of the 
quantitative measurements taken 
during the assay where the black 
dashed arrows represent the 
measurement being taken for the 
primary data (B) displacement, (C) 
circularity, (D) membrane protrusions 
and (E) motility for WT (Ax2) (left) and 
lpin2- (middle) cells. Secondary plot data 
for (F) displacement, (G) circularity, (H) 
membrane protrusions and (I) motility 
with WT shown in black circles and 
lpin2- shown in blue squares (right). P 
value: * P value =  0.05. Data 
presented as mean (+/- SEM) n = 30 
cells. 
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3.3.2 Analysis of lpin2- Cell Development in the Presence of VPA 
Due to the expression of LPIN2 during D. discoideum development and as previous 
studies have shown VPA to inhibit development of D. discoideum within 24 hours 
(Williams, et al., 2002), cell development was investigated. In this assay, WT and 
lpin2- cell development was compared in both the absence (control) and presence 
of VPA (0.3 mM-1 mM) (Figure 3.12). Under control conditions, both WT and lpin2- 
cells developed into multicellular fruiting bodies containing a basal disc, stalk and 
spore head of a similar size. In the presence of 0.3 mM and 0.5 mM VPA, both WT 
and lpin2- cells developed into finger structures. In the presence of 1 mM VPA, both 
cell lines developed into mounds, suggesting LPIN2 is not the target of, or regulated 
by, VPA during development.  
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Figure 3.12. WT and lpin2- development in both the absence and presence of VPA.  WT 
(Ax2) (left) and lpin2- (right) cells were developed for 24 hours on nitrocellulose 
membranes in both the absence (top row) and presence (descending rows) of 0.3 mM, 0.5 
mM and 1 mM VPA. Images were taken of an overhead view (left) of the whole membrane 
and of a single fruiting body (right). Fruiting bodies developed in both cell lines in the 
absence of VPA and developed into fingers in the presence of 0.3 mM and 0.5 mM and into 
mounds in the presence of 1 mM VPA. n = 3. Scale bar of the overhead view represents 0.5 
mm and of the side view 0.1 mm. 
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3.3.3 Analysis of lpin2- Cell Development in the Presence of Anti-Seizure Compounds 
and LiCl 
LPIN2 was also investigated as a possible target of other potential anti-seizure 
compounds and the BD treatment LiCl. D. discoideum cells were starved for 24 
hours on nitrocellulose filters in both the absence (control) and presence of a range 
of compounds at concentrations which blocked fruiting body development in WT 
cells (Figure 3.13). The compounds tested were structural derivatives of VPA, VPD 
(6.5 mM) and PIA (1.4 mM) (Eickholt, et al., 2005; Ludtmann, Boeckeler and 
Williams 2011; Elphick, et al., 2012), the main components of the MCT diet DA (1.65 
mM) and OA (0.22 mM) and two branched chain compounds, 4-EOA (0.5 mM), 
which has known neuroprotection effects and 2-MHA (0.5 mM), which does not 
control seizures and was used as a negative control (Chang, et al., 2012; Chang, et 
al., 2013; Chang, et al., 2015 Chang, et al., 2016). Both WT and lpin2- cells 
developed into mature fruiting bodies after 24 hours of starvation under control 
conditions. In the presence of all compounds tested, both WT and lpin2- cells 
developed into fingers or mounds, suggesting that the mechanism of action of 
these compounds does not involve LPIN2 in D. discoideum.  
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Figure 3.13. WT and lpin2- development in both the absence and presence of a range of 
other compounds. WT (Ax2) (left)) and lpin2- (right) cells were developed for 24 hours on 
nitrocellulose membranes both in the absence (top row) and presence (descending rows) 
of VPD, PIA, DA, OA, 4-EOA, 2-MHA and LiCl at the stated concentrations to the left of the 
development images. Images were taken of an overhead view of the whole membrane 
(left) and of a single fruiting body (right). Both cell lines developed into fruiting bodies in 
the absence of any compound. In the presence of VPD, PIA, DA, OA, 4-EOA, 4-MOA and LiCl 
both WT and lpin2- cells developed to the finger or mound stage. n = 3. Scale bar of the 
overhead view represents 0.5 mm and of the side view 0.1 mm. 
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3.4 Discussion  
Previous research determining the mechanism of action of VPA has shown the AED 
reduces phosphoinositide levels in a time and dose-dependent manner (Chang, et 
al., 2012). This chapter, therefore, reports the phenotypic characterization of D. 
discoideum knockout mutants of all 5 PI3K (PIKA, PIKB, PIKC, PIKF, PIKG) and PTEN 
(termed pi3k-/pten-), PLC and LPIN2 during acute cell behaviour and development in 
response to a range of anti-seizure compounds and the BD treatment LiCl. PI3K and 
PTEN were phenotypically characterized in response to VPA during acute cell 
behaviour and development as this has not been conducted previously.  
 
A key component of the PI salvage pathway is the signalling molecule PIP2, which 
can be phosphorylated by PI3K into PIP3 to regulate a number of signalling 
pathways. This reaction is reversible, whereby PTEN dephosphorylates PIP3 back 
into PIP2. Due to the importance of both the forward and reverse reactions,       
pi3k1-5-/pten- cells lacking all 5 D. discoideum PI3K and PTEN was created by 
Hoeller and Kay (2007). The phenotype of these cells was investigated to determine 
VPA sensitivity or resistance during acute and chronic drug exposure. During acute 
cell behaviour, pi3k1-5-/pten- cells were sensitive to VPA, although the extent of 0.5 
mM VPA inhibition on cell displacement, circularity and membrane protrusions was 
not as severe compared with WT cells. This could be due to D. discoideum PIP3 
chemotactic gradients arising at the plasma membrane. This allows the cell to 
orientate itself to external cAMP gradients, thereby enabling the cell to move 
forward. However, starvation of pi3k1-5-/pten- cells with pulsate cAMP enables the 
cells to become chemotactically competent (Hoeller and Kay, 2007). Consistent 
with previous studies, pi3k1-5-/pten- cells were able to chemoattract like WT cells 
(Hoeller and Kay, 2007), suggesting cell displacement and membrane protrusions 
would also be similar to WT, as it is the protrusions which enables the cell to move 
towards a cAMP gradient. In contrast, it has previously been reported that pi3k1-5-
/pten- cells had a 36 % reduction in motility compared with WT cells (Hoeller and 
Kay, 2007), which was not demonstrated in this experiment. The reason for these 
differences could be genetic variation within the same and different D. discoideum 
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WT strains between different laboratories. This arises as gene duplications are 
common and can result from the number of times a cell has divided (copy number) 
(Bloomfield, et al., 2008). To continue investigating these two proteins, 
independent cell lines lacking all 5 D. discoideum PI3K and PTEN should be 
characterized in both the absence and presence of VPA to ensure there are no 
single mutational effects nor that the phenotype of one mutant is concealed by the 
other.  
 
Chronic VPA treatment of pi3k1-5-/pten- was investigated as all of the genes 
ablated in the mutant are expressed during the D. discoideum developmental cycle. 
This involved comparing fruiting body development of pi3k1-5-/pten- cells with WT, 
in both the absence and presence of VPA. Unlike previous work (Hoeller and Kay, 
2007), under control conditions both WT and pi3k1-5-/pten- cells developed into 
mature fruiting bodies of similar size. In the presence of VPA, the drug blocked 
development of mature fruiting bodies, whereby both cell lines developed into 
fingers and mounds. These results are consistent with the molecular phenotype 
shown previously where there was a reduction in PIP and PIP2 levels by 28 % and  
44 % in pi3k1-5-/pten- cells compared with WT, which was significantly reduced in 
the presence of 0.5 mM VPA (Chang, et al., 2012). In addition, VPA has been shown 
to enhance the effects of a PI3K inhibitor in WT cells (Chang, et al., 2012). This 
result suggests that VPA acts like a PI3K inhibitor in D. discoideum and together 
with the VPA-sensitive phenotype shown here during D. discoideum development, 
it appears that neither PI3K nor PTEN are targets, or are regulated by, VPA in D. 
discoideum.  
 
In addition to investigating VPA, a range of structurally related compounds, key 
components of the MCT diet or branched compounds, as well as the BD treatment 
LiCl, were also tested on pi3k1-5-/pten- cell development. In the presence of all of 
the compounds tested (VPD, PIA, DA, OA, 4-EOA, 2-MHA and LiCl) both WT and 
pi3k1-5-/pten- cells developed into fingers, slugs or mounds, and thereby 
demonstrated drug-sensitivity. This result suggests that the mechanism of action of 
all of these compounds does not involve the 5 PI3K or PTEN in D. discoideum. This 
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result was of interest as previous studies have linked the PI3K/PIP3/Akt pathway, 
apoptosis and PTEN with seizure generation (Backman, et al., 2001; Shinoda, 2004) 
and the compounds tested here do not appear to target PI3K nor PTEN. Apoptosis 
can be caused by the catabolite farnesol, a component of the cholesterol/ 
isoprenoid biosynthetic pathway, whose mechanism of action is suppressed by the 
PI salvage pathway component DAG (Taylor, et al., 2005). This therefore, suggests a 
role of the PI salvage pathway in seizure prevention independent of PI3K and PTEN.  
 
As the pi3k1-5-/pten- cells were sensitive to all compounds tested, the PI salvage 
pathway component PLC was investigated. PLC is the enzyme responsible for the 
hydrolysis of PIP2 into IP3 and DAG, thereby diminishing PIP2 levels. plc- cells were 
created by Drayer et al (1994) and these were used for phenotypic characterization 
during acute and chronic VPA exposure. Under control conditions and acute 
treatment of VPA, plc- cells responded almost identically to WT, with a dose-
dependent reduction in displacement, membrane protrusions and motility, 
correlated with an increase in circularity when exposed to higher VPA 
concentrations. This suggests that PLC is not a target of VPA in D. discoideum. The 
similarity of the plc- cell behaviour to WT is consistent with a previous report 
(Drayer, et al., 1994). A point mutation resulting in loss-of-function of PLC was 
identified in a drug-resistant epilepsy patient (Kurian, et al., 2010). This mutation in 
PLC resulted in neurological regression and death (Kurian, et al., 2010). Additionally, 
a PLC knockout mouse (PLC1-/-) displayed an epileptic phenotype and PLC4-/- 
mutant mice demonstrated signs of ataxia (affected coordination, speech and 
balance) (Kim, et al., 1997), suggesting a role of PLC in mammalian development. 
However, VPA does not appear to target or regulate PLC in response to acute VPA 
treatment during the early stages of D. discoideum development. This difference 
between D. discoideum and the mammalian phenotype could be a result of other 
cellular effects. This is because mammals contain multiple PLC isoforms, whereas D. 
discoideum has only one. Therefore, ablation of one PLC isoform in mammalian 
models may result in the upregulation of other PLC isoforms, which in turn results 
in the upregulation of other inositol phosphate and DAG species which are 
responsible for the epileptic phenotype demonstrated in PLC knockout mice.  
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Next, the D. discoideum developmental cycle was investigated by comparing plc- 
cells with WT in both the absence and presence of VPA. Both cell lines developed 
into mature fruiting bodies over 24 hours under control conditions, consistent with 
previous work (Drayer, et al., 1994). In the presence of VPA, both WT and plc- cells 
developed into fingers or mounds over 24 hours, suggesting that during chronic 
exposure to VPA, PLC is not a target of the drug in D. discoideum. However, the PI 
salvage pathway has been linked with seizures where kainic acid, a seizure inducing 
compound, resulted in mild seizures in rats with severe hippocampal damage and 
sustained release of IP3 within the initial 10 minutes of seizure induction (Bodjarian, 
et al., 1993). In C. elegans, VPA has been shown to reduce inositol-1-phosphate and 
DAG levels (Tokuoka, Saiardi and Nurrish, 2008), highlighting the potential target of 
VPA to be a component of the PI salvage pathway. 
 
In addition to VPA, a range of structurally related analogues, key components of the 
MCT diet and branched chain anti-seizure compounds, as well as the BD treatment 
LiCl, were investigated on plc- cell development. In the presence of VPD, PIA, DA, 
OA, 4-EOA, 2-MHA and LiCl, both WT and plc- cells developed into fingers or 
mounds within 24 hours, suggesting PLC is not the target of these compounds nor 
the BD treatment in D. discoideum. In addition to epilepsy, both reaction products 
of PLC, IP3 and DAG, have been implicated with BD. PLC was a protein of interest as 
a range of studies have associated lithium treatment with a decrease in inositol and 
an increase in DAG levels in GH3 pituitary tumour cells (Drummond and Raeburn, 
1984), neuroblastoma x glioma hybrid cells (NG108-15) (Brami, Leli and Hauser, 
1991; Brami, Leli and Hauser, 1993) and in rat (Sherman, et al., 1981) and mouse 
(Sade, et al., 2016) models. However, PLC does not appear to be a target, or is 
regulated by, the anti-seizure or BD compounds tested in this study in D. 
discoideum. 
 
Next, Lpin2, the enzyme responsible for the dephosphorylation of PA into DAG, was 
investigated. LPIN2 was an enzyme of interest as it controls lipid homeostasis by 
regulating cell growth and signalling (Banfić, et al., 1993; Cerbón, et al., 2005), 
glucose metabolism and lipid regulation (Milne, et al., 2008). Phenotypic 
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characterization of lpin2- cells begun with acute cell behaviour where both WT and 
lpin2- cells behaved in a similar manner for displacement and membrane 
protrusions. The lpin2- cells had a lower circularity value compared with WT and 
moved significantly faster compared with parental WT. In the presence of VPA, 
both cell lines had a dose-dependent reduction in displacement, membrane 
protrusions and motility, correlating with an increase in circularity. However, this 
dose-dependent effect in the presence of VPA was typically delayed in lpin2- cells 
compared with WT, with statistically significant differences between WT and lpin2- 
cell displacement in the presence of 0.1 mM VPA. However, this VPA concentration 
is lower than the therapeutic concentration (0.3 mM-0.6 mM) (Kanner, 2003; 
Vázquez-Calvo et al., 2013). These results suggest that LPIN2 is not the target of 
VPA in D. discoideum during acute cell behaviour. The lpin2- cells increased motility 
observed during control conditions is similar to that of LPIN2 deficient mice which 
displayed abnormal uncontrollable movement (ataxic gait) with rapid tail flicking 
compared with WT mice (Dwyer, et al., 2012).  
 
The D. discoideum developmental cycle was then investigated to determine the 
effects of chronic VPA treatment on lpin2- cells. Under control conditions, both WT 
and lpin2- cells were able to develop into similar sized mature fruiting bodies. In the 
presence of VPA, both cell lines developed into finger or mound structures, 
suggesting LPIN2 is not a target of VPA during D. discoideum development. LPIN2 
was a protein of interest as epilepsy patients can develop a condition called 
rhabdomyolysis, which is associated with seizures and results in damaged skeletal 
muscle breakdown (Walker, Duddy and Sagar, 1993). A study carried out in 1976 
concluded that the onset of rhabdomyolysis in an epilepsy patient was associated 
with administration of the AED phenytoin, however, this has rarely been reported 
(Michael and Mitch, 1976; Kim, et al., 2016). Rhabdomyolysis arises from deficiency 
within LPIN1, resulting from a homozygous frameshift mutation and from both 
chromatids on chromosome 2 being maternally inherited (Michot, et al., 2010; 
Michot, et al., 2012; Meijer, et al., 2015). Therefore, it was a possibility that VPA 
targets or regulates LPIN2.  
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Other anti-seizure treatments, including VPA structurally related compounds (VPD 
and PIA), key components of the MCT diet (DA and OA) and branched compounds 
(4-EOA and 2-MHA) as well as the BD treatment LiCl were tested on lpin2- cell 
development. In the presence of all of these compounds, both WT and lpin2- cells 
developed into finger or mounds over 24 hours, with drug sensitivity suggesting 
LPIN2 is not the target, or is regulated by these compounds in D. discoideum. LPIN 
proteins are of interest in epilepsy and BD research as the reaction product DAG 
has increased levels during seizures (Yoshida, et al., 1987). Also, LPIN 
phosphorylation activates the mTOR pathway (Huffman, Mothe-Satney and 
Lawrence, 2002) which is important in epilepsy research as it regulates synaptic 
plasticity (Tang, et al., 2002), neuronal development, dendrite growth and 
morphology (Takei, et al., 2004; Jaworski, et al., 2005; Kumar, et al., 2005). 
Inhibitors of the mTOR pathway have been shown in animal models to reduce 
seizures and delay their development as well as prevent epileptogenesis (Zeng, et 
al., 2008; Ehninger, et al., 2008; Meikle, et al., 2008;  van Vliet, et al., 2012). 
However, LPIN2 does not appear to be a target, or is regulated, by VPA in this 
study. 
3.5 Summary 
In D. discoideum the 5 PI3K, PTEN, PLC and LPIN2 are not essential for survival. Cell 
lines in which these genes had been ablated were used for phenotypic 
characterization in both the absence and presence of a range of anti-seizure 
compounds and the BD drug LiCl. Characterization begun using pi3k1-5-/pten- cells 
which had all D. discoideum PI3K and PTEN removed, therefore, preventing the 
forward and reverse reaction of PIP2 to PIP3. The pi3k1-5-/pten- cells were sensitive 
to VPA during acute and chronic drug exposure, suggesting these proteins are not a 
target, or are regulated by VPA in D. discoideum. The pi3k1-5-/pten- cells were also 
sensitive to the other anti-seizure compounds (VPD, PIA, DA, OA, 4-EOA and 2-
MHA) and LiCl, highlighting these proteins are not targets or regulated by the 
compounds tested in this study in D. discoideum. The plc- cells were then 
characterized, where the hydrolysis reaction of PIP2 into IP3 and DAG was blocked. 
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During acute expose to VPA, plc- cells had a dose-dependent reduction in cell 
movement mirroring that of WT cells. This was also demonstrated during chronic 
VPA treatment, suggesting VPA sensitivity in D. discoideum is not due to PLC. The 
plc- cells were also sensitive to VPD, PIA, DA, OA, 4-EOA, 2-MHA and LiCl during 
development, suggesting PLC is not targeted or regulated by these drugs in D. 
discoideum. Finally, lpin2- cells were characterized in the presence of a range of 
anti-seizure compounds and a BD treatment (VPA, VPD, PIA, DA, OA, 4-EOA, 2-MHA 
and LiCl) and showed sensitivity to all of these compounds. These results suggest 
that the mechanisms of action of these compounds is not through LPIN2 in D. 
discoideum. In this study, neither PI3K, PTEN, PLC nor LPIN2 are targets, or are 
regulated by VPA or the anti-seizure compounds tested here nor the BD treatment 
LiCl in D. discoideum.   
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4. Bioinformatic Analysis of CDSA, 
CDIPT and DGKA 
Research conducted in D. discoideum to investigate the molecular effects and 
target(s) of VPA has proposed a role for the drug regulating phosphoinositide and 
phospholipid signalling in both a time and dose-dependent manner (Chang, et al., 
2012; Elphick, et al., 2012). To investigate the mechanism of this effect, a range of 
enzymes involved in regulating phosphoinositide signalling have been investigated 
as potential targets for VPA by gene ablation or overexpression. This approach 
suggested that PI3K signalling, inositol recycling and de novo inositol biosynthesis 
and production are unlikely to be responsible for the effects of VPA (Chang, et al., 
2012; Frej, et al., 2016). The previous chapter described the analysis of VPA-
sensitivity in cells lacking all 5 D. discoideum PI3K and PTEN, PLC and LPIN2, with all 
3 cell lines showing sensitivity during both acute and chronic VPA treatment. These 
results suggested there are other targets of VPA responsible for this mechanism. 
One unexplored target for this effect is through the inhibition of the PI salvage 
pathway (Figure 4.1). 
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Figure 4.1. Simplified phosphatidylinositol salvage pathway. Regulation of inositol 
signalling involves both the phosphatidylinositol (PI) salvage pathway (black) and the 
inositol phosphate signalling pathway (blue) where phosphatidylinositol- 4,5-bisphosphate 
(PIP2) is hydrolysed to produce inositol-1,4,5-triphosphoate (IP3) and diacylglycerol. IP3 is 
dephosphorylated into inositol-1,4-bisphosphate (IP2), inositol-1-phosphate (IP) and 
inositol (I). Meanwhile, DAG is phosphorylated to form phosphatidic acid (PA) by 
diacylglycerol kinase (DGK) and converted into cytidine diphosphate diacylglycerol (CDP-
DAG) by a condensation reaction requiring CTP catalysed by cytidine diphosphate-
diacylglycerol synthase (CDS). CDP-DAG is then converted into PI by cytidine diphosphate- 
diacylglycerol-inositol 3-phosphatidyltransferase (CDIPT). PI then undergoes two 
phosphorylation reactions to produce phosphatidylinositol-4, 5-bisphosphate. The 
interconnected and cyclic nature of this pathway suggests that inhibition of any enzyme 
may impact the other components.  
 
D. discoideum is a useful model to study the PI salvage pathway since the model 
contains one isoform of each of the 3 key proteins- CDSA, CDIPT and DGKA. CDSA 
(UniProt ID: Q54N49) is a key enzyme involved in the PI salvage pathway as it 
catalyses the condensation reaction of PA and CTP into CDP-DAG. This reaction is a 
rate-limiting step due to the small size of the CDP-DAG pool (Raetz and Kennedy, 
1973; Wu, et al., 1995; Lykidis, et al., 1997). CDP-DAG is a precursor to PI, PG, PE, PS 
and cardiolipin (Thompson and MacDonald, 1975; Shen, et al., 1996;  Henry, 
Kohlwein and Carman, 2012; Lilley, et al., 2014). CDIPT (UniProt ID: Q54P27) is an 
important enzyme within the PI salvage pathway as it catalyses the formation of PI 
from CDP-DAG. PI is an essential product as it comprises 2-12 % of the total 
phospholipids within eukaryotic cells (Flint, et al., 1986). PI is phosphorylated into 
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various PI- species which regulate a number of signalling pathways, including 
tyrosine kinases, G-protein coupled receptors, membrane anchoring and 
transduction pathways of calcium and PKC  (Lykidis, et al., 1997; Bankaitis and 
Grabon, 2011). DGKA (UniProt ID: P34125) is a fundamental enzyme as it regulates 
two signalling molecules, DAG and PA. DAG is required for triacylglycerol synthesis 
(Dahlqvist, et al., 2000), synaptic plasticity (Lee, Kim and Tanaka-Yamamoto, 2016), 
PKC (van Baal, et al., 2005) and the Kennedy pathway components PC and PE 
(Kennedy and Weiss, 1956;  Tokuoka, Saiardi and Nurrish, 2008; Gibellini and Smith, 
2010). PA regulates cell growth and signalling (Banfić, et al., 1993; Cerbón, et al., 
2005), lipid regulation and glucose metabolism (Milne, et al., 2008). Therefore, 
CDSA, CDIPT and DGKA are key PI salvage pathway proteins and could potentially 
be the molecular target of VPA in D. discoideum. 
 
This chapter, therefore, describes the bioinformatic analysis of the D. discoideum PI 
salvage pathway proteins CDSA, CDIPT and DGKA. In order to gain a detailed 
understanding of the structural characteristics and evolutionary conservation of 
these 3 proteins throughout different kingdoms, the D. discoideum protein 
sequences and domain structures were compared to that of a range of other 
species, including Homo sapiens (humans). This was achieved by comparing the D. 
discoideum protein sequence of each specific gene of interest to a database of 
amino acid sequences, to identify related sequences by a homology search (protein 
basic local alignment search tool (BLAST) analysis) (Altschul, et al., 1990). The 
evolutionary similarities and differences between each protein in a range of 
organisms was then determined by construction of a phylogenetic tree. Protein 
sequences were aligned with conserved amino acids in both D. discoideum and H. 
sapiens to a range of other organisms. The presence and location of protein 
structural domains was then compared in D. discoideum and H. sapiens proteins in 
order to determine functional similarity.  
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4.1 CDSA 
4.1.1 CDSA BLAST Analysis 
To determine the similarity of the D. discoideum CDSA protein to that of other CDS 
isoforms across various kingdoms, BLAST analysis was conducted. This involved 
comparing the D. discoideum CDSA protein sequence (DDB_G0269742) to all 
sequenced genomes from other species. This analysis revealed a number of related 
CDSA proteins across a range of species of similar lengths, with homologous 
proteins being defined as having an expectation (E)-value below 10-40 as previously 
suggested (Table 4.1) (Eichinger, et al., 2005). Homologous CDSA proteins were 
found in a range of kingdoms including Animalia, Plantae and Fungi, which all had a 
similar percentage of identity (ranging from 33- 42 %). The large number of CDSA 
homologs suggests a high degree of evolutionary conservation, highlighting the 
importance of CDP-DAG signalling.  
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Organism Protein 
Name 
Accession Number Protein 
Length 
(aa) 
Identity 
(%) 
E-
value 
Dictyostelium discoideum (social 
amoeba) 
CDSA XP_646241.1 479 100 0 
Homo sapiens (human)  CDS1 NP_001254.2 461 35 2e-92 
CDS2 NP_003809.1 479 34 2e-82 
Rattus norvegicus (rat) CDS1 NP_112521.2 461 36 8e-92 
CDS2 NP_446095.1 
 
443 34 4e-80 
Mus musculus (mouse) 
 
CDS1 NP_775546.2 461 36 2e-91 
CDS2 NP_619592.1 444 34 3e-83 
Danio rerio (zebrafish) CDS1 XP_001341899.2 431 35 1e-91 
CDS2 NP_957480.1 444 34 2e-85 
Drosophila melanogaster (fruit 
fly) 
CDSA NP_524661.1 
 
447 34 2e-80 
Xenopus tropicalis (frog) CDS1 XP_002937924.1 441 35 3e-90 
CDS2 NP_001119975.1 465 33 4e-92 
Caenorhabditis elegans (worm) CDS NP_501298.1 
 
465 35 2e-89 
Arabidopsis thaliana (plant) CDS1 OAP19122.1 421 39 2e-98 
CDS2 OAP01102.1 423 38 6e-98 
CDS3 NP_194407.5 471 35 4e-95 
Saccharomyces cerevisiae 
(budding yeast) 
CDS1 AJP87380.1 
 
457 39 8e-85 
Rhizophagus irregularis (fungus) CDS PKC68884.1 
 
437 42 3e-110 
 
Table 4.1.  D. discoideum CDSA protein homology search results identifying related 
proteins in other organisms. The accession numbers of related proteins are given and the 
name of the organism to which they relate. Protein length in number of amino acids are 
stated in addition to the percentage of identity relating to the D. discoideum protein. 
Statistical significance of a given pairwise alignment relating to the scoring system and size 
of the database used for comparison is shown by the E-value, with lower E-values 
indicating greater significance in homology. Results obtained using the NCBI PSI-BLAST 
database. 
 
4.1.2 CDSA Phylogenetic Analysis 
In order to determine the evolutionary conservation of the different CDS protein 
isoforms, a phylogenetic tree was constructed. This involved using the software 
Molecular Evolutionary Genetic Analysis (MEGA) 7 and the method neighbour- 
joining. Reliability of the tree nodes were assessed using the bootstrap test (500 
replicates) and evolutionary distances were computed using the Poisson correction 
method (Kumar, Stecher and Tamura, 2016). Comparison of the entire CDS protein 
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sequences in a range of organisms showed conservation of the two CDS isoforms in 
higher organisms of the Animalia kingdom and a cluster towards the bottom of the 
tree for genus with one isoform, followed by the Plantae kingdom (Figure 4.2). The 
first node had a bootstrap value of 49 and separated the vertebrate and 
invertebrate CDS proteins. The bootstrap value of the second node was 39, which 
separated D. discoideum CDSA from the 3 Arabidopsis thaliana (plants) CDS 
isoforms, consistent with the higher percentage of identity between these two 
proteins compared with higher organisms such as H. sapiens and Drosophila 
melanogaster (fruit flies). From this phylogenetic analysis, there are 3 clear groups 
of CDS clustering, of CDS1, CDS2 and organisms with only one isoform. This 
suggests conservation of each protein isoform. 
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Figure 4.2. Phylogenetic analysis of CDS proteins within a range of kingdoms. The 
evolutionary relationship between CDS proteins is shown via a bootstrap consensus tree 
generated using the neighbour-joining method with bootstrap test (500 replicates) and the 
Poisson correction method computing the evolutionary distances from the Molecular 
Evolutionary Genetic Analysis (MEGA) 7 software. Numbers on the tree represent the 
percentage of replicate trees in which the associated taxa are clustered together. E. coli 
CDSA represents the root of the tree. D. discoideum CDSA is highlighted in blue and the two 
H. sapiens isoforms are shown in pink with the clustering of CDS1 and CDS2 shown by the 2 
braces. Scale bar indicates the number of amino acid substitutions per site. 
 
4.1.3 CDSA Sequence Alignment 
Due to high sequence conservation in mammals, flies, yeast and bacteria, the CDS 
catalytic site has been predicted between amino acids 273-284 and 361-407 
(Lykidis, et al., 1997). Therefore, sequence alignment analysis was employed in 
order to determine the conservation of this predicted catalytic site in D. discoideum 
and a range of other organisms (Supplementary Figure S1). A high degree of amino 
acid homology was observed around two sites in the sequence alignment, between 
amino acids 265-282 and 351-406; and 248-265 and 333-389 in H. sapiens CDS1 and 
CDS2 respectively, and amino acids 280-297 and 369-425 in D. discoideum (Figure 
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4.3). The high degree of homology within these two sites suggests the likely 
similarity of function of CDS in a range of organisms, consistent with a conserved 
cellular function.  
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Figure 4.3. Conservation of the CDS predicted catalytic site. Sequence alignment of the 
predicted catalytic site based on high amino acid conservation in a range of organisms. The 
names of the species used for comparison in the alignment are shown to the far left. The 
amino acid start position is shown to the left of the sequence and the end amino acid 
residue number of each line is shown to the right of the alignment. An intervening region is 
represented by ‘.’. Identical amino acids to the D. discoideum protein are highlighted in 
blue. The multiple sequence alignment was produced using Clustal Omega and Multiple 
Align Show (bioinformatics.org).  
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4.1.4 CDSA Domain Structure and Analysis 
Due to the conservation of the CDS protein across a range of kingdoms, the 
domain structure of the D. discoideum CDSA protein was compared to that of the 
two human isoforms, CDS1 and CDS2 (Figure 4.4). The D. discoideum CDSA protein 
(479 amino acids) is of similar size to the two human isoforms (469 and 479 amino 
acids for CDS1 and CDS2 respectively). Domain structure analysis showed 
conservation of 6 transmembrane domains in both D. discoideum CDSA and the 2 
H. sapiens isoforms, all of which comprise of 20 amino acids. High homology of two 
locations in the sequence alignment suggested the possible active site are in similar 
locations in both D. discoideum CDSA and the 2 H. sapiens isoforms, which 
comprises of 23 amino acids and 45 amino acids respectively. The final 
transmembrane domain is located within the second highly conserved area in all 
isoforms. The similarity in domain structure between the H. sapiens and D. 
discoideum isoforms is consistent with both enzymes having a related function.  
 
 
 
Figure 4.4. Domain structure analysis of D. discoideum CDSA and H. sapiens CDS1 and 
CDS2. Schematic representation of the domain structure of CDS proteins in D. discoideum 
(UniProt ID: Q55D90) and H. sapiens (UniProt ID CDS1: Q92903 and CDS2: O95674). The 
domains shown are transmembrane domains (green) and the potential active site (red) 
with overlapping transmembrane domain and potential catalytic site is highlighted 
(yellow). The name of the organism and CDS isoform are shown to the left of the diagram 
and the protein length in amino acids (aa) is shown to the right of the alignment. There is 
an identical number of transmembrane domains in both organisms and the catalytic sites 
are located in similar locations. 
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4.2 CDIPT 
4.2.1 CDIPT BLAST Analysis 
The protein sequence of the single D. discoideum CDIPT protein was compared to 
the corresponding protein isoforms across other kingdoms. This was achieved by 
BLAST analysis, where the D. discoideum CDIPT (DDB_G0284857) protein sequence 
was compared against all sequenced genomes within the NCBI PSI-BLAST database. 
Homologous proteins were selected with E-values below 10-40 as previously 
described (Eichinger, et al., 2005). This analysis resulted in a number of CDIPT 
homologs from a range of species which had similar protein lengths (Table 4.2). 
CDIPT homologous proteins were found in fungi, invertebrates and vertebrates. 
Due to the high number of CDIPT homologs, it is suggested that there is a high 
degree of evolutionary conservation of the CDIPT protein, highlighting the 
importance of this enzyme. 
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Organism Protein 
Name 
Accession Number Protein 
Length 
(aa) 
Identity 
(%) 
E-
value 
Dictyostelium discoideum (social 
amoeba) 
CDIPT XP_638368 207 100 0 
Homo sapiens (human) CDIPT  NP_006310.1 213 38 2e-43 
Papio anubis (baboon) CDIPT  XP_003918743 213 38 1e-41 
Rattsu norvegicus (rat) CDIPT NP_620254.1 213 37 7e-42 
Mus musculus (mouse) 
 
CDIPT NP_080914.1 213 37 2e-41 
Danio rerio (zebrafish) CDIPT  NP_996971.1 213 36 3e-40 
Drosophilia willistoni (fruit fly) CDIPT XP_002075282.1 226 40 1e-40 
Anoplophora glabripennis 
(beetle) 
CDIPT XP_018572854.1 217 39 3e-43 
Pogona vitticeps (central bearded 
dragon) 
CDIPT XP_020654544.1 215 38 2e-41 
Xenopus tropicalis (frog) CDIPT NP_001072374.1 218 41 1e-49 
Pristionchus pacificus (parasitic 
nematode) 
CDIPT PDM75564.1 216 38 4e-42 
Orbicella faveolata (coral) CDIPT XP_020607792.1 217 41 5e-43 
Basidiobolus meristosporus 
(fungus) 
CDIPT ORY03900.1 223 42 1e-48 
 
Table 4.2.  D. discoideum CDIPT protein homology search results identifying related 
proteins in other organisms. The accession numbers of related proteins are given and the 
name of the organism to which they relate. Protein length in number of amino acids are 
stated in addition to the percentage of identity relating to the D. discoideum protein. 
Statistical significance of a given pairwise alignment relating to the scoring system and size 
of the database used for comparison is shown by the E-value, with lower E-values 
indicating greater significance in homology. Results obtained using the NCBI PSI-BLAST 
database. 
 
4.2.2 CDIPT Phylogenetic Analysis 
The evolutionary conservation of CDIPT was determined via phylogenetic analysis. 
This involved using the neighbour-joining method of the MEGA 7 software, where 
the reliability of the tree nodes was measured using the bootstrap test of 500 
replicates and the Poisson correction method to compute evolutionary distances 
(Kumar, Stecher and Tamura, 2016). Comparison of the entire CDIPT protein 
sequence across a range of organisms showed evolutionary conservation of the 
protein (Figure 4.5). At the first node there was a bootstrap value of 85, which 
separated eukaryotes and prokaryotes. The second node has a bootstrap value of 
94 and separated multicellular organisms of the Animalia kingdom with single 
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celled eukaryotes and plants. The third node has a bootstrap value of 46, separating 
Fungi from Prosista, Plantae and yeast. D. discoideum CDIPT is located at the end of 
the fourth node where it is separated from plants and yeast, correlating with 
highest identity to Basidiobolus meristosporus (fungus). This phylogenetic analysis 
shows that CDIPT is conserved across a large range of kingdoms, with the D. 
discoideum protein showing weak correlation with plant and yeast isoforms. 
 
 
 
Figure 4.5. Phylogenetic analysis of CDIPT proteins within a range of kingdoms. The 
evolutionary relationship of CDIPT proteins is shown via a bootstrap consensus tree 
generated using the Molecular Evolutionary Genetic Analysis (MEGA) 7 software 
neighbour-joining method with bootstrap test (500 replicates) and the Poisson correction 
method to compute the evolutionary distances. Numbers on the tree represent the 
percentage of replicate trees in which the associated taxa are clustered together. M. 
tuberculosis CDIPT represents the root of the tree. D. discoideum CDIPT is highlighted in 
blue and the H. sapiens isoform in pink. Scale bar indicates the number of amino acid 
substitutions per site.  
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4.2.3 CDIPT Sequence Alignment 
High homology across mammalian and yeast CDIPT proteins has previously been 
identified, suggesting conserved catalytic activity and regulatory role (Lykidis, et al., 
1997). For this reason, the CDIPT protein sequence was aligned across a range of 
organisms to determine conservation of the protein (Supplementary Figure S2). A 
high degree of amino acid conservation was observed between CDIPT protein 
isoforms, particularly between amino acids 9-87 in H. sapiens, D. discoideum, Mus 
musculus (mouse), Danio rerio (zebrafish) and Xenopus tropicalis (frog), suggesting 
this may be the catalytic site (Figure 4.6). There is also conservation of 4 aspartic 
acid resides throughout all kingdoms which is required for magnesium ion binding 
and catalytic activity (Fischl, et al., 1986; Nogly, et al., 2014). The strong sequence 
homology within CDIPT proteins, in a broad range of organisms, suggests a widely 
conserved function for this enzyme.   
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Figure 4.6. Conservation of the CDIPT predicted catalytic site. Sequence alignment of the 
CDIPT protein in a region of high homology in a range of organisms. The names of the 
species used for comparison in the alignment are shown to the far left. The amino acid 
start position is shown to the left of the sequence and the end amino acid residue number 
of each line is shown to the right of the alignment. Identical amino acids to the D. 
discoideum protein are highlighted in blue with conserved aspartic acid residues shown in 
yellow. The multiple sequence alignment was produced using Clustal Omega and Multiple 
Align Show (bioinformatics.org).  
 
4.2.4 CDIPT Domain Structure and Analysis 
Since, CDIPT appeared to be well conserved across a range of kingdoms, the 
domain structure of the D. discoideum protein was compared to that of the H. 
sapiens isoform (Figure 4.7). The D. discoideum CDIPT protein (207 amino acids) is 
of similar size to the H. sapiens CDIPT isoform (213 amino acids). Domain structure 
analysis showed conservation of 4 transmembrane domains in D. discoideum CDIPT 
and 5 transmembrane domains within the H. sapiens isoform, all of which comprise 
of 16-20 amino acids. An area of high homology within the protein sequence 
alignment, possibly suggesting the location of the enzymes active site, is located in 
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identical positions in D. discoideum and H. sapiens, comprising of 39 amino acids in 
both organisms.  
 
 
Figure 4.7. Domain structure analysis of D. discoideum and H. sapiens CDIPT. Schematic 
representation of the domain structure of CDIPT proteins in D. discoideum (UniProt ID: 
Q54P27) and H. sapiens (UniProt ID: O14735). The domains shown are transmembrane 
domains (green) and the potential active site (red), with overlapping transmembrane 
domain and potential catalytic site is highlighted (yellow). The name of the organism and 
CDIPT isoform are shown to the left of the diagram and the protein length in amino acids 
(aa) is shown to the right of the alignment.  There is a similar number of transmembrane 
domains in both organisms and the catalytic site is in identical locations in both organisms. 
4.3 DGKA 
4.2.1 DGKA BLAST Analysis 
The D. discoideum DGKA protein sequence (DDB_G0277223) was compared to 
other protein isoforms across all sequenced genomes within the NCBI PSI-BLAST 
database. Homologs were determined by having E-values below 10-40 as previously 
described (Eichinger, et al., 2005). BLAST analysis resulted in identification of a 
number of homologs to DGKA from a range of species which had similar protein 
lengths (Table 4.3). These DGKA homologous proteins were found mainly across 
the Animalia and Plantae kingdoms. These results suggest that there is a high 
degree of evolutionary conservation of DGK proteins, highlighting the importance 
of this enzyme.  
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Organism Protein 
Name 
Accession Number Protein 
Length 
(aa) 
Identity 
(%) 
E-
value 
Dictyostelium discoideum (social 
amoeba) 
DGKA XP_642726.1 887 100 0 
Homo sapiens (humans) DGK AAH31870.1 735 31 1e-66 
DGK NP_001337634.1 804 33 5e-74 
DGK BAA05132 791 31 2e-67 
DGK BAC11809.2 1214 30 1e-44 
DGK NP_003638 567 31 2e-61 
DGK AAB60859 1117 29 2e-52 
DGK NP_821077 1220 32 2e-49 
DGK NP_001338 942 37 3e54 
DGK NP_004708.1 1065 29 7e-50 
DGK NP_001013764 1271 30 3e-43 
Mus musculus (mouse) 
 
DGK NP_058091 730 32 5e-67 
DGK NP_001348615 802 32 7e-75 
DGK NP_619591.1 788 31 1e-67 
DGK NP_808314.2 1220 30 9e-46 
DGK NP_062378.1 564 29 5e-62 
DGK NP_612179.2 929 29 1e-53 
DGK NP_001074805 1180 32 5e-50 
DGK NP_950176.1 934 36 1e-55 
DGK NP_001074675.1 1071 29 3e-51 
DGK AAH75627.1 1118 31 1e-43 
Danio rerio (zebrafish) DGK NP_001038780 727 32 3e-76 
DGK XP_021322198.1 786 30 8e-61 
DGK XP_005172373 1074 31 4e-47 
DGK NP_001165699.1 564 30 4e-60 
DGK XP_003201445.1 1300 31 2e-69 
DGK XP_021334551.1 1329 31 1e-47 
DGK XP_009298312.1 968 27 4e-52 
Drosophilia melanogaster (fruit 
fly) 
DGK1 BAA04135.1 1454 30 2e-59 
Xenopus tropicalis (frog) DGK NP_001096214.1 785 33 2e-71 
Caenorhabditis elegans (worm) DGK NP_001024382.1 794 35 2e-56 
Arabidopsis thaliana (plant) DGK1 NP_196409.1 728 32 5e-51 
DGK2 NP_201182.1 712 38 9e-62 
DGK6 NP_194542.2 466 30 3e-40 
 
Table 4.3.  D. discoideum DGKA protein homology search results identifying related 
proteins in other organisms. The accession numbers of related proteins are given and the 
name of the organism to which they relate. Protein length in number of amino acids are 
stated in addition to the percentage of identity relating to the D. discoideum protein. 
Statistical significance of a given pairwise alignment relating to the scoring system and size 
of the database used for comparison is shown by the E-value, with lower E-values 
indicating greater significance in homology. Results obtained using the NCBI PSI-BLAST 
database. 
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4.2.2 DGKA Phylogenetic Analysis 
Phylogenetic analysis was then used to determine the evolutionarily conservation 
of DGK. To do this, MEGA 7 software was used to create a phylogenetic tree via the 
neighbour-joining method. Reliability of the tree nodes were measured using the 
bootstrap test of 500 replicates and evolutionary distances were computed using 
the Poisson correction method (Kumar, Stecher and Tamura, 2016). The resulting 
phylogenetic tree shows evolutionary conservation of DGK proteins present across 
a range of organisms, with distinct clusters grouping the different DGK types (1-5 
(Figure 4.8). The first node has a bootstrap value of 19 which separated type 1 DGK 
(DGK-, - and -) from the remaining 4 groups, suggesting that between the DGK 
subtypes there is large sequence variation. The second node, which has a bootstrap 
value of 5 separates DGK types 2-4 with DGK type 5 and organisms with one protein 
isoform. Most likely, these low bootstrap values are a result of the characteristic 
domain structures of each group, which are missing in the other subtypes. The next 
node with a bootstrap value of 61 separates type 5 DGK (DGK-) and A. thaliana 
and Caenorhabditis elegans (worm) DGK-1 and -2 from D. discoideum DGKA and A. 
thaliana DGK-3-7. D. discoideum DGKA is separated from A. thaliana DGK 3-7 at the 
fourth clade, which has a bootstrap value of 35. This phylogenetic analysis suggests 
that the D. discoideum DGKA protein is closely related to the DGK- isoform present 
in a range of higher organisms, including H. sapiens and M. musculus.  
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Figure 4.8. Phylogenetic analysis of DGK proteins within a range of kingdoms. A bootstrap 
consensus tree showing the evolutionarily conservation of DGK generated using the 
Molecular Evolutionary Genetic Analysis (MEGA) 7 software neighbour-joining method with 
bootstrap test (500 replicates) and the Poisson correction method to compute the 
evolutionary distances. Numbers on the tree represent the percentage of replicate trees in 
which the associated taxa are clustered together. E. coli DGKA represents the root of the 
tree. D. discoideum CDSA is highlighted in blue and the two H. sapiens isoforms are shown 
in pink with the clustering of DGK types 1-5 shown by the 4 braces. Scale bar indicates the 
number of amino acid substitutions per site. 
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4.2.3 DGKA Sequence Alignment 
To determine the conservation of the DGK catalytic site in D. discoideum compared 
with a range of other organisms (Figure 4.9), including all H. sapiens isoforms 
(Figure 4.10), amino acids within this region were aligned. A high degree of amino 
acid conservation across the catalytic site between a range of organisms and 
between the different H. sapiens isoforms was shown in the two sequence 
alignments. This confirms the similarity of function of the DGK protein in a range of 
organisms and between the different isoforms, thereby suggesting these proteins 
all have a similar function.   
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Figure 4.9. Conservation of the DGK catalytic site. Sequence alignment of the catalytic site 
of a number of organisms showing high amino acid homology. The names of the species 
used for comparison in the alignment are shown to the far left of the sequence.  The amino 
acid start position is shown to the left of the sequence and the end amino acid residue 
number of each line is shown to the right of the alignment. Identical amino acids to the D. 
discoideum protein are highlighted in blue. The multiple sequence alignment was produced 
using Clustal Omega and Multiple Align Show (bioinformatics.org).  
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Figure 4.10. Conservation of the DGK catalytic site between D. discoideum and the 10 H. 
sapiens isoforms. Sequence alignment of the catalytic site of D. discoideum DGKA and the 
10 H. sapiens DGK isoforms. The names of the species and DGK isoforms used for 
comparison in the alignment are shown to the far left.  The amino acid start position is 
shown to the left of the sequence and the end amino acid residue number of each line is 
shown to the right of the alignment. Identical amino acids to the D. discoideum protein are 
highlighted in blue. The multiple sequence alignment was produced using Clustal Omega 
and Multiple Align Show (bioinformatics.org). 
 
4.2.4 DGKA Domain Structure and Analysis 
Since DGK appears to be a well conserved enzyme across a range of kingdoms, the 
domain structure of the D. discoideum DGKA protein was compared to that of the 
10 H. sapiens DGK isoforms, DGK-, -, -, -, -, -, -, -, - and - (Figure 4.11). 
The D. discoideum DGKA protein (887 amino acids) is of similar size to the 10 H. 
sapiens DGK isoforms (ranging 567-1271 amino acids). Domain structure analysis 
showed conservation of phorbol-ester/ DAG type 1 binding domains in all isoforms 
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ranging between 50 or 51 amino acids in D. discoideum and between 47-58 amino 
acids across the 10 H. sapiens isoforms. The phorbol-ester domains are followed by 
the catalytic site in all DGK isoforms and comprise of 143 amino acids in D. 
discoideum and between 134-141 amino acids in H. sapiens. The different DGK 
isoforms also have unique domains which are not present in D. discoideum DGKA 
and are characteristic of the 5 DGK subgroups.  
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Figure 4.11. Domain structure analysis of D. discoideum DGKA and the 10 H. sapiens DGK 
isoforms. Schematic representation of the domain structure of DGK proteins in D. 
discoideum and H. sapiens. H. sapiens contain 10 DGK isoforms. D. discoideum DGKA 
protein (UniProt ID: P34125) was compared to that of the 10 human DGK isoforms, DGK- 
(UniProt ID: P23743), DGK- (UniProt ID: Q9Y6T7), DGK- (UniProt ID: P49619), DGK- 
(UniProt ID: P49619), DGK- (UniProt ID: P52429), DGK-zeta (UniProt ID: Q13574), DGK-eta 
(UniProt ID: Q86XP1), DGK- (UniProt ID: P52824), DGK-iota (UniProt ID: O75912) and DGK-
 (UniProt ID: Q5KSL6). The domains shown are the phorbol- ester/ DAG type 1 binding 
domain (blue), catalytic site (red), EF hand domain (yellow), PH domain (light green), SAM 
domain (purple), ANK domain (dark green), Ras- associating domain (grey) and PDZ binding 
domain (orange). The organism name and protein isoform is shown to the left of the 
diagram and the number of amino acids (aa) in the protein to the right.  
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4.4 Discussion 
Previous studies researching the molecular target of VPA in regulating 
phosphoinositide and inositol phosphate signalling have been unable to identify a 
potential molecular target for this drug in D. discoideum (Chang, et al., 2012; Frej, 
et al., 2016). Identifying this target remains important, since similar effects on 
phosphoinositide levels have been identified using primary mammalian neurons 
and in vivo models (Williams, et al., 2002; Chang, et al., 2013). Therefore, finding a 
target of VPA to regulate these effects, which may be conserved in mammalian 
systems, is needed. In this chapter, D. discoideum PI salvage pathway proteins 
CDSA, CDIPT and DGKA are investigated using bioinformatic analysis for homology 
to mammalian proteins and to other kingdoms. In silico analysis included 
comparison of amino acid sequence conservation, domain structure and catalytic 
motifs across a range of organisms of these 3 proteins. These experiments suggest 
the D. discoideum proteins CDSA, CDIPT and DGKA are orthologues of the 
mammalian proteins with high conservation and so may retain common cellular 
functions from D. discoideum to mammals. 
 
Bioinformatic analysis involved comparing D. discoideum proteins to isoforms 
present in other organisms and determining their evolutionarily conservation. This 
begun with BLAST analysis to identify significantly homologous proteins. This was 
achieved by setting the E-value threshold to a minimum of 10-40. This E-value 
represents the number of expected matches from a random database, with lower 
values indicating higher significance since the value decreases exponentially as the 
number of matches increases. This was then followed by the construction of a 
phylogenetic tree to determine the evolutionary characteristics of D. discoideum 
and related protein isoforms from a range of organisms (taxa) based upon both 
similar and different genetic characteristics. The nodes of the tree represent 
common ancestors and the branches indicate groups of descendant taxa separated 
by species. Bootstrap values present on the phylogenetic tree represent a 
resampling analysis test to determine whether nodes are recovered in the same 
position if a single amino acid within the protein is removed across the whole 
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sequence. Therefore, the higher the bootstrap value, the more likely the species is 
located in the correct position. Analysis then continued with aligning the catalytic 
site of these proteins, as this domain will be highly conserved in proteins with 
similar functions. Where the location of the catalytic site is unknown, the whole 
protein sequence was aligned to predict this site from areas of high conservation as 
shown previously (Lykidis, et al., 1997). Finally, the locations of significant protein 
domains were aligned to determine whether these are conserved in both D. 
discoideum and H. sapiens isoforms. 
 
Bioinformatic analysis revealed a number of significantly homologous proteins to D. 
discoideum CDSA in a range of organisms from mammals to plants and fungi. 
Identity values of all CDS isoforms ranged between 33-42 %, which is consistent 
with a previous study that found a functional link between a tomato pathogenesis 
related protein and a human glioma pathogenesis related protein where sequences 
were 35 % identical (Szyperski, et al., 1998). Strong conservation of CDS proteins is 
shown by the low E-values across a large range of species, suggesting CDS is highly 
conserved throughout evolution. CDS conservation is also highlighted in the 
phylogenetic tree, where there is clear clustering of CDS1, CDS2 (in H. sapiens, 
Rattus norvegicus (rat), M. musculus, X. tropicalis and D. rerio) and single CDS(A) 
isoforms (C. elegans, D. discoideum and S. cerevisiae), with the exception of A. 
thaliana and Escherichia coli (bacteria). These results suggest evolutionary 
conservation of CDS proteins, with distinct sequences in organisms with single CDS 
isoforms and the evolutionary changes between CDS1 and CDS2. Similarity in CDS 
proteins across a range of kingdoms is also supported by two areas of high 
sequence homology, which has previously been suggested as the catalytic site in 
mammals, flies, yeast and bacteria (between amino acids 273-284 and 361-407) 
(Lykidis, et al., 1997). Consistent with this previous work, 2 areas were identified 
with high protein sequence homology, between amino acids 265-282 and 351-406 
(H. sapiens CDS1), 248-265 and 333-389 (H. sapiens CDS2) and 280-297 and 369-
425 (D. discoideum CDSA). This result highlights the evolutionary preservation of 
the CDS catalytic site and therefore, the similarity in roles these proteins would 
conduct in the respective organisms. This was also supported by domain analysis, 
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where both D. discoideum and H. sapiens CDS protein isoforms have 2 potential 
catalytic sites and 5 transmembrane domains at similar locations, suggesting 
comparable protein structure between the two organisms. CDS transmembrane 
domains are important as they are involved in the synthesis of cardiolipin and PG at 
the inner matrix side of the mitochondria and for the production of PI at the 
cytoplasmic side of the endoplasmic reticulum (Thompson and MacDonald, 1975; 
Kuchler, Daum and Paltauf, 1986; Shen, et al., 1996; Henry, Kohlwein and Carman, 
2012; Lilley, et al., 2014). This is of interest in epilepsy research as both CDP-DAG 
and PG accumulate following VPA treatment (Ju and Greenberg, 2003). Therefore, 
due to the highly conserved protein sequence and the similarity in domain 
structure, all CDS proteins most likely fulfil a common function in D. discoideum and 
mammals. Therefore, this could provide a common mechanism to regulate the 
effects of VPA in both D. discoideum and mammalian models.  
 
Bioinformatic analysis was then conducted on CDIPT, where a number of 
significantly homologous proteins to the D. discoideum isoform were identified. The 
homologous proteins were identified in a range of kingdoms including mammals, 
reptiles, parasitic nematode and fungus. All of these homologous proteins had 
similar protein lengths (ranging 207-223 amino acids) and identity (ranging           
36-42 %), suggesting conservation of the enzyme across a range of species. High 
sequence homology was also illustrated in the phylogenetic tree. Alignment of the 
D. discoideum and other homologous CDIPT protein sequences revealed a high 
degree of homology between amino acids 9-87 in H. sapiens, D. discoideum, M. 
musculus and D. rerio, suggesting the location of the CDIPT catalytic site. In all 
organisms, ranging from mammals to bacteria, there were 4 conserved aspartic 
acid resides. Aspartic acid resides are also conserved in PS synthase (catalyses the 
formation of PS from CDP-DAG) and PG synthase (catalyses the formation of PG 
from CDP-DAG) (Nikawa, Kodaki and Yamashita, 1987). The role of these aspartic 
acid residues in phosphotransferase enzymes is to direct magnesium or manganese 
ion binding, which is required for enzyme activity. These residues have also been 
suggested to be the inositol binding site (Fischl, et al., 1986; Nogly, et al., 2014). The 
areas of high sequence conservation across all organisms suggests that these CDIPT 
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proteins have a common ancestor and therefore, a similar role. Domain analysis 
also showed a comparable number of transmembrane domains in D. discoideum (4) 
and H. sapiens (5) which are located in similar positions, suggesting the two 
proteins are of similar structure. The transmembrane domains enable the enzyme 
to fold into a dimer and conduct its catalytic activity through substrate and 
magnesium or manganese ion binding (Nogly, et al., 2014). CDIPT is a protein of 
interest as a VPA target as the reaction product PI decreases during seizures 
(Yoshida, et al., 1987). The high conservation of CDIPT protein sequences in a range 
of organisms and the similarity in domain structure, suggests that all CDIPT proteins 
most likely have a common function in mammals and D. discoideum. Therefore, the 
mechanism of action of VPA is most likely conserved in both D. discoideum and 
mammalian models. 
 
D. discoideum DGKA was the final protein bioinformatic analysis was conducted on. 
DGKA was a protein of interest as DGK- (Ishisaka, et al., 2013), - (Leach, et al., 
2007), and - (Rodriguez de Turco, et al., 2001) have been linked with epilepsy and 
VPA is known to alter DAG signalling (Yoshida, et al., 1987; Tokuoka, Saiardi and 
Nurrish, 2008). Proteins with significantly high homology to D. discoideum DGKA 
were determined by BLAST analysis and were identified within a range of organisms 
including mammals, worm and plants. There was a large range in protein lengths 
(ranging 466- 1454 amino acids) of related DGKA orthologues, due to the presence 
of 10 isoforms present in higher organisms. When comparing individual isoforms, 
e.g. DGK- , protein lengths are similar. All proteins in a range of organisms had a 
similar identity to the D. discoideum DGKA (ranging 27-38 %), suggesting 
evolutionary conservation of this enzyme. This was supported by the phylogenetic 
tree. The tree nodes suggest common ancestors of DGK proteins. Groups of 
descendant taxa were separated by the branches of different species with clear 
clusters of DGK types 1-5, which are based upon different functional domains and 
therefore resulted in low bootstrap values. High sequence homology was then 
identified when aligning the catalytic sites of DGK- isoforms in H. sapiens and M. 
musculus, DGK- of D. rerio, DGK-5 of A. thaliana and DGKA of D. discoideum and D. 
Chapter 4   Bioinformatic Analysis of CDSA, CDIPT and DGKA 
 130 
melanogaster and when aligning all 10 H. sapiens isoforms and D. discoideum 
DGKA. The high areas of sequence homology across all proteins, suggests a 
conserved function between all H. sapiens DGK isoforms and the single D. 
discoideum DGKA. Domain analysis followed, which confirmed the evolutionary 
conservation of 2 or 3 phorbol-ester/ DAG type 1 binding domains prior to the 
catalytic site. Each DGK subtype has specific domains. Type 1 (DGK-, - and -) 
isoforms have recovering homology domains and EF hand motifs. Type 2 (DGK-,     
-, -) have pleckstrin homology domains. Type 3 (DGK-) isoforms have 
arachidonate- containing DAG domains. Type 4 (DGK- and -) contain PDZ domains 
and ANK domains. Finally, type 5 (DGK-) have 3 phorbol-ester/ DAG type 1 binding 
domains and Ras associating domains. The recoverin homology domains and EF 
hand motifs of type 1 are involved in calcium binding, which initiates 
conformational changes in the enzymes tertiary structure. Calcium binding also 
initiates movement of the enzyme from the cytosol to the plasma membrane 
where the enzyme is functionally active (Sakane, et al., 1991; Yamada, et al., 1997). 
The type 2 DGKs plekstein homology domains are responsible for the translocation 
of the enzyme from the cytosol to the plasma membrane by binding to intracellular 
PIP2, thereby regulating the levels of this signalling molecule (Kume, et al., 2016). 
Type 3 DGKs have arachidonate- containing DAG domains which enables the 
catalysis of sn-2 arachidonoyl-DAG (Tang, et al., 1996; Lung, et al., 2009). The PDZ 
domains of DGK- and type 4 DGKs bind gamma-1-syntrophin within the cytoplasm, 
causing the translocation of the enzyme to the nucleus (Hogan, et al., 2001). The 
ANK domains are used for protein- protein interactions to enable the translocation 
of the enzyme from the cytosol to plasma membrane (Santos, et al., 2002). The 
type 5 Ras associating domain is responsible for the binding of RhoA, a homolog of 
Ras, which inhibits DGK enzyme activity (Houssa, et al., 1999). Therefore, as the 
amino acid sequence and the core domain structures in DGKA is highly conserved 
among a range of organisms, all DGK proteins are likely to have a common function 
in both D. discoideum and mammalian models. Therefore, D. discoideum could be 
used as a biomedical model to investigate DGK as a potential target to VPA.  
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4.5 Summary 
In this chapter, bioinformatic analysis has identified evolutionary conservation of 
CDS, CDIPT and DGK proteins across a number of organisms, including D. 
discoideum and H. sapiens. There is clear separation of organisms with single and 
multiple protein isoforms, highlight the evolutionary conservation and differences 
within the protein sequences. The data suggests a similar function of all 3 proteins 
within D. discoideum and H. sapiens homologs, with conservation of key protein 
sequences and domains, suggesting all of the protein isoforms have a similar 
function in both D. discoideum and mammalian models.  
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5. Analysis of CDSA as a Target of VPA 
The PI salvage pathway enzyme CDS catalyses a condensation reaction between PA 
and CTP to produce CDP-DAG and pyrophosphate (Figures 1.4 and 5.1). CDP-DAG is 
an important branch point intermediate as it acts as a precursor for PI through the 
PI salvage pathway and cardiolipin, PG, PS, PE and PC via the CDP-DAG pathway 
(Thompson and MacDonald, 1975; Shen, et al., 1996; Henry, Kohlwein and Carman, 
2012; Lilley, et al., 2014). CDS is predominantly present within the endoplasmic 
reticulum and mitochondria (Raetz and Kennedy, 1973), where the enzyme 
regulates rapid PI turnover and signalling in a rate-limiting step due to the small size 
of the CDP-DAG pool (Nickels, Buxeda and Carman, 1994;  Lykidis, et al., 1997). CDS 
is investigated here as a target of VPA due to CDP-DAG being a precursor of a large 
range of signalling molecules and for its role within the PI salvage pathway.  
 
 
Figure 5.1. The catalytic activity of cytidine diphosphate diacylglycerol synthase. A 
condensation reaction converts phosphatidic acid (PA) and cytidine triphosphate (CTP) into 
cytidine diphosphate- diacylglycerol (CDP-DAG), catalysed by CDP-DAG synthase (CDS).  
 
D. discoideum has a single Cds gene, CdsA (DDB_G0269742), which has a length of 
3688 bp. This includes three introns and encodes a protein of 479 amino acids.                     
D. discoideum CdsA is expressed during the vegetative phase of the life cycle 
(Stajdohar, et al., 2015). The D. discoideum CDSA protein shares 35 % and 34 % 
identity to H. sapiens CDS1 and CDS2 orthologues respectively (Chapter 4), implying 
a similar catalytic role of the enzymes in both organisms. This chapter, therefore, 
describes the creation of a CDSA knockout construct and subsequent attempts to 
ablate the gene in D. discoideum. In addition, an RFP-cdsA overexpression construct 
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was created. The resulting WT::RFP-cdsA overexpressing cells were phenotypically 
characterized during D. discoideum growth and development, in both the absence 
and presence of anti-seizure compounds, including VPA and the BD treatment LiCl.  
5.1 Construction of CdsA Knockout Vector  
A CdsA knockout vector was created using the pLPBLP (Faix et al., 2004) 
background. To this vector, two distal PCR amplified regions of the CdsA gene were 
inserted on either side of a blasticidin resistance cassette (Figures 5.2A and 5.2B). 
The 490 bp 5’ fragment started 64 bp within the open reading frame and contained 
no introns. The 508 bp 3’ fragment within the coding sequence contained one 
intron, removing a total of 584 bp of coding sequence, resulting in the cloning of 
899 bp of exon sequence. Restriction mapping (Figure 5.2C) was used to confirm 
the presence of the four restriction sites used for cloning (BamHI, PstI, HindIII and 
KpnI) the two CdsA fragments into the CdsA knockout vector. Single digests resulted 
in a single band corresponding to the CdsA knockout vector at approximately 5500 
bp. The presence of the two distal fragments within the CdsA knockout vector were 
excised by double digests which produced two bands, one at either 490 bp or 510 
bp, indicating the presence of the cdsA 5’ and 3’ fragments respectively. The second 
band (5000 bp confirmed the 5’ region and 4900 bp for the 3’ fragment) 
corresponded to the remaining CdsA knockout plasmid. The knockout cassette 
(approximately 2560 bp) contained the two cdsA gene fragments and the blasticidin 
resistance cassette, which was excised from the recombinant plasmid 
(approximately 2900 bp) by a further digest using the enzymes BamHI and KpnI.  
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Figure 5.2. Confirmation of the CdsA knockout construct. (A) CdsA genomic DNA with the 
region to be removed shown in yellow. The arrows indicate the locations of the primers 
used to amplify the 5’ and 3’ genomic DNA fragments and the cut sites BamHI (B), PstI (P), 
HindIII (H) and KpnI (K) which were added onto these fragments. (B) Plasmid map of 
pLPBLP-cdsA containing the two CdsA fragments located on either side of the blasticidin 
resistance cassette (Bsr). (C) Restriction mapping of the CdsA knockout vector by single and 
double digests visualised following gel electrophoresis with a ladder (L), negative control 
with no vector (-ve), uncut knockout vector (U), single digests to confirm individual enzyme 
activity of BamHI (B), PstI (P), HindIII (H) and KpnI (K) and double digests to confirm the 5’ 
and 3’ fragments within the vector using BamHI-PstI (B-P) and HindIII-KpnI (H-K) and the 
linearized knockout cassette used for electroporation with BamHI-KpnI (B-K). Molecular 
weights of the DNA ladder are indicated on the left of the gel image (10037 bp- 200 bp) and 
the expected plasmid insert sizes are provided (arrows) to the right of the image. 
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5.2 Screening of Potential cdsA- D. discoideum Cells  
To create cdsA- D. discoideum cells, the CdsA knockout cassette (Figure 5.2) was 
excised from the CdsA knockout construct and electroporated into WT cells. 
Transformant cells were selected for resistance to blasticidin during growth which 
was added to the media. Surviving colonies were screened by PCR for homologous 
integration of the knockout cassette into genomic DNA, thereby creating cdsA- cells. 
Homologous recombinant cells were then determined by PCR screening. This 
involved designing primers which confirmed the presence of the two distal CdsA 
gene fragments by amplifying genomic DNA from outside to within the fragment 
(genomic control), resulting in a 530 bp and 510 bp band for the 5’ and 3’ terminus 
respectively. Primers also amplified from within the fragment into the vector 
blasticidin resistance cassette (vector control) at the 5’ (590 bp) and 3’ (600 bp) 
terminus. Knockout diagnostic primers confirmed homologous recombination by 
using the genomic control primer located outside of the fragment and the primer 
located within the blasticidin resistance cassette (650 bp for the 5’ terminus and 
710 bp for the 3’ terminus).  
 
Numerous attempts were made to create and identify a cdsA- mutant using the 
CdsA knockout cassette. In the event of the mutant being an auxotroph, cdsA- cells 
were grown in the presence of the products CDP-DAG is a substrate for, PI and PG. 
After 16 electroporations, 329 blasticidin resistant colonies were screened. 195 of 
the 329 blasticidin resistant colonies were grown in the presence of PI (100 M), 
117 in media containing PG (100 M) and 17 were grown in the presence of PI (100 
M) and PG (100 M). However, no cdsA- cells were identified This approach was 
taken as previous studies have shown CDSA to be essential in organisms with one 
protein isoform (Shen and Dowhan, 1996; Sato, et al., 2000; Ganong and Raetz, 
1982). 
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Figure 5.3. PCR screening of potential cdsA- transformant cells. (A) Schematic 
representation of the CdsA knockout construct and the locations of the screening primers 
(arrows) and corresponding PCR product (dotted line) used for determining homologous 
integration- genomic (pink), vector (blue) and knockout diagnostic (yellow) primers and the 
predicted sizes of these products. (B) 5’-terminal PCR screening of WT and blasticidin- 
resistant cells with genomic control (G), vector control (V) and knockout diagnostic (K). PCR 
products are shown where the genomic control (G) band is amplified from WT DNA, 
genomic (G) and vector (V) control bands are amplified from non-homologous integrant 
(NH) DNA and all 3 bands (G, V and knockout diagnostic (K)) are amplified from the 
potential knockout (cdsA-) DNA. DNA ladder and the corresponding molecular weights are 
indicated on the left of the gel image (1000 bp- 200 bp). 
5.3 Preparing a CdsA Overexpression Construct  
To overexpress CDSA, WT::RFP-cdsA cells were created by PCR amplifying CdsA 
cDNA and inserting the resulting PCR fragment into a 5’ RFP tagged overexpression 
construct (389-19 mRFPmars) (Basu, et al., 2013; Fey, et al., 2013) (Figure 5.4). 
Primers were designed which amplified the whole CdsA cDNA (1440 bp) to which 5’ 
BamHI and 3’ EcoRI cut sites were added and this PCR product was cloned into the 
5’ RFP overexpression construct. The presence of the two restriction sites used for 
cloning (BamHI and EcoRI) were confirmed by restriction mapping and produced a 
single band at approximately 7340 bp. Insertion of the CdsA cDNA PCR fragment 
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was confirmed by a double restriction digest using the same two enzymes which 
produced one band at 1440 bp corresponding to the PCR amplified CDSA cDNA and 
the RFP-plasmid band at 3900 bp. The construct was sequenced to ensure that no 
mutations were present in the inserted PCR product. The 5’ RFP tagged CdsA 
overexpression construct was then electroporated into D. discoideum cells and 
selected by growth in the presence of neomycin (G418), creating WT::RFP-cdsA 
cells.  
 
 
 
Figure 5.4. Confirmation of the RFP-cdsA overexpression construct. (A) Schematic 
representation of CdsA cDNA with the arrows indicating the locations of the primers used 
for PCR amplification and the cut sides of BamHI (B) and EcoRI (E) used for cloning the CdsA 
cDNA into the 5’ RFP expression vector. (B) Confirmation of the inserted CdsA cDNA into 
the RFP expression vector by a series of single and a double restriction digest visualised 
following gel electrophoresis with a ladder (L), uncut vector (U), single digests to confirm 
individual enzyme activity of BamHI (B) and EcoRI (E) and a double digest using BamHI-
EcoRI (B-E) to confirm the presence of CdsA PCR fragment. To the left of the gel image is 
the DNA ladder molecular weights (10037 bp-1000 bp) and to the right is the expected PCR 
fragment insert size (arrow). 
 
Western blotting was used to confirm RFP-CDSA expression in WT::RFP-cdsA cells, 
by comparison with WT cells using MccA (also Mccc1) as a protein loading control 
(Davidson, King and Insall, 2013). WT cells had no expression of RFP, whereas the 
neomycin resistant WT::RFP-cdsA cells had a band corresponding to RFP-CDSA 
expression at the expected size (83 kDa) (Figure 5.5A). RFP expression was also 
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verified by fluorescence microscopy, which showed RFP localized within the cytosol 
in both WT::RFP and WT::RFP-cdsA cells (Figure 5.5B).  
 
  
 
Figure 5.5. CDSA expression and localization. (A) Western blot showing WT cells 
expressing the loading control MccA only and WT::RFP- cdsA cells expressing MccA and 
RFP-CDSA. (B) WT::RFP and WT::RFP-cdsA cells visualized using fluorescence microscopy 
with RFP localized within the cytosol in both cell lines. Scale bars represent 10 m.  
5.4 Phenotypic Characterization of WT::RFP-cdsA Cells  
WT::RFP-cdsA cells were then phenotypically characterized through a series of 
experiments and compared with WT::RFP cells in both the absence and presence of 
VPA during cell growth and development. WT::RFP-cdsA cells were then 
characterized in the presence of a range of anti-seizure compounds and the BD 
treatment LiCl during D. discoideum development. 
 
5.4.1 Analysis of WT::RFP-cdsA Cell Growth in the Presence of VPA 
Cell growth was investigated on WT::RFP-cdsA cells in both the absence and 
presence of VPA as the drug is known to have a dose-dependent effect on WT cell 
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proliferation (Terbach, et al., 2011). WT::RFP and WT::RFP-cdsA cells were grown in 
the presence of increasing VPA concentrations (ranging between 0.01 mM-2 mM), 
including therapeutic concentrations (0.3 mM-0.6 mM) (Kanner, 2003; Vázquez-
Calvo, et al., 2013), for 168 hours (Figure 5.6). In the absence of VPA there was no 
significant difference in cell growth between WT::RFP and WT::RFP-cdsA cells 
(Figure 5.6A and 5.6B). In the presence of increasing VPA concentrations, both cell 
lines showed a dose-dependent reduction in cell growth, with no significant 
differences in cell number between the two cell lines. This result suggests the 
growth-inhibitory effect of VPA is not dependent on CDSA overexpression. This was 
additionally shown in a secondary plot which compared the rate of cell growth 
against log VPA concentration (Figure 5.6C). The calculated IC50 value for WT::RFP 
was 0.5  0.05 mM and for WT::RFP-cdsA was 0.3  0.09 mM, highlighting VPA 
growth inhibition at similar concentrations. 
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Figure 5.6. WT::RFP and WT::RFP-cdsA growth in both the absence and presence of VPA. 
(A) WT::RFP and (B) WT:RFP-cdsA cell proliferation was determined in both the absence 
(control, black) and presence of VPA at the indicated concentrations (of increasing shades 
of blue) for 168 hours. (C) A secondary plot comparing the normalized change in the rate of 
cell growth between 96 and 144 hours plotted against log VPA concentration for WT::RFP 
and WT::RFP-cdsA cells. No significant differences in cell proliferation was identified under 
control conditions or in the presence of VPA using the Kruskal- Wallis test and Dunns post 
hoc test. Data presented as mean (+/- SEM). n =6.  
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5.4.2 Analysis of WT::RFP-cdsA Cell Development in the Presence of VPA 
When D. discoideum cells are starved, they enter the developmental cycle, whereby 
single cells migrate together to form multicellular fruiting bodies after 24 hours 
(Figure 1.6). VPA is known to inhibit this developmental cycle (Williams, et al., 
2002). D. discoideum development was investigated using WT::RFP and WT::RFP-
cdsA cells in both the absence (control) and presence of VPA (0.3 mM-1 mM) 
(Figure 5.7). Under control conditions, both cell lines were able to develop into 
multicellular fruiting bodies of similar size and shape, containing a basal disc, stalk 
and spore head. In the presence of 0.3 mM and 0.5 mM VPA, both cell lines 
developed into finger structures. When exposed to 1 mM VPA, both cell lines 
developed to the mound stage. These results suggest that elevating CDSA levels has 
no impact on the inhibitory effects of VPA during D. discoideum development.  
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Figure 5.7. WT::RFP and WT::RFP-cdsA development in both the absence and presence of 
VPA. WT::RFP (left) and WT::RFP-cdsA (right) cells were developed on nitrocellulose 
membranes in both the absence (top row) and presence (descending rows) of 0.3 mM, 0.5 
mM and 1 mM VPA for 24 hours. Images were then taken of an overhead view (left) of the 
whole membrane and of a single fruiting body (right). Both cell lines produced fruiting 
bodies in the absence of VPA and developed into fingers in the presence of 0.3 mM and 0.5 
mM and into a mound in the presence of 1mM VPA. n = 3. Scale bar of the overhead view 
represents 0.5 mm and of the side view 0.1 mm. 
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5.4.3 Analysis of WT::RFP-cdsA Cell Development in the Presence of Anti-Seizure 
Compounds and LiCl 
It was then assessed whether CDSA overexpression was a target for other anti-
seizure compounds and the BD treatment LiCl. The compounds tested have 
previously been shown to have an effect on D. discoideum cell growth, 
development, alter phosphoinositide and inositol phosphate levels; and effect in 
vivo epilepsy model epileptic discharges (Williams, et al., 1999; Williams, et al., 
2002; Eickholt, et al., 2005; Ludtmann, Boeckeler and Williams, 2011; Elphick, et al., 
2012; Chang, et al., 2012; Chang, et al., 2013; Chang, et al., 2015; Chang, et al., 
2016). Cells were starved on nitrocellulose filters for 24 hours to induce 
development in both the absence (control) and presence of a range of compounds 
at concentrations which blocked fruiting body formation in WT cells (Figure 5.8). 
VPA structurally related compounds VPD (6.5 mM) and PIA (1.4 mM) (Eickholt, et 
al., 2005;  Elphick, et al., 2012) were tested, along with DA (1.65 mM) and OA (0.22 
mM) which are key components of the MCT diet (Chang, et al., 2012; Chang, et al., 
2013; Chang, et al., 2015; Chang, et al., 2016). A branched chain compound with 
seizure control and neuroprotective effects, 4-EOA (0.5 mM) (Chang, et al., 2013; 
Chang, et al., 2015), was also tested. As a negative control, 2-MHA (0.5 mM) which 
was used as it has not been shown to have activity in D. discoideum nor in seizure 
prevention (Chang, et al., 2012). Both WT::RFP and WT::RFP-cdsA cells were able to 
develop into mature fruiting bodies after 24 hours under control conditions. In the 
presence of all the compounds tests, WT::RFP and WT::RFP-cdsA cells developed to 
the finger or mound stage. These results suggest that the mechanism of action of 
these compounds does not involve elevating the activity of CDSA.  
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Figure 5.8. WT::RFP and WT::RFP-cdsA development in both the absence and presence of 
a range of other compounds. WT::RFP (left) and WT::RFP-cdsA (right) cells were developed 
on nitrocellulose membranes for 24 hours in both the absence (top row) and presence 
(descending rows) of VPD, PIA, DA, OA, 4-EOA, 2-MHA and LiCl at the stated concentrations 
to the left of the development images. Images were taken of an overhead view of the 
whole membrane (left) and of a single fruiting body (right). Both cell lines developed into 
fruiting bodies in the absence of any compound. In the presence of VPD, PIA, DA, OA, 4-
EOA, 2-MHA and LiCl both WT::RFP and WT::RFP-cdsA cells developed to the finger or 
mound stage. n = 3. Scale bar of the overhead view represents 0.5 mm and of the side view 
0.1 mm. 
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5.5 Discussion  
D. discoideum phosphoinositide levels are reduced in a dose-dependent manner in 
the presence of VPA (Chang, et al., 2012). To determine the mechanism of action of 
VPA, a range of proteins have previously been investigated as molecular targets of 
the drug. These studies resulted in the elimination of de novo inositol production, 
de novo inositol biosynthesis, inositol recycling and PI3K activity (Chang, et al., 
2012; Frej, et al., 2016). This leaves the PI salvage pathway as potentially containing 
the molecular target of VPA in reducing phosphoinositide levels. This chapter has, 
therefore, reported several attempts to ablate the encoding gene (Figures 5.2 and 
5.3), the creation of CDSA overexpression cells (Figure 5.4 and 5.5) and their 
characterization in both the absence and presence of anti-seizure compounds, 
including VPA and the BD treatment LiCl (Figures 5.6-5.8).    
 
To ablate CDSA from D. discoideum, a knockout vector was created and used to 
transform cells. Previous studies have shown CDS ablation is lethal in organisms 
which only contain one CDS gene, including yeast (Shen and Dowhan, 1996), 
cyanobacteria (Sato, et al., 2000) and E. coil (Ganong and Raetz, 1982). However, 
CDS null cyanobacteria cells were created by supplementing media with PG 
liposomes (Sato, et al., 2000) and it is known that D. discoideum can uptake 
endogenous fatty acids (Elphick, et al., 2012). Therefore, D. discoideum media was 
supplemented with PI, PG or a combination of PI and PG. However, this resulted in 
no cdsA- cells. Lethality is also seen when ablating PS synthase, another component 
of the CDP-DAG pathway, and mutants only survive when media is supplemented 
with ethanolamine or choline (Atkinson, et al., 1980). Research conducted using E. 
coil suggests that the inviable nature of cds null cells is due to an increase in cellular 
pH, to above pH 8, which is a result of the build-up of the substrate PA (Ganong and 
Raetz, 1982). PA is able to accumulate within cells due to the larger size of the PA 
pool compared with the CDP-DAG pool (Raetz and Kennedy, 1973). The PA pool is 
approximately 20 times higher compared with CDP-DAG in E. coli (Raetz and 
Kennedy, 1973) and 99 % larger than CDP-DAG in bovine brain (Thompson and 
MacDonald, 1976). However, when CDSA was ablated in D. melanogaster, the 
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resulting phenotype was of significant accumulation of neutral lipids with reduced 
cell and organ size which was rescued with CDSA overexpression (Liu, et al., 2014). 
In yeast, a point mutation in CDS caused a reduction of enzyme activity and 
resulted in inositol excretion into growth medium (Shen and Dowhan, 1996).  
 
An overexpression approach was then taken. The overexpressing N-terminal tagged 
CDSA cells, WT::RFP-cdsA, was created and initially characterized by Western 
blotting, which confirmed RFP-CDSA expression. Protein localization was then 
investigated by fluorescence microscopy which showed RFP localization within the 
cytosol in WT::RFP and WT::RFP-cdsA cells, which is comparable with CDSA 
overexpression in HeLa cells (Qi, et al., 2016). In yeast, enzyme activity of CDSA is 
within the mitochondria and endoplasmic reticulum (Nickels, Buxeda and Carman, 
1994). These findings suggest that CDSA may reside in the cytosol and translocate 
to specific organelles for activity in D. discoideum. Translocation of enzymes from 
one site of the cell to another is demonstrated by a number of enzymes, e.g. 
sphingosine kinase 1 which moves from the cytoplasm to the plasma membrane 
(Jarman et al., 2010) and cytidine triphosphate:phosphocholine cytidyltransferase- 
 which is soluble in an inactive state within the cytosol and insoluble on activation 
(Aitchison, Arsenault and Ridgway, 2015) where it becomes membrane bound 
(Morand and Kent, 1989; Ridsdale, et al., 2001). However, it cannot be ruled out 
that the fusion of RFP to CDSA may affect the localization and function of this 
enzyme, potentially resulting in an inactive enzyme.  
 
The effects of VPA on WT::RFP-cdsA cell growth was then investigated. Both the 
control cells WT::RFP and WT::RFP-cdsA had similar rates of cell growth in the 
absence of VPA, with no significant differences between the two cell lines 
identified. This result is consistent with previous work where overexpression of 
human CDS1 within primate cells had no effect on the rate of PI synthesis, a 
downstream regulator of the cell cycle (Deguchi, et al., 2002). A second study 
showed the levels of CDP-DAG remained constant within native COS-7 monkey 
fibroblast-like cells and overexpressing CDS1 cells (Lykidis et al., 1997). These 
results suggest that even with abundant enzyme, the rate of PA conversion into 
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CDP-DAG remains constant, and therefore no effect on cell growth would be 
expected as CDS activity would be equal in both control and overexpressing cells.   
During chronic VPA treatment, both WT::RFP and WT::RFP-cdsA cells exhibited a 
dose-dependent reduction of cell growth with increasing VPA concentration. The 
similarity in cell growth between the two cell lines in response to VPA suggests that 
the mechanism of action of the drug is independent of CDSA activity in D. 
discoideum. CDSA was investigated as a potential VPA target as depression is well 
characterized in epilepsy patients (Schmitz, Robertson and Trimble, 1999), effecting 
9-37 % of patients (Kwon and Park, 2014). Depression has been associated with a 
reduction in CDP-DAG levels, where anti-depressant medications, such as 
maprotiline, paroxetine and imipramine, counteracting this reduction (Tyeryar, 
Vongtau and Undieh, 2008; Aboukhatwa and Undieh, 2010). Interestingly, some 
AEDs, including VPA, also have mood stabilizing effects as well as treating seizures, 
with Lamotrigine also being used as a treatment for depression (Kwon and Park, 
2014). This suggests the regulation of CDP-DAG and other PI salvage pathway 
components is important in both seizure control and mood stabilization. For this 
reason, VPA was investigated as a potential activator of CDSA during cell growth, 
when the gene is highly expressed (Stajdohar, et al., 2015), to counteract the 
reduction in CDP-DAG levels which is associated with depression.  
 
WT::RFP and WT::RFP-cdsA cell development was then investigated in both the 
absence and presence of VPA. Under control conditions, both cell lines developed 
into similar sized fruiting bodies. In the presence of VPA, CDSA overexpression did 
not alter VPA-sensitivity, where both cell lines developed to the finger and mound 
stages. These results suggest that CDSA activity is not enhanced by VPA during the 
D. discoideum developmental cycle. It has previously been found that 30 minutes of 
VPA treatment results in a significant increase in CDP-DAG and PG, suggesting the 
mechanism of action of VPA involves accumulation of CDP-DAG (Ju and Greenberg, 
2003). It was, therefore, investigated here whether chronic VPA treatment for 24 
hours would alter fruiting body development. Although CDP-DAG can only be 
synthesised by CDSA, the results investigating overexpressed CDSA within D. 
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discoideum show VPA sensitivity, suggesting CDSA is not regulated by VPA during 
the developmental cycle. 
 
A range of anti-seizure compounds were then investigated on WT::RFP and 
WT::RFP-cdsA cell development. These compounds included a range of VPA 
structurally related compounds, active components of the MCT diet and the BD 
treatment LiCl. In the presence of all of these compounds (VPD, PIA, DA, OA, 4-EOA, 
2-MHA and LiCl) WT::RFP and WT::RFP-cdsA cells developed to the finger or mound 
stage. These results suggest, that like VPA, the mechanism of action of these 
compounds does not involve elevation of CDSA activity in D. discoideum. 
Interestingly, in a similar way to VPA, which is used to treat both epilepsy and BD, 
the common BD treatment lithium also results in an accumulation of CDP-DAG, by 
approximately 10-fold (Stubbs Jr. and Agranoff, 1993). Accumulation of CDP-DAG 
from lithium treatment has been demonstrated numerous times using human SK-N-
SH neuroblastoma cells (Stubbs Jr. and Agranoff, 1993), human neutrophils (Stubbs 
Jr., et al., 1992)  and human platelets (Watson, Shipman and Godfrey, 1990). These 
results suggest VPA and lithium have similar mechanisms of action, independent of 
elevating CDSA activity in D. discoideum.   
5.6 Summary 
In D. discoideum it is probable that CDSA is essential for cell survival, consistent 
with previous work in other species containing one CDS isoform. In an attempt to 
overcome the challenges of creating cdsA- cells, media was supplemented with PI, 
PG or a combination of the two, however, this was not successful. Therefore, an 
overexpression approach was taken. Western blot analysis identified RFP-CDSA 
within WT::RFP-cdsA cells, with expression localized within the cytosol. WT::RFP-
cdsA cells were sensitive to VPA at similar concentrations to WT::RFP cells, 
indicating CDSA is not involved in the inhibitory effects of VPA on D. discoideum 
growth and development. Additionally, WT::RFP-cdsA cells were also sensitive to 
other anti-seizure compounds and to the BD treatment LiCl. However, as there was 
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no change in cellular phenotype compared with WT cells, it is unknown whether 
the RFP-cdsA protein has active enzymatic activity.   
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6. Analysis of CDIPT as a Target of VPA 
CDIPT (also known as PI synthase) is the enzyme responsible for the production of 
PI from the condensation reaction of CDP-DAG and myo- inositol within the PI 
salvage pathway (Figures 1.4 and 6.1). PI is an essential phospholipid, forming 2-12 
% of the total phospholipids in eukaryotic cells (Flint, et al., 1986). Phosphorylation 
of the inositol head group of PI results in PI- polyphosphates which regulate G- 
protein coupled receptors, tyrosine kinases (Lykidis, et al., 1997), membrane 
anchoring and calcium/ PKC signal transduction pathways (Antonsson, 1997; 
Bankaitis and Grabon, 2011). CDIPT is a protein of interest as a target of VPA due to 
the essential nature of PI and its role in calcium signalling which is altered in BD 
patients during manic episodes (Carman and Wyatt, 1979; Cipriani, et al., 2016).  
 
 
 
Figure 6.1 The catalytic activity of cytidine diphosphate-diacylglycerol-inositol 3 
phosphatidyltransferase. Cytidine diphosphate- diacylglycerol (CDP-DAG) and inositol (Ins) 
are converted into phosphatidylinositol (PI) by cytidine diphosphate-diacylglycerol-inositol 
3 phosphatidyltransferase (CDIPT) via a condensation reaction in the phosphatidylinositol 
salvage pathway in D. discoideum.  
 
The D. discoideum Cdipt gene (DDB_G0284857) has a length of 2735 bp, which 
includes one intron and encodes a protein of 207 amino acids. D. discoideum has 
one CDIPT isoform, which is expressed during the vegetative phase of the D. 
discoideum life cycle (Stajdohar, et al., 2015). D. discoideum CDIPT has similar 
homology to the H. sapiens orthologue (38 % identity) (Chapter 4), suggesting a 
similar catalytic role for both proteins. This chapter reports the creation of two 
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knockout constructs to interrupt and ablate Cdipt and an RFP-cdipt expression 
construct to overexpress the gene. This chapter then describes the phenotypic 
characterization of these overexpressing cells, WT::RFP-cdipt, during cell growth 
and development in both the absence and presence of anti-seizure compounds, 
including VPA and the BD treatment LiCl.  
6.1 Construction of Cdipt Knockout Vector Part 1 
A Cdipt knockout vector was created which contained two distal Cdipt gene 
fragments produced by PCR, which were inserted into a pLPBLP vector (Faix et al., 
2004) on either side of a blasticidin resistance cassette (Figure 6.2A and 6.2B). The 
5’ fragment consisted of 463 bp, starting 19 bp outside of the open reading frame 
and contained one intron. The 3’ fragment consisted of 350 bp with no introns and 
170 bp of regulatory sequence past the stop codon, resulting in the cloning of 532 
bp of exon sequence. The construct had 110 bp removed from the coding 
sequence. Restriction mapping (Figure 6.2C) was used to confirm the presence of 
the four restriction sites used for cloning in the two distal gene fragments into the 
pLPBLP vector (BamHI, PstI, NcoI and KpnI). Single restriction digests resulted in a 
single band at approximately 5250 bp which corresponds to the size of the pLPBLP 
plasmid and the additional two Cdipt fragments. Restriction mapping was then used 
to show the correct sized fragments within the knockout construct at 
approximately 460 bp for the 5’ and 350 bp for the 3’ regions. There was also a 
second larger band corresponding to the remaining recombinant plasmid (4800 bp 
and 5000 bp confirming the 5’ and 3’ regions respectively). A further digest using 
BamHI and KpnI was conducted to excise the knockout cassette, which contained 
the 5’ and 3’ Cdipt gene fragments flanking either side of a blasticidin resistance 
gene, from the recombinant Cdipt knockout plasmid. Two bands were obtained, 
one at 2400 bp which corresponded to the knockout cassette and the second at 
2900 bp of the remaining pLPBLP plasmid.  
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Figure 6.2 Confirmation of the Cdipt knockout construct 1. (A) Cdipt genomic DNA with 
the yellow box showing the region to be knocked out and the arrows indicating the 5’ and 
3’ genomic DNA fragments which were PCR amplified using primers containing cut sites for 
BamHI (B), PstI (P), NcoI (N) and KpnI (K). (B) Plasmid map of pLPBLP-cdipt containing the 5’ 
and 3’ Cdipt fragments cloned on either side of the blasticidin resistance cassette by BamHI 
(B), PstI (P), NcoI (N) and KpnI (K). (C) Confirmation of the Cdipt inserts within the pLPBLP 
vector by a series of single and double restriction digests visualised following gel 
electrophoresis with a ladder (L), negative control without any plasmid (-ve), uncut 
knockout vector (U), single digests confirming individual enzyme activity of BamHI (B), PstI 
(P), NcoI (N) and KpnI (K) and double digests to confirm the presence of the 5’ and 3’ CDIPT 
fragments using BamHI-PstI (B-P) and NcoI-KpnI (N-K) and the linearized knockout cassette 
used for electroporation with BamHI- KpnI (B-K). Molecular weights of the DNA ladder are 
indicated on the left of the gel image (10037 bp- 200 bp) and the expected plasmid insert 
sizes are given (arrows) to the right of the image. 
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6.2 Screening Potential cdipt- D. discoideum Cells Part 1 
To ablate the Cdipt gene in D. discoideum, the Cdipt knockout cassette (Figure 6.2) 
was electroporated into WT cells and selected by growth in the presence of 
blasticidin. PCR screening of surviving colonies was then conducted to identify 
transformant cells which had the knockout cassette integrated into the Cdipt gene, 
thereby creating cdipt- cells. For PCR screening (Figure 6.3A), primers were 
designed around the 5’ and 3’ regions of the blasticidin resistance cassette which 
amplified a product from the endogenous gene (genomic control), resulting in a 5’ 
(500 bp) and 3’ (450 bp) band for both WT and transformant cells. A second primer 
set amplified a product from the gene fragment into the vector sequence (vector 
control), which resulted in a 530 bp or 500 bp band for the 5’ and 3’ screen only in 
transformant cells. Finally, homologous recombinant cells were identified by 
amplifying a region that will be produced (560 bp and 530 bp band for the 5’ and 3’ 
Cdipt fragments respectively) only in cdipt- cells covering the endogenous gene 
fragment and the blasticidin resistance cassette (knockout diagnostic).  
 
Numerous attempts were made to identify a cdipt- mutant using the Cdipt knockout 
cassette. A total of 6 electroporations yielded 293 independent blasticidin resistant 
mutants that were individually screened (Figure 6.3B and 6.3C). From this work, no 
cdipt- cells were identified. Around 28 transformants were additionally grown in the 
presence of PI (100 M) in case the null mutant was an auxotroph. This approach 
was taken as CDIPT has been shown to be essential in other organisms with one 
protein isoform (Nikawa, Kodaki and Yamashita, 1987; Wang and Montell, 2006). 
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Figure 6.3 PCR screening of potential cdipt- transformant cells using knockout cassette 1. 
(A) Schematic representation of the Cdipt gene containing the homologous integrated 
knockout construct. The locations of the screening primers (arrows) and the corresponding 
PCR product (dotted line) used for determining homologous integration are shown for 
genomic (pink), vector (blue) and knockout diagnostic (yellow) primers and the predicted 
sizes of these products. (B) 5’-terminal PCR screening of blasticidin-resistant cells with 
genomic control (G), vector control (V) and knockout diagnostic (K). PCR products are 
shown where the genomic control (G) band is amplified from WT DNA, genomic (G) and 
vector (V) control bands are amplified from non-homologous integrant (NH) DNA and all 3 
bands are (G, V and knockout diagnostic (K)) are amplified from the potential knockout 
(cdipt-) DNA. Molecular weights of the DNA ladder are indicated on the left of the gel image 
(1000 bp- 200 bp). 
6.3 Construction of cdipt- Knockout Vector Part 2 
To overcome the unsuccessful creation of cdipt- D. discoideum cells, a second Cdipt 
knockout plasmid was produced. This second knockout plasmid had an increased 
size of exon sequence (from 532 bp to 563 bp) and reduced number of base pairs 
being deleted (from 110 bp to 5 bp), to increase the likelihood of homologous 
integration (Figure 6.4A). The second Cdipt recombinant plasmid was produced in 
the same way as the first, whereby two Cdipt PCR amplified DNA fragments (317 bp 
and 357 bp for the 5’ and 3’ fragments respectively) located within the coding 
sequence were inserted on either side of a blasticidin resistance gene. Restriction 
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mapping (Figure 6.4C) was used to confirm the presence of the four restriction 
enzyme cut sites used for cloning (BamHI, PstI, HindIII and KpnI) by a single digest, 
resulting in one band at 5000 bp. The presence of the Cdipt 5’ (320 bp) and 3’ (360 
bp) fragments within the knockout vector were confirmed by double restriction 
digests, whereby two bands were obtained, one whose size confirmed the correct 
insertion of the Cdipt fragment and the second being the remaining recombinant 
plasmid (4900 bp and 5000 bp for 5’ and 3’ gene fragments respectively). The 
knockout cassette was excised from the vector using the enzymes BamHI and KpnI, 
which produced a band at 2600 bp, with the remaining plasmid band at 2900 bp.  
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Figure 6.4 Confirmation of the Cdipt knockout construct 2. (A) Cdipt genomic DNA with 
the region to be knocked out highlighted in yellow and the 5’ and 3’ genomic DNA 
fragments which were PCR amplified using primers containing cut sites for BamHI (B), PstI 
(P), HindIII (H) and KpnI (K). (B) pLPBLP-cdipt plasmid map containing the 5’ and 3’ Cdipt 
fragments cloned into either side of the blasticidin resistance cassette. (C) Confirmation of 
the Cdipt inserts in the pLPBLP vector by a series of single and double restriction digests 
visualised following gel electrophoresis with a ladder (L), negative control with no plasmid 
(-ve), uncut knockout vector (U), single digests confirming individual enzyme activity of 
BamHI (B), PstI (P), HindIII (H) and KpnI (K) and double digests confirming the presence of 
the 5’ and 3’ fragments using BamHI-PstI (B-P) and HindIII-KpnI (H-K) and the linearized 
knockout cassette used for electroporation excised with BamHI- KpnI (B-K). To the left of 
the gel image are the molecular weights of the DNA ladder (10037 bp- 200 bp) and to the 
right are the expected plasmid insert sizes (arrows). 
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6.4 Screening and Confirmation of Potential cdipt- D. 
discoideum Cells Part 2 
The second Cdipt knockout cassette was then digested and electroporated into WT 
D. discoideum cells (Figure 6.4). Transformant cells were selected by growth in the 
presence of blasticidin. Surviving colonies were screened by PCR to identify cdipt- 
homologous recombinants. For this vector, new screening primers for the genomic 
control, which amplified DNA from outside to within the fragment of interest at the 
5’ (330 bp) and 3’ (370 bp) region were produced, where a band for this control was 
expected in both WT and transformant cells. New vector control primers were also 
produced which confirmed the 5’ (390 bp) and 3’ (280 bp) Cdipt fragments were 
located on either side of the blasticidin resistance cassette and so a band would 
only be amplified from transformant cell DNA containing the blasticidin resistance 
cassette (Figure 6.5A). Potential homologous recombinant cells were identified 
using the knockout diagnostic primers where DNA was amplified from outside the 
inserted fragment to within the blasticidin resistance cassette, with expected PCR 
products of 450 bp for the 5’ fragment and 590 bp for the 3’ fragment.  
 
Numerous attempts were again made to identify a cdipt- mutant using the second 
Cdipt knockout vector. Transformation of the second Cdipt knockout cassette 
resulted in 427 blasticidin resistant colonies, of which 232 colonies were grown in 
media supplemented only with blasticidin and 195 colonies were grown in media 
supplemented with blasticidin and PI (100 M) (the product of CDIPT). Whilst 
screening transformant colonies grown in media containing PI and blasticidin, 8 
independent colonies were identified which contained a PCR fragment amplified 
using the 3’ knockout diagnostic primers. However, this band was smaller than 
expected (approximately 140 bp). When the 5’ terminus was screened, 3 of these 8 
independent colonies also amplified a 5’ knockout diagnostic band of the expected 
size (Figure 6.5B and 6.5C). To determine whether these 3 transformant colonies 
which amplified both the 5’ and 3’ knockout diagnostic band were cdipt- cells, the 
PCR fragment produced using the 3’ knockout diagnostic primers for each 
transformant was cloned into TA and sequenced. Sequencing confirmed that these 
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colonies contained the Cdipt 3’ fragment, however, a loop had formed, resulting in 
part of the sequence being lost (Figure 6.5D) and thereby resulted in a larger 
number of base pairs being deleted from the Cdipt gene within these 3 colonies. In 
the subsequent process of isolating isogenic cell lines of these 3 independent 
transformants, all the cell lines ceased to grow.   
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Figure 6.5. PCR screening of potential cdipt- transformant cells using knockout cassette 2. 
(A) Schematic representation of the Cdipt gene containing the homologous integrated 
knockout construct. The locations of the screening primers (arrows) and the corresponding 
PCR product (dotted line) used for determining homologous integration are shown- 
genomic (pink), vector (blue) and knockout diagnostic (yellow) primers along with the 
predicted sizes of the products. (B) 3’- and (C) 5’ PCR screening of transformant cells 
showing the genomic control (G), vector control (V) and knockout diagnostic (K). PCR 
products are shown where the genomic control (G) band is amplified from WT DNA, 
genomic (G) and vector (V) control bands are amplified from non-homologous integrant 
(NH) DNA and all 3 bands are (G, V and knockout diagnostic (K)) are amplified from the 
potential knockout (cdipt-) DNA. (D) Illustration of the 3’ knockout diagnostic PCR fragment 
taken from sequencing results where the region in grey indicates the size of the 3’ 
fragment sequence which formed a loop and was additionally knocked out, resulting in a 
smaller 3’ fragment adjacent to the blasticidin resistance cassette. Molecular weights of 
the DNA ladder (1000 bp-200 bp) are indicated on the left of the gel image. 
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6.5 Preparing a Cdipt Overexpression Construct  
To create WT::RFP-cdipt D. discoideum cells, an 5’ RFP tag overexpression construct 
(389-19 mRFPmrs) (Basu, et al., 2013; Fey et al., 2013) containing PCR amplified 
Cdipt cDNA was created (Figure 6.6A). Cdipt cDNA (624 bp) was amplified using 
primers containing cut sites for the restriction enzymes BamHI and EcoRI and this 
fragment was cloned into the 5’ RFP tagged overexpression construct. Restriction 
mapping was used to confirm the presence of the two restriction sites used for 
cloning (BamHI and EcoRI), which produced a single band at approximately 6500 
bp. A double digest using the same two restriction enzymes confirmed the insertion 
of the Cdipt cDNA PCR amplified product with a band at approximately 620 bp and 
a second band at 5900 bp corresponding to the RFP plasmid (Figure 6.6B). This 
construct was sequenced to ensure that there were no mutations in the inserted 
PCR product. WT::RFP-cdipt D. discoideum cells were then created by 
electroporating the 5’ RFP tagged-cdipt overexpression construct into WT cells and 
selecting cells by growth in the presence of neomycin (G418).  
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Figure 6.6 Confirmation of the RFP-cdipt overexpression construct. (A) Schematic 
representation of Cdipt cDNA showing the primer locations (arrows) used for PCR 
amplification and the cut sites BamHI (B) and EcoRI (E) used for cloning the Cdipt cDNA into 
the 5’ RFP- expression vector. (B) Confirmation of Cdipt cDNA inserted into the RFP- 
expression vector by a series of single and a double restriction digest visualised following 
gel electrophoresis with a ladder (L), uncut vector (U), single digests confirming individual 
enzyme activity of BamHI (B) and EcoRI (E) and a double digest to confirm the presence of 
Cdipt PCR fragment using BamHI-EcoRI (B-E). DNA ladder molecular weights (1000 bp-     
200 bp) are indicated on the left of the gel image and to the right is the expected PCR 
fragment insert size (arrow). 
 
CDIPT expression within WT::RFP-cdipt cells was examined by Western blotting. 
Comparison was made to WT cells and protein loading was identified by comparing 
with MccA (also known as Mccc1) expression (Davidson, King and Insall, 2013). As 
expected, there was no expression of RFP in WT cells and surprisingly there was low 
RFP-CDIPT expression in the neomycin resistant WT::RFP-cdipt cells at the expected 
size (77 kDa) (Figure 6.7A). Fluorescence microscopy was then used to confirm RFP 
localization in WT::RFP and WT::RFP-cdipt cells. In these experiments WT::RFP cells 
showed fluorescence with no specific localization, consistent with the RFP protein 
being present in the cytosol. In contrast, WT::RFP-cdipt cells showed florescence at 
low level within the cytosol and high levels of fluorescence localized within puncta 
(Figure 6.7B). As CDIPT has transmembrane domains, the puncta staining could be a 
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membrane compartment, with the possibility of vesicles. The cytosolic RFP signal 
could be a result of cleavage of the fluorescent tag from the full-length protein.  
 
 
Figure 6.7. CDIPT expression and localization. (A) Western blot of WT cells expressing no 
RFP and WT::RFP-cdipt cells showing a control MccA band to compare protein loading 
between the two cell lines and a weak RFP-CDIPT band in WT::RFP-cdipt cells. (B) WT:: RFP 
and WT::RFP-cdipt cells were visualized using fluorescence microscopy. RFP in WT cells 
showed cytosolic localization whereas RFP-CDIPT appears to be mainly localized within 
membrane bound vesicles and at low levels within the cytosol. Scale bars represent 10 m. 
6.6 Phenotypic Characterization of WT::RFP-cdipt Cells  
Since CDIPT ablation appeared to be lethal, an overexpression approach was taken 
to manipulate levels of the enzyme. Phenotypic changes caused by the 
overexpression of CDIPT in WT::RFP-cdipt cells were investigated through a series 
of experiments by comparison with WT::RFP cells. These experiments involved 
determining the effects of VPA on growth and development in these two cell lines. 
WT::RFP-cdipt cells were then exposed to a range of anti-seizure compounds and 
the BD treatment LiCl during D. discoideum development.  
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6.6.1 Analysis of WT::RFP-cdipt Cell Growth in the Presence of VPA 
Since WT::RFP-cdipt cells had the RFP-CDIPT protein mainly localized within 
membrane bound vesicles, these cells were assessed for altered susceptibility to 
VPA during growth. Cell growth was initially investigated as VPA inhibits D. 
discoideum cell proliferation in a dose-dependent manner (Terbach, et al., 2011). 
WT::RFP and WT::RFP-cdipt cells were grown for 168 hours in a range of VPA 
concentrations (0.01 mM-2 mM), widely spanning the therapeutic (plasma) 
concentration of 0.3 mM-0.6 mM (Kanner, 2003; Vázquez-Calvo, et al., 2013) 
(Figure 6.8). Under control conditions, in the absence of VPA, no difference in cell 
growth between the two cell lines was identified. In the presence of VPA, however, 
WT::RFP cells showed a dose-dependent reduction on cell growth (Figure 6.8A), 
whereas WT::RFP-cdipt cells appeared to be less sensitive to VPA at 0.125 mM and 
0.25 mM. At 0.5 mM VPA there was a statistically significant difference (P value 
0.0005) using the Kruskal- Wallis test between the two cell lines, suggesting altering 
CDIPT expression reduces VPA-sensitivity during cell growth (Figure 6.8B). The IC50 
values for the two cell lines also illustrated WT::RFP-cdipt cell resistance to VPA 
during chronic exposure, with IC50 values of 0.5  0.08 mM VPA for WT::RFP cells 
and 1.1  0.02 mM for WT::RFP-cdipt cells (Figure 6.8C). 
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Figure 6.8. WT::RFP and WT::RFP-cdipt growth in both the absence and presence of VPA. 
(A) WT::RFP and (B) WT:RFP-cdipt cell proliferation was determined in both the absence 
(control, black) and presence of VPA at indicated concentrations (at increasing shades of 
blue) VPA for 168 hours. (C) A secondary plot illustrating the normalized change in the rate 
of cell growth between 96 and 144 hours plotted against log VPA concentration for 
WT::RFP and WT::RFP-cdipt cells. Statistically significant differences in cell proliferation 
were identified at 0.5 mM VPA tested between the two cell lines using the Kruskal- Wallis 
test and Dunns post hoc test. Data presented as mean (+/- SEM). n =6. *** P value = 
0.0005. 
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6.6.2 Analysis of WT::RFP-cdipt Cell Development in the Presence of VPA  
The D. discoideum developmental cycle results from starvation and involves single 
cells migrating together to form a fruiting body (Figure 1.6). Previous work using D. 
discoideum has shown VPA to inhibit fruiting body formation (Williams, et al., 
2002). In order to investigate the effects of VPA on WT::RFP and WT::RFP-cdipt cell 
development, cells were starved for 24 hours on nitrocellulose filters to induce 
development in both the absence (control) and presence of 0.3 mM, 0.5 mM and 1 
mM VPA (Figure 6.9). Both cell lines in the absence of VPA were able to develop 
into fruiting bodies containing a basal disc, stalk and spore head of similar size, 
showing that an altering CDIPT activity does not effect D. discoideum development. 
In the presence of 0.3 mM and 0.5 mM VPA, WT::RFP cells developed to the finger 
stage. In contrast, WT::RFP-cdipt cells developed into multicellular fruiting bodies 
resembling control conditions in the presence of 0.3 mM and 0.5 mM VPA. This 
data suggests that altering CDIPT levels in D. discoideum causes resistance to VPA 
dependent inhibition during development.    
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Figure 6.9. WT::RFP and WT::RFP-cdipt development in both the absence and presence of 
VPA. WT::RFP (left) and WT::RFP-cdipt (right) cells were developed on nitrocellulose 
membranes for 24 hours both in the absence (top row) and presence (descending rows) of 
0.3 mM, 0.5 mM and 1 mM VPA. Images were taken of an overhead view (left) of the 
whole membrane and of a single fruiting body (right). Both cell lines developed into mature 
fruiting bodies in the absence of VPA. WT::RFP cells in the presence of 0.3 mM and 0.5 mM 
developed to the finger stage and when exposed to 1 mM VPA into a mound after 24 
hours. In contrast, WT::RFP-cdipt cells were resistant to the effects of VPA and contained  
to develop into mature fruiting bodies when exposed to 0.3 mM and 0.5 mM VPA and into 
a mound in the presence of 1 mM VPA. n = 3. Scale bar of the overhead view represents 0.5 
mm and of the side view 0.1 mm. 
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6.6.3 Analysis of WT::RFP-cdipt Cell Development in the Presence of Anti-Seizure 
Compounds and LiCl 
WT::RFP-cdipt cells were also investigated as a potential target of other anti-seizure 
compounds and a BD treatment due to the use of VPA in both disorders. The 
compounds chosen for analysis have previously been shown to have an effect on 
growth, development and inositol phosphate and phosphoinositide signalling in D. 
discoideum and in mammalian epilepsy models (Williams, et al., 1999; Williams, et 
al., 2002; Eickholt, et al., 2005; Ludtmann, Boeckeler and Williams, 2011; Elphick, et 
al., 2012; Chang, et al., 2012; Chang, et al., 2013; Chang, et al., 2015; Chang, et al., 
2016). Cells were starved for 24 hours on nitrocellulose filters to induce 
development in both the absence (control) and presence of a range of anti-seizure 
compounds at concentrations which blocked WT development (Figure 6.10). VPD 
(6.5 mM) and PIA (1.4 mM) were selected as they are structurally related to VPA 
(Eickholt, et al., 2005; Ludtmann, Boeckeler and Williams, 2011; Elphick, et al., 
2012) and DA (1.65 mM) and OA (0.22 mM) were chosen as they are key 
components of the MCT diet, used for the treatment of drug-resistant epilepsy 
(Chang, et al., 2012; Chang, et al., 2013; Chang, et al., 2016). Branched chain fatty 
acids were also investigated, including 4-EOA (0.5 mM) which has proven anti-
seizure and neuroprotection effects and 2-MHA (0.5 mM) which tested as a 
negative control as it has no activity in D. discoideum nor does it have an effect on 
preventing seizures (Chang, et al., 2012; Chang, et al., 2013; Chang et al., 2015). As 
shown previously, both cell lines under control conditions were able to develop into 
mature fruiting bodies with a basal disc, stalk and spore head. In the presence of 
VPD, DA, OA, 4-EOA, 2-MHA or LiCl neither WT::RFP and WT::RPF-cdipt developed 
into mature fruiting bodies, suggesting that the mechanism of action of these 
compounds does not involve altering CDIPT levels. However, in the presence of PIA, 
WT::RFP cells developed to the mound stage whereas WT::RFP-cdipt cells 
developed into mature fruiting bodies after 24 hours resembling control conditions. 
This result suggests that the mechanism of action of PIA does involve regulating 
CDIPT during D. discoideum development.  
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Figure 6.10. WT::RFP and WT::RFP-cdipt development in both the absence and presence 
of a range of other compounds. WT::RFP (left) and WT::RFP-cdipt (right) cells were 
developed on nitrocellulose membranes for 24 hours both in the absence (top row) and 
presence (descending rows) of VPD, PIA, DA, OA, 4-EOA, 2-MHA and LiCl at the stated 
concentrations to the left of the development images. Images were taken of an overhead 
view of the whole membrane (left) and of a single fruiting body (right). Both cell lines 
produced fruiting bodies in the absence of any compound. In the presence of VPD, DA, OA, 
4-EOA, 2-MHA and LiCl both WT::RFP and WT::RFP-cdipt cells developed to the mound 
stage. However, in the presence of 1.4 mM PIA, WT::RFP-cdipt cells were able to develop 
into mature fruiting bodies at concentrations where WT::RFP developed into mounds. n = 
3. Scale bar of the overhead view represents 0.5 mm and of the side view 0.1 mm. 
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6.7 Discussion 
VPA has been shown to reduce D. discoideum phosphoinositide levels (Chang, et al., 
2012). To investigate targets for this effect, a range of mutants were assessed, 
enabling the elimination of PI3K activity, inositol recycling, de novo inositol 
biosynthesis and de novo inositol production (Chang, et al., 2012; Frej, et al., 2016) 
as a mechanism of action of VPA. One remaining unexplored option is the PI salvage 
pathway. For this reason, this chapter has investigated CDIPT, the enzyme 
responsible for the deAMPylation of CDP-DAG and myo-inositol into PI. This chapter 
has described attempts to ablate the encoding gene (Figures 6.2- 6.5), the 
overexpression of CDIPT (Figure 6.6 and 6.7) and characterization of this mutant in 
both the absence and presence of a range of anti-seizure compounds including VPA 
and LiCl, a BD treatment (Figures 6.8-6.10).  
 
In order to ablate CDIPT from D. discoideum cells, two cdipt knockout constructs 
were created using the pLPBLP vector (Faix, et al., 2004). The first knockout 
cassette contained targeting regions including non-coding sequence and deleted a 
large region of the open reading frame. The second construct contained more exon 
sequence in the targeting region to increase the likelihood of homologous 
integration but deleted only a small central region of the gene. Using the second 
construct, 3 independent cdipt- cell lines were identified, however, all 3 cell lines 
died shortly after isolation. From this result, it may be the case that CDIPT is vital in 
D. discoideum. This is supported by studies in other organisms including yeast 
(Nikawa, Kodaki and Yamashita, 1987), T. brucei (Martin and Smith, 2006) and 
Drosophila (Wang and Montell, 2006). For this reason, potential cdipt- cells were 
grown in media supplemented with the enzyme product PI to increase the chances 
of identifying a knockout cell line as it has previously been shown that D. 
discoideum cells can take up exogenous fatty acids (Elphick, et al., 2012). A 
rationale for this vital function may be that CDIPT is a downstream regulator of the 
cell cycle G1 phase and therefore, removal of this protein would prevent cells 
progressing into the cell cycle (Deguchi, et al., 2002).  
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Since ablation of CDIPT did not provide a practical approach, the protein was 
overexpressed with an N-terminal RFP-tag, resulting in WT::RFP-cdipt cells. 
Characterization of the resulting mutant initially involved Western blotting to 
ensure the presence of the entire RFP-CDIPT in WT::RFP-cdipt cells. Unfortunately, 
low levels of soluble RFP-CDIPT was detected in the WT::RFP-cdipt neomycin 
resistant cells by Western blotting. As the WT::RFP-cdipt cells were resistant to the 
selection marker neomycin, and should be expressing the protein, cells were 
examined using fluorescence microscopy. WT::RFP cells were used as a control 
which showed RFP present in the cytosol. In contrast, WT::RFP-cdipt cells showed 
RFP-CDIPT mainly localized within puncta. Due to the transmembrane domains 
present within the CDIPT protein structure there is a high chance the puncta 
staining is a membrane compartment, such as a vesicle. The low RFP-CDIPT 
expression within the cytosol suggests the protein is slightly overexpressed or the 
RFP tag has been cleaved from the full length protein. This localization was 
inconsistent with other models, where the protein has been found to localize within 
the endoplasmic reticulum in mammals (Deguchi, et al., 2002; Williamson and 
Morré, 1976) and plants (Carman and Dougherty, 1980; Löfke, et al., 2008), 
although it has also been detected within the Golgi and plasma membrane 
(Williamson and Morré, 1976). This resistant phenotype is unusual when the 
soluble protein is expressed in the cytosol at low levels, suggesting these cells could 
be overexpressing CDIPT or CDIPT is knocked-down. In order to determine whether 
these cells are overexpressing or have CDIPT knockdown, Western blotting using a 
CDIPT specific antibody would need to be conducted and CDIPT expression within 
WT and WT::RFP-cdipt cells would need to be compared. If the amount of CDIPT is 
higher in WT::RFP-cdipt cells, this mutant is overexpressing CDIPT. However, if 
there is a reduction in CDIPT, then the cells are a knockdown. Other approaches 
that can be taken are thin layer chromatography to quantify production of PI 
(Chang, et al., 2012) and thereby determine enzyme activity or by conducting PI: 
inositol exchange reactions (Lykidis, et al., 1997).   
There are two possible reasons for this puncta staining. The first is simply that 
aggregation of the overexpressed protein into membrane bound vesicles is due to 
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the tight regulation of the CDP-DAG pool, the substrate of CDIPT, which has been 
reported previously (Lykidis et al., 1997) and therefore, maintains near WT levels of 
PI. The second explanation is that CDIPT overexpression results in the sequestering 
of the overexpressed and endogenous protein, resulting in a knockdown of CDIPT. 
When proteins are tightly regulated the cell prevents toxicity by packing excess 
protein into storage vesicles in a process shown in mammalian models during drug-
induced phospholipidosis (Yamamoto, et al., 1971; Seiler and Wassermann, 1975). 
Phospholipidosis can be caused by cationic amphiphilic drugs which result in 
increased production of PI, leading to accelerated formation of membrane bound 
vesicles as shown by the malarial drug chloroquine (Matsuzawa and Hostetler, 
1980). These vesicles may then be acting as autophagosomes to enable the excess 
protein to be degraded by lysosomes, as it is known that early structures of 
autophagy are formed close to the endoplasmic reticulum (Axe, et al., 2008), 
mitochondria (Hamasaki, et al., 2013)  and Golgi (Ge, et al., 2013). The reason for 
this is that the Unc-51 autophagy activating kinase localizes first to CDIPT enriched 
subdomains in order for punctate autophagosome structures to be formed from PI 
(Nishimura, et al., 2017). 
Despite the low level of expression and the cellular localization of CDIPT, cell 
growth was compared between WT::RFP and WT::RFP-cdipt cells in both the 
absence and presence of VPA. WT::RFP-cdipt cells grew at a similar rate to WT::RFP 
cells, with no significant differences identified under control conditions. In 
Arabidopsis when the two CDIPT isoforms were overexpressed, the resulting plants 
had decreased leaf size area compared with control (Löfke, et al., 2008), suggesting 
CDIPT overexpression results in reduced cell growth. However, this was not seen in 
WT::RFP-cdipt cells, where the protein is located within puncta and so differences 
between cell growth of CDIPT overexpressed in plants and D. discoideum were not 
unexpected.  
 
Chronic VPA treatment on cell growth resulted in a dose-dependent reduction in 
cell number for WT::RFP cells. In contrast, WT::RFP-cdipt cells were resistant to VPA 
at physiological concentrations (0.3 mM- 0.6 mM) (Kanner, 2003; Vázquez-Calvo et 
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al., 2013). These results suggest that the mechanism of action of VPA relies on 
altering the activity of CDIPT and thus the levels of PI. This theory supports work 
published in 1987 which found the levels of PI to decrease during seizures in 
association with increased free fatty acids and DAG (Yoshida, et al., 1987). In this 
study a number of salvage pathway components were measured (PI, PIP, PIP2, DAG 
and PA) as well as free fatty acids from forebrain tissue of rats at 1, 20 and 60 
minutes after seizure induction by bicuculline. During the 60 minutes, DAG levels 
increased alongside a progressive reduction in PI whilst PIP, PIP2 and PA did not 
change. At the start of the seizure the levels of free fatty acids increased but 
dropped during seizure progression as the free fatty acids were converted into 
triglycerides (Yoshida et al., 1987). The mechanism of action of VPA, therefore, may 
be in regulating PI levels during D. discoideum cell growth. 
 
The D. discoideum developmental cycle was also investigated. WT::RFP and 
WT::RFP-cdipt cells developed into mature fruiting bodies of similar size under 
control conditions. In the presence of 0.3 mM- 1 mM VPA, WT::RFP cell 
development was delayed at the finger and mound stage. In contrast, WT::RFP-
cdipt cells were resistant to the effect of VPA at therapeutic concentrations (0.3 
mM and 0.5 mM) and continued to develop into mature fruiting bodies, although 1 
mM VPA blocked development. In D. discoideum it is likely that distorted levels of 
CDIPT and PI are responsible for VPA resistance. VPA resistance in this mutant is 
key as this drug is used to control seizures in epilepsy patients. Both 
epileptogenesis and seizures are generated from calcium-dependent signalling 
pathways, where prolonged seizures rely on a constant supply of PIP2, whose 
hydrolysis into IP3 releases stored calcium (Alswied and Parekh, 2015). The supply 
of PIP2 relies on PI synthesis and phosphorylation, suggesting PI is important in 
seizure generation and progression. Therefore, if the mode of action of VPA relies 
on altering PI levels, this will in turn effect calcium signalling. Of interest, calcium-
dependent signalling pathways are being used as targets for new AEDs, e.g. 
levetiracetam whose mode of action in part modulates the influx of calcium 
(Niespodziany, Klitgaard and Margineanu, 2001; Steinlein, 2014).   
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A range of anti-seizure compounds, including those structurally related to VPA and 
components of the MCT diet and the BD treatment LiCl, were also investigated 
during D. discoideum development. In the presence of VPD, DA, OA, 4-EOA, 2-MHA 
and LiCl both WT::RFP and WT::RFP-cdipt developed to the finger or mound stage. 
However, in the presence of 1.4 mM PIA, at a concentration where WT::RFP 
development was inhibited, WT::RFP-cdipt cells developed into mature fruiting 
bodies resembling control conditions. In D. discoideum, therefore, it is likely that 
distorted levels of CDIPT are responsible for PIA resistance, suggesting VPA and PIA 
regulate the same targets. Sensitivity of WT::RFP-cdipt cells to VPD was not 
unexpected as previous studies have shown VPD and VPA work through a similar 
target, but through altered pathways (Ludtmann, Boeckeler and Williams, 2011). In 
this study, both VPA and LiCl were found to increase pERK2 levels, whereas, this is 
only partially achieved with VPD treatment in D. discoideum (Ludtmann, Boeckeler 
and Williams, 2011). This suggests a similar mode of action of VPA and VPD, 
however altering CDIPT levels is not common to both treatments.  
6.8 Summary 
In D. discoideum it is likely that CDIPT expression is essential for cell survival, 
consistent with previous studies in models containing one protein isoform. This is 
also the case when media is supplemented with the reaction product PI. This 
function made gene ablation complex, and so an overexpression approach was 
employed. Western blot analysis identified low levels of soluble RFP-CDIPT in 
WT::RFP-cdipt cells, with fluorescence microscopy showing RFP-CDIPT localized 
within membrane bound vesicles. WT::RFP-cdipt cells showed resistance to VPA 
during both growth and development at therapeutic concentrations, indicating a 
role for CDIPT in VPA cellular function. WT::RFP-cdipt cells were also resistant to the 
effect of PIA, suggesting this drug has a similar mode of action to VPA. It remains to 
be determined if this VPA-resistance is derived from slightly elevated or depleted 
CDIPT levels.  
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7. Analysis of DGKA as a Target of VPA 
DGK is the enzyme responsible for the phosphorylation of DAG to form PA within 
the PI salvage pathway (Figure 1.4 and Figure 7.1) Both DAG and PA are important 
signalling molecules, where DAG is involved in the signalling of PKC (van Baal, et al., 
2005), synaptic plasticity (Lee, Kim and Tanaka-Yamamoto, 2016) and the synthesis 
of triglycerides and PC and PE via the Kennedy pathway (Kennedy and Weiss, 1956; 
Gibellini and Smith, 2010). PA has a role in cell growth (Banfić, et al., 1993), lipid 
regulation (Cerbón, et al., 2005) and calcium signalling (Carpio and Dziak, 1998). 
DGK is a protein of interest as a VPA target due to the number of signalling 
pathways both DAG and PA regulate. A previous study using C. elegans has shown 
VPA effects DAG signalling (Tokuoka, Saiardi and Nurrish, 2008). Additionally, 
knockout studies have linked DGK- (Leach, et al., 2007), - (Rodriguez de Turco, et 
al., 2001) and - to epilepsy and DGK- (Ishisaka, et al., 2013) and - to BD (Baum, 
et al., 2008; Squassina, et al., 2009; Kakefuda, et al., 2010).  
 
 
Figure 7.1. The catalytic activity of diacylglycerol kinase. Diacylglycerol (DAG) is 
phosphorylated into phosphatidic acid (PA) by diacylglycerol kinase (DGK) in the 
phosphatidylinositol salvage pathway.  
 
In D. discoideum there is only one DGK gene, DgkA (DDB_G0277223) of 4751 bp 
with one intron, which encodes a protein of 887 amino acids. This gene is expressed 
during the developmental cycle, with peak expression at 8 hours and 24 hours after 
induction of starvation (Parikh, et al., 2010; Stajdohar, et al., 2015). D. discoideum 
DGKA has similar homology to all 10 H. sapiens orthologues (ranging from 27-33 % 
identity), with highest identity to H. sapiens DGK- (37 % identity) (Chapter 4). This 
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suggests that the D. discoideum DGKA may act as a generic DGK, thereby regulating 
the same pathways as the 10 H. sapiens DGKs.   
 
Studies researching D. discoideum DGKA have previously been undertaken. In 1996, 
Abu- Elneel, Karchi and Ravid created a cell line in parental JH10 which they 
believed to have ablated MHC-PKC. However, in 2002, De La Roche et al., published 
work reporting the mislabelling of this MHC-PKC mutant to be the single DGK in D. 
discoideum, dgkA. Abu- Elneel, Karchi and Ravid (1996) investigated the localization 
of MHC, where protein expression was identified at the cell membrane in WT 
(JH10) cells, but this was impaired in dgkA- (JH10) cells. The authors also found a 
delay in development of mature fruiting bodies in dgkA- (JH10) cells from 24 hours 
to 44-48 hours with upward extensions from the spore fruiting body head 
compared with WT (JH10) cells (Abu-Elneel, Karchi and Ravid, 1996).  
 
This chapter, therefore, describes the ablation of DgkA via a knockout construct in 
the Ax2 background and the creation of a rescue cell line. Phenotypic 
characterization of both the ablated dgkA- and rescue dgkA-/+ cells are described. 
Phenotypic characterization involved investigating the localization of MHC in the 
dgkA- cells. The effects of VPA were then investigated during growth, acute cell 
behaviour and development of dgkA- cells with resistant phenotypes being rescued 
on the reintroduction of the gene in dgkA-/+ cells. The effects of other anti-seizure 
compounds and the BD treatment LiCl were also investigated on dgkA- and dgkA-/+ 
cell development. DAG levels were then quantified by an ELISA assay in both the 
absence and presence of all compounds tested.  
7.1 Confirmation of DgkA Knockout Vector  
A previously made recombinant pLPBLP plasmid (Faix, et al., 2004) containing two 
distal PCR amplified DgkA gene fragments inserted on either side of a blasticidin 
resistance cassette was initially examined to verify the presence of the two DgkA 
fragments (Figure 7.2A and 7.2B). The 5’ fragment was 556 bp which started 173 bp 
within the open reading frame and contained no introns. Similarly, the 3’ fragment 
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was 484 bp and only consisted of coding sequence with no introns, resulting in the 
cloning of 729 bp exon sequence. The construct would, therefore, remove 1562 bp 
of coding sequence. Restriction mapping (Figure 7.2C) confirmed the presence of 
the four restriction sites used for cloning the two distal DgkA PCR fragments into 
the pLPBLP vector (BamHI, PstI, NcoI and HindIII). A series of single restriction 
digests resulted in a single band at approximately 5500 bp, corresponding to the 
two DgkA fragments inserted into the pLPBLP plasmid. Restriction mapping also 
confirmed the insertion of the correct sized DgkA fragments within the knockout 
plasmid, producing two bands of 560 bp for the 5’ gene fragment and the 
remaining plasmid at 4900 bp. The 3’ fragment was identified at 480 bp with the 
remaining plasmid at 5000 bp. The knockout cassette containing the 5’ and 3’ DgkA 
gene fragments located on either side of the blasticidin resistance cassette were 
then excised from the pLPBLP-dgkA recombinant plasmid using the enzymes BamHI 
and HindIII. Two bands were obtained, one at 2570 bp consistent with the size of 
the DgkA knockout cassette and the second of the remaining pLPBLP plasmid at 
2900 bp.   
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Figure 7.2. Confirmation of the DgkA knockout construct. (A) DgkA genomic DNA with the 
yellow box indicating the region knocked out and the arrows indicating the 5’ and 3’ 
genomic DNA fragments which were PCR amplified using primers containing cut sites for 
BamHI (B), PstI (P), NcoI (N) and HindIII (H). (B) Plasmid map of pLPBLP-DgkA containing the 
5’ and 3’ DgkA fragments cloned into the plasmid on either side of the blasticidin resistance 
cassette by BamHI (B), PstI (P), NcoI (N) and HindIII (H). (C) Confirmation of the DgkA 
inserts within the pLPBLP-dgkA vector by a series of single and double restriction digests 
visualised following gel electrophoresis with a ladder (L), negative control without plasmid 
(-ve), uncut knockout vector (U), single digests confirming individual enzyme activity of 
BamHI (B), PstI (P), NcoI (N) and HindIII (H) and double digests confirming the presence of 
the 5’ and 3’ fragments using BamHI-PstI (B-P) and NcoI-HindIII (N-H) and the linearized 
knockout cassette used for electroporation with BamHI- HindIII (B-H). Molecular weights of 
the DNA ladder are indicated on the left of the gel image (10037 bp- 200 bp) and the 
expected plasmid insert sizes are given (arrows) to the right of the image. 
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7.2 Screening Potential dgkA- D. discoideum Cells 
To ablate DgkA from D. discoideum, the DgkA knockout cassette (Figure 7.2) was 
electroporated into WT cells and selected for resistance to blasticidin during cell 
growth. Surviving colonies were screened by PCR to identify transformant cells 
which had the knockout cassette integrated into the DgkA gene, creating dgkA- 
cells. PCR screening involved designing primers around the two dgkA fragments and 
the blasticidin resistance gene to amplify a region from outside to inside the 
targeting fragment of the 5’ (520 bp) and 3’ (540 bp) terminal (genomic control). 
Primers were also designed to amplify a region from within the targeting fragment 
into the blasticidin resistance gene (product size expected at 660 bp for the 5’ 
region and 680 bp for the 3’ region in transformant colonies only) (vector control). 
Finally, primers were used which amplified outside the targeting fragment into the 
blasticidin resistance gene (knockout diagnostic), which had a product size 
expected at 730 bp for both the 5’ and 3’ regions (Figure 7.3A).  
 
Numerous attempts were made to identify dgkA- mutants using the DgkA knockout 
cassette. A total of 5 electroporations resulted in 206 blasticidin resistant colonies 
which were individually screened (Figure 7.3B and 7.3C). This approach identified 7 
dgkA- homologous integrants. Single isogenic lines of 3 of these homologous 
integrants were obtained by inoculating cells from an individual colony grown on 
each of the 3 R. planticola plates.  
 
To ensure the potential dgkA- mutants had lost part of the coding region in these 3 
cell lines, complementary cDNA was synthesised and analysed by RT- PCR.  Since 
DgkA is expressed following starvation (Parikh, et al., 2010; Stajdohar, et al., 2015), 
cells which had developed for 8 hours were used for analysis. Loss of part of the 
DgkA gene was confirmed using primers which annealed to the region deleted in 
the potential dgkA- cells. RT-PCR resulted in a 529 bp product only in WT cells, 
confirming the 3 homologous integrants as dgkA- cells. Control primers for the 
housekeeping gene Ig7 (which produces mitochondrial large subunit ribosomal 
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RNA) was also amplified (approximately 540 bp) as a control to confirm the PCR was 
working (Figure 7.3.D and 7.3E).  
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Figure 7.3. PCR screening of dgkA- isogenic transformant cell lines. (A) Schematic 
representation of the DgkA gene containing the homologous integrated knockout 
construct. The locations of the screening primers (arrows) and the corresponding PCR 
product (dotted line) used for determining homologous integration- genomic (pink), vector 
(blue) and knockout diagnostic (yellow) primers and the predicted sizes of the products are 
shown. (B) 5’- and (C) 3’- PCR screening of blasticidin-resistant cells with genomic control 
(G), vector control (V) and knockout diagnostic (K). PCR products are shown where the 
genomic control (G) band is amplified from WT DNA, genomic (G) and vector (V) control 
bands are amplified from non-homologous integrant (NH) DNA and all 3 bands are (G, V 
and knockout diagnostic (K)) are amplified from the potential knockout (dgkA-) DNA. (D) 
Schematic representation of the DgkA gene with the yellow box indicating the region 
deleted from the gene with the arrows indicating the locations of the two RT-PCR primers. 
(E) RT-PCR of control Ig7 (C) and DgkA primers within the deleted region (D) PCR products 
where cDNA from WT provides products for both control and the deleted DgkA region and 
dgkA- cell lines only have a control Ig7 PCR product.  Molecular weights of the DNA ladder 
are indicated on the left of the gel image (1000 bp- 200 bp). 
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7.3 Confirming the DgkA Insert Within the Overexpression 
Construct  
This was followed by creating dgkA-/+ rescue cells. A pTX-DGK (GFP-DgkA) 
expression plasmid was kindly provided by T. Egelhoff (De La Roche, et al., 2002). 
On obtaining this plasmid, restriction mapping verified the presence of the DgkA 
PCR fragment. Single digests with XbaI or SalI linearized the plasmid and resulted in 
a single band at approximately 10000 bp. A double digest using the same two 
restriction enzymes was used to excise the DgkA fragment (approximately 2550 bp) 
from the remaining GFP plasmid (approximately 9000 bp) (Figure 7.4). The GFP-
dgkA expression construct was then electroporated into dgkA- cells and selected for 
by growth in the presence of blasticidin and neomycin (G418).  
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Figure 7.4. Confirming the DgkA insert within the GFP-dgkA overexpression construct. (A) 
Schematic representation of DgkA cDNA with the arrows indicating the locations of the 
primers used for PCR amplification and the cut sides SalI (S) and XbaI (X) used for excising 
the DgkA PCR fragment from the 5’ GFP-dgkA expression vector. (B) Confirmation of the 
inserted DgkA cDNA PCR fragment into the GFP-DgkA expression vector by a series of 
single and a double restriction digest visualised following gel electrophoresis with a ladder 
(L), uncut vector (U), single digests confirming cut sites of SalI (S) and XbaI (X) and a double 
digest using SalI-XbaI (S-X) confirming the presence of DgkA PCR fragment. To the left of 
the gel is the DNA ladder molecular weights (10037 bp-2500 bp) and to the right is the 
expected PCR fragment insert size (arrow). 
 
Western blotting was used to confirm the expression of GFP-DGKA within dgkA-/+ 
cells, which was compared with WT and dgkA- cells. Expression of the protein MccA 
(also Mccc1) (Davidson, King and Insall, 2013) was used as a loading control. WT 
and dgkA- cells did not express GFP as expected, whereas dgkA-/+ cells displayed 
GFP-DGKA expression at the expected size (126 kDa) (Figure 7.5A), confirming 
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reintroduction of the protein. DGKA localization was also investigated by 
fluorescence microscopy, where GFP-DGKA was localized to the cytosol (Figure 
7.5B).  
 
 
 
Figure 7.5. GFP-DGKA expression and localization. (A) Western blot showing WT and dgkA- 
cells expressing no GFP and dgkA-/+ cells showing GFP-DGKA expression with protein 
loading for all 3 cells being shown by the control MccA. (B) dgkA-/+ cells were visualized 
using fluorescence microscopy. GFP-DGKA showed cytosolic localization. Scale bar 
represents 10 m. 
7.4 Phenotypic Characterization of dgkA- and dgkA-/+ Cells 
In order to investigate DGK as a target of VPA, a range of experiments were 
conducted using WT, dgkA- and dgkA-/+ cells. Characterization involved investigating 
the localization of the MHC protein and the phenotypic changes in both the absence 
and presence of VPA during cell growth, acute cell behaviour and development by 
comparing WT, dgkA- and dgkA-/+ cells. DGKA was then investigated as to whether it 
was a target of other anti-seizure compounds or the BD treatment LiCl by 
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development assays. To determine changes in molecular DAG levels, an ELISA assay 
was conducted in both the absence and presence of all compounds tested.  
 
7.4.1 Localization of MHC in dgkA- Cells During the Vegetative Phase 
Immunohistochemistry was used to investigate the localization of the MHC since 
this was altered in the dgkA- (JH10) cells when compared with WT (JH10) (Abu-
Elneel, Karchi and Ravid, 1996). In WT (JH10) cells, the MHC protein was present as 
a loose fibrous network within the cytoplasm, but this was altered in dgkA- (JH10) 
cells where MHC formed a dense cortical ring. To determine MHC localization 
within dgkA- (Ax2) cells, immunohistochemistry was conducted by fixing cells to 
coverslips using paraformaldehyde (Figure 7.6). WT (Ax2) and dgkA- (Ax2) cells 
were stained with antibodies either for calreticulin (control) or MHC. Both WT (Ax2) 
and dgkA- (Ax2) cells showed a similar staining of calreticulin within the 
endoplasmic reticulum. In both vegetative WT (Ax2) and dgkA- (Ax2) cells, MHC was 
located within the cytoplasm as a loose fibrous network with clear adhesion sites, 
consistent with the location of MHC previously reported and from other studies 
(Abu-Elneel, Karchi and Ravid, 1996; Heid, et al., 2004).  
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Figure 7.6. Comparison of myosin II heavy chain localization in WT and dgkA- cells. WT 
and dgkA- cells visualized using immunofluorescence. WT and dgkA+ cells show cytoplasmic 
localization of myosin II heavy chain (MHC). Scale bars represent 10 m. 
 
7.4.3 Analysis of MHC Movement in Response to cAMP 
Since there was no apparent gross difference in MHC localization between WT 
(Ax2) and dgkA- (Ax2) growing cells, early development was induced by starvation 
in the presence of pulsate cAMP. Following induction of early development, cells 
were washed and stimulated with a single pulse of cAMP and images were 
recorded at regular intervals over 120 seconds. Both WT (Ax2) and dgkA- (Ax2) cells 
were electroporated with GFP- tagged fluorescent constructs. This enabled the 
visualisation of F-actin-GFP from cells electroporated with the LB150B construct 
(control) (Kortholt, et al., 2011) or MHC-GFP from cells containing the pBIGGFPmyo 
construct (Keizer-Gunnink, Kortholt and van Haastert, 2007) kindly provided by 
Arjan Kortholt. Under control conditions, F-actin-GFP was transient to the cell 
membrane in both cell lines (Figure 7.7). In response to cAMP, no difference in F-
actin localization was shown between WT (Ax2) or dgkA- (Ax2) cells. MHC was 
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localized within the cytosol under control conditions in both WT (Ax2) and dgkA- 
(Ax2) cells. In response to cAMP stimulation, WT (Ax2) cell MHC was located within 
the cytoplasm. In contrast, in dgkA- (Ax2) cells, MHC localized to the cell cortex as a 
dense cortical ring within 30 seconds of cAMP stimulation, consistent with dgkA- 
(JH10) cells (Abu-Elneel, Karchi and Ravid, 1996).  
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Figure 7.7. F-actin- GFP and myosin II heavy chain-GFP localization in response to cAMP 
stimulation. GFP tagged F-actin and myosin II heavy chain (MHC) localization in WT (Ax2) 
and dgkA- (Ax2) cells containing the F-actin-GFP tagged plasmid or the MHC-GFP tagged 
plasmid. Cells were visualized using fluorescence microscopy with images taken at the 
started times to the left of the image after cAMP stimulation. WT and dgkA- cells show no 
difference in F-actin localization after cAMP stimulation, with cAMP stimulation causing 
MHC localization within the cytoplasm in WT cells and in contrast, to the cell cortex in 
dgkA- cells.  n= 7-10. Scale bars represent 10 m. 
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7.4.4 4 Analysis of DGKA on Cell Growth in the Presence of VPA 
The effects of VPA on cell growth were then investigated. Cell growth was 
investigated as previous work has shown VPA to cause a dose-dependent inhibition 
in D. discoideum (Terbach, et al., 2011). WT and dgkA- cells were grown in the 
presence of increasing VPA concentrations (ranging 0.01 mM- 2 mM) spanning the 
therapeutic concentration (Kanner, 2003; Vázquez-Calvo, et al., 2013) for 168 hours 
(Figure 7.8). In the absence of VPA, WT and dgkA- cells grew at a similar rate (Figure 
7.8A and 7.8B). In the presence of VPA, both WT and dgkA- cells showed a dose-
dependent reduction on cell growth, with no significant differences being 
identified. Comparison of the rate of cell growth between WT and dgkA- cells when 
exposed to differing VPA concentrations is displayed in a secondary plot (Figure 
7.8C) with the corresponding calculated IC50 values. For WT cells the VPA IC50 value 
was 0.7 mM and for dgkA- cells 0.5 mM. These results suggest DGKA is not a target 
of VPA during the vegetative phase of D. discoideum cells. 
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Figure 7.8. WT and dgkA- growth in both the absence and presence of VPA. (A) WT and (B) 
dgkA- cell proliferation was determined both in the absence (control, black) and presence 
of VPA at the indicated concentrations for 168 hours. (C) A secondary plot comparing the 
normalized change in the rate of cell growth between 96 and 144 hours plotted against log 
VPA concentration for WT and dgkA- cells. No significant differences in cell proliferation 
was identified under control conditions or in the presence of VPA using the Kruskal- Wallis 
test and Dunns post hoc test. Data presented as mean (+/- SEM). n =6.  
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7.4.5 Analysis of DGKA on Acute Cell Behaviour in the Presence of VPA  
Since loss of DGKA did not alter the effect of VPA on cell growth, the D. discoideum 
developmental cycle was then investigated. In these experiments, acute cell 
behaviour was investigated using cells in early development as this is when DgkA is 
most highly expressed and cells are chemotactically competent (Xu, et al., 2007). 
This assay was employed since VPA inhibits D. discoideum movement and causes 
loss of cell shape from amoeboid to round (Xu, et al., 2007). Experiments initially 
involved imaging cells prior to and 10 minutes following 0.5 mM VPA treatment to 
determine any differences between WT and dgkA- cells. In WT cells, exposure to   
0.5 mM VPA resulted in cells halting movement and becoming circular in shape 
(Figure 7.9A). In contrast, dgkA- cells in the presence of 0.5 mM VPA continued 
moving and remained amoeboid in shape, thereby showing resistance to VPA at 
this concentration (Figure 7.9B).  
 
VPA dependent changes in cell behaviour were then quantified using time-lapse 
microscopy. Computer-generated cell outlines were used to detect variations in the 
shortest distance individual cells travelled (displacement), cell shape (circularity, 
with round cells given an arbitrary value of “1”), membrane protrusions and speed 
of cell speed (motility) (Figure 7.9C). A control period of 225 seconds was used to 
establish any differences in cell behaviour between WT, dgkA- and dgkA-/+ cells 
before being exposed to a range of VPA concentrations (0.1 mM- 0.7 mM), 
including the therapeutic concentration, for 525 seconds (Table 7.1 and Figure 
7.9D- 7.9G). During control conditions with no VPA exposure, there was no change 
in WT, dgkA- or dgkA-/+ cell behaviour with regard to cell displacement, circularity, 
membrane protrusions and motility. No significant differences were identified 
between the 3 cell lines in the absence of VPA. However, in the presence of 0.5 mM 
VPA upwards, WT cells had a near block in all cell behaviour criteria measured, 
whereas dgkA- behaved in a similar way to control conditions and therefore 
resistant to VPA at this concentration. VPA sensitivity was then restored in dgkA-/+ 
cells. Significant differences were identified between WT and dgkA-, and dgkA- and 
dgkA-/+ cells at either or both 0.3 mM and 0.5 mM VPA for displacement (P values 
ranging between 0.0230- 0.0403), circularity (P value ranging between 0.0001- 
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0.0006), membrane protrusions (P value ranging between 0.0001-0.0129) and 
motility (P values 0.0001).  
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Cell 
Line 
[VPA] (mM) VPA 
IC50 
Value 
(mM) 
Control 0.01 0.1 0.3 0.5 0.7 
Displacement (m)  
WT 67.2 
 4.2  
70.9 
 3.2 
58.7 
 4.3  
47.3 
 3.4 
40.0 
 3.5  
46.5 
 2.9  
0.4 
  
0.08 
dgkA- 83.7 
 7.1  
65.5 
 4.8  
68.6 
 5.7  
64.9 
 6.0  
53.0 
 5.1 
43.6 
 2.5  
0.8 
  
0.06 
dgkA-/+ 76.1 
 5.1  
70.9 
 3.8  
58.7 
 4.9  
56.0 
 3.6  
56.0 
 1.7  
54.0 
 2.8 
- 
Circularity  
WT 0.71 
 0.004  
0.67  
 0.004 
0.73  
 0.004  
0.85 
 0.004 
0.90 
 0.001 
0.88 
 0.004 
- 
dgkA- 0.63 
 0.004  
0.67 
 0.003 
0.64 
 0.004 
0.67 
 0.004 
0.74 
 0.004 
0.83 
 0.004  
- 
dgkA-/+ 0.68 
 0.004  
0.70 
 0.004  
0.85 
 0.003 
0.87 
 0.003 
0.88 
 0.002 
0.86 
 0.003 
- 
Protrusions  
WT 8.7 
 0.13  
9.0 
 0.07 
5.8 
 0.17  
3.6 
 0.05 
1.5 
 0.06 
1.7 
 0.07 
0.2 
 0.05 
dgkA- 10.1 
 0.10  
8.6 
 0.05 
7.3 
 0.05 
7.7 
 0.07 
6.2 
 0.04 
3.6 
 0.14 
0.6 
 0.04 
dgkA-/+ 7.1 
 0.04 
8.5 
 0.12 
4.6 
 0.05 
4.1 
 0.04 
2.7 
 0.12 
1.8 
 0.05 
0.2 
 0.11 
Motility (m/sec)  
WT 0.013 
 
0.0009  
0.016  
 
0.0009  
0.010 
  
0.0005 
0.004 
  
0.006 
0.003 
  
0.0002 
0.002 
  
0.0003 
0.2 
  
0.03 
dgkA- 0.019 
  
0.0011 
0.012 
  
0.0011 
0.014 
 
0.0007  
0.015 
  
0.0007 
0.008 
 
0.0006  
0.004 
 
0.0004  
0.5 
  
0.04 
dgkA-/+ 0.020 
 
 0.0010 
0.016 
  
0.0007 
0.011 
 
0.0006  
0.003 
 
0.0005  
0.002 
 
0.0009  
0.001 
 
0.0005  
0.2  
 
0.02 
 
Table 7.1. WT, dgkA- and dgkA-/+ changes in acute cell behaviour in both the absence and 
presence of VPA. Comparison of WT, dgkA- and dgkA-/+ acute cell behaviour values of total 
displacement during the assay and average circularity, protrusions and motility within the 
final 300 seconds. The calculated IC50 values are shown to the right of the table for each cell 
line for displacement, number of protrusions and motility. Data presented as mean (+/- 
SEM). n = 30.  
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Detailed analysis of cell behaviour in these experiments was then conducted. 
Analysis of displacement (Figure 7.10A), circularity (Figure 7.10B), membrane 
protrusions (Figure 7.10C) and motility (Figure 7.10D) at 750 seconds, or within the 
final 300 seconds, showed a shift in the curve to the right for the dgkA- cells. This 
shift highlights dgkA- cells partial resistance to VPA. The curve returned closer 
towards WT for dgkA-/+ cells, highlighting restoration of VPA sensitivity. This partial 
resistance of dgkA- cells is also illustrated in the IC50 values calculated for each 
condition (Table 7.1). An IC50 could not be calculated for circularity due to the data 
points increasing with higher VPA concentrations rather than decreasing, therefore, 
drug inhibition cannot be measured. VPA partial resistance of dgkA- cells is also 
shown by the IC50 values being at least double that of WT and dgkA-/+ cells. 
Statistically significant differences between WT, dgkA- and dgkA-/+ cells also 
highlights dgkA- cell resistance to VPA. From these results, it can be suggested that 
DGKA is a target of VPA during D. discoideum acute cell behaviour. 
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Figure 7.9. WT, dgkA- and dgkA-/+ acute 
cell behaviour in both the absence and 
presence of VPA primary plots. (A) WT 
and (B) dgkA- cell shape at 0 seconds and 
750 seconds after addition of 0.5 mM VPA 
where WT cells were circular 750 seconds 
after drug addition and dgkA- cells were 
amoeboid. (C)  Schematic of the 
quantitative measurements taken during 
the assay where the black dashed arrows 
represent the measurement being taken 
for the primary data for (D) displacement, 
(E) circularity, (F) membrane protrusions 
and (G) motility for WT cells (left), dgkA- 
(middle) and dgkA-/+ cells. Data presented 
as mean (+/- SEM) n =30 cells. Scale bar 
represents 12 m.
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 Figure 7.10. WT, dgkA- and 
dgkA-/+ acute cell behaviour in 
the presence of VPA secondary 
plots. (A) Displacement, (B) 
circularity, (C) membrane 
protrusions and (D) motility 
secondary plots for WT (black 
circles), dgkA- (blue squares) 
and dgkA-/+ (pink triangles) 
comparing the total 
displacement at 750 seconds or 
comparing average circularity, 
membrane protrusions or 
motility between 450 seconds 
and 750 seconds between the 3 
cell lines with calculated IC50 
stated in the graphs which show 
dgkA- partial resistance to VPA 
up to 0.5 mM compared with 
WT and the restoration of VPA 
sensitivity in dgkA-/+ cells. 
Significant differences between 
WT and dgkA- cells are shown by 
black stars, between WT and 
dgkA-/+ cells with a pink star and 
between dgkA- and dgkA-/+ with 
blue stars using the Kruskal- 
Wallis test and Dunns post hoc 
test. P value: * P value =  0.05, 
** P value =  0.01 and *** P 
value =  0.001. Data presented 
as mean (+/- SEM) n =30 cells.  
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7.4.6 Analysis of DGKA Cell Development in the Presence of VPA  
The DgkA gene is expressed during the D. discoideum developmental phase and 
VPA is known to block fruiting body formation (Williams, et al., 2002). For these 
reasons, the effect of VPA was investigated on WT, dgkA- and dgkA-/+ fruiting body 
formation by starving cells on nitrocellulose filters for 24 hours in both the absence 
and presence VPA (0.3 mM, 0.5 mM and 1 mM) (Figure 7.11). WT cells developed 
into typical fruiting bodies containing a basal disc, stalk and spore head under 
control conditions (Figure 7.11A). The dgkA- cells were also able to develop into 
fruiting bodies containing a basal disc, stalk and spore head, however, the fruiting 
bodies which developed were smaller than WT, consistent with the previous report 
of DgkA ablation in JH10 cells (Abu-Elneel, Karchi and Ravid, 1996). WT fruiting 
body size was restored on reintroduction of DgkA within dgkA-/+ cells. In the 
presence of 0.3 mM and 0.5 mM VPA, WT cells developed into finger structures. In 
contrast, dgkA- cells continued to develop into full fruiting bodies resembling 
control conditions in the presence of 0.3 mM and 0.5 mM VPA (Figure 7.11B). 
Sensitivity of 0.3 mM and 0.5 mM VPA was restored in dgkA-/+ cells which 
developed into finger structures. In the presence of 1 mM VPA, WT, dgkA- and   
dgkA-/+ cells developed into mounds after 24 hours. These results suggest that 
DGKA is a target, or is regulated by VPA at therapeutic concentrations during D. 
discoideum development.
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Figure 7.11. WT, dgkA- and dgkA-/+ development in 
both the absence and presence of VPA.  WT (left), 
dgkA- (middle) and dgkA-/+ (right) cells were developed 
on nitrocellulose membranes for 24 hours in both the 
absence (top row) and presence (descending rows) of 
0.3 mM, 0.5 mM and 1 mM VPA and images were 
taken of an overhead view (left) of the whole 
membrane and of a single fruiting body (right).  All cells 
produced fruiting bodies in the absence of VPA, though 
the dgkA- cells developed into smaller fruiting bodies 
compared with control which was rescued in dgkA-/+ 
cells. WT and dgkA-/+ cells in the presence of 0.3 mM 
and 0.5 mM developed to the finger stage and at 1 mM 
VPA developed into a mound after 24 hours. In 
contrast, dgkA- cells were resistant to VPA and still able 
to develop into mature fruiting bodies when exposed 
to 0.3 mM and 0.5 mM VPA and to a mound in the 
presence of 1 mM VPA. n = 3. Scale bars of the 
overhead view indicates 0.5 mm and side view 0.1 mm. 
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7.4.7 Analysis of DGKA Cell Development in the Presence of Anti-Seizure Compounds 
and LiCl 
DGKA was then investigated as a potential target for other anti-seizure compounds 
and the BD treatment LiCl. The anti-seizure compounds selected have previously 
been shown to have an active effect on both D. discoideum and in in vivo epilepsy 
models (Williams, et al., 1999; Williams, et al., 2002; Eickholt, et al., 2005; Chang, et 
al., 2012; Elphick, et al., 2012; Chang, et al., 2013; Chang, et al., 2015; Chang, et al., 
2016). These experiments repeated the format of VPA analysis, with cells plated on 
nitrocellulose filters for 24 hours in the absence (control) and presence of a range 
of anti-seizure compounds and the BD drug LiCl at concentrations which blocked 
formation of fruiting bodies in WT cells (Figure 7.12). The compounds tested were 
VPD (6.5 mM) (Eickholt, et al., 2005) and PIA (1.4 mM) (Elphick, et al., 2012) which 
are structurally related to VPA. DA (1.65 mM) and OA (0.22 mM) were also tested 
which are key components of the MCT diet (Chang, et al., 2012; Chang, et al., 2013; 
Chang, et al., 2016). Branched compounds 4-EOA (0.5 mM) (Chang, et al., 2013; 
Chang, et al., 2015), which has been shown to control seizures and has 
neuroprotective effects was also tested, along with 2-MHA (0.5 mM) as a negative 
control as it is not active in D. discoideum nor in seizure control (Chang, et al., 
2012). Under control conditions, WT, dgkA- and dgkA-/+ cells were able to develop 
into mature fruiting bodies after 24 hours. In the presence of VPD, PIA, DA, OA, 4-
EOA and LiCl at concentrations where WT cells developed into fingers or mounds, 
dgkA- cells continued to develop into mature fruiting bodies resembling control 
conditions. The resistant phenotype shown to these compounds was restored back 
to that of WT in dgkA-/+ cells. In the presence of 2-MHA, WT, dgkA- and dgkA-/+ cells 
developed into mounds after 24 hours. These results suggest that the compounds 
VPD, PIA, DA, OA and 4-EOA have a similar mechanism of action as VPA in 
regulating DGKA during D. discoideum development. Interestingly, the structurally 
unrelated compound LiCl also appears to target DGKA in D. discoideum, suggesting 
a conserved mechanism of action in the treatment of both epilepsy and BD.  
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7.12. WT, dgkA- and dgkA-/+ development in both the absence and presence of a range of 
other compounds.  WT (left), dgkA- (middle) and dgkA-/+ (right) cells were developed on 
nitrocellulose membranes for 24 hours in the absence (top row) and presence (descending 
rows) of VPD, PIA, DA, OA, 4-EOA, 2-MHA and LiCl at the stated concentrations to the left 
of the development images. Images were taken as an overhead view of the whole 
membrane and of a single fruiting body (right). All cells developed into fruiting bodies in 
the absence of any compound. In the presence of VPD, PIA, DA, OA, 4-EOA and LiCl at 
concentrations which inhibited WT development, dgkA- cells developed into mature 
fruiting bodies and compound sensitivity was restored in the dgkA-/+ cells. In the presence 
of 2-MHA, WT, dgkA- and dgkA-/+ cells developed to the mound stage. n = 3. Scale bar for 
overhead view represents 0.5 mm and of the side view 0.1 mm.  
Chapter 7   Analysis of DGKA as a Target of VPA 
 203 
7.4.8 Analysis of DAG Levels in dgkA- and dgkA-/+ Cells in Response to Other 
Compounds  
As the dgkA- mutant was resistant to both VPA, a range of other anti-seizure 
compounds and LiCl, these compounds were also assessed for their effect on DAG 
levels. In these experiments, cells were pulsed with cAMP for 5 hours to allow cells 
to enter early development prior to being exposed to a range of compounds for 10 
minutes (Figure 7.13). It was previously demonstrated during the acute cell 
behaviour assays that 10 minutes is enough time for cells to respond to VPA. Under 
control conditions, WT cells had an average DAG level of 0.17  0.06 ng per 5x106 
cells. The dgkA- cells had an approximate 89 % reduction in levels of DAG (average 
0.02  0.01 ng per 5x106 cells) compared with WT cells. The levels of DAG in      
dgkA-/+ cells were not restored back to that of WT but were slightly increased by 
approximately 2-fold (average 0.04  0.03 ng per 5x106 cells) compared with dgkA- 
cells.  
 
DAG levels were then quantified in WT, dgkA- and dgkA-/+ cells following exposure 
to VPA. DAG levels increased by approximately 2.3-fold and 1.8-fold in WT cells (to 
0.39  0.17 ng per 5x106 cells and to 0.31  0.09ng per5x 106 cells) and by 3.5-fold 
and 5.0-fold in dgkA-/+ (to 0.14  0.03 ng per 5x106 cells and to 0.20  0.08 ng per 
5x106 cells) when treated with 0.3 mM or 0.5 mM VPA respectively (Figure 7.13A). 
In the presence of 0.3 mM VPA, there was minute change in DAG levels in dgkA- 
cells (to 0.01  0.01 ng per 5x106 cells) and no detectable DAG when cells were 
exposed to 0.5 mM VPA. Statistically significant differences in DAG levels were 
identified between WT and dgkA- cells (P value 0.01) and between dgkA- and 
dgkA-/+ cells (P value 0.05). No statistically significant changes were identified 
between WT and dgkA-/+. These results suggest that the mode of action of VPA 
involves increasing DAG levels. An increase in DAG levels, therefore, appears to 
inhibit D. discoideum acute cell behaviour (displacement, membrane protrusions 
and motility) and development.  
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DAG levels were then quantified in WT, dgkA- and dgkA-/+ cells following exposure 
to LiCl. A similar effect was seen in the presence of LiCl, where WT DAG levels were 
raised approximately 2.8-fold (to an average of 0.48  0.13 ng per 5x106 cells) and 
dgkA-/+ 5,5-fold to an average of 0.22  0.11 ng per 5x106 cells) compared with 
control (Figure 7.13A). As with VPA treatment, dgkA- cells had no detectable DAG 
when exposed to LiCl, with statistically significant differences being detected 
between WT and dgkA- cells (P value 0.01) and dgkA- cells with dgkA-/+ (P value 
0.05). These results suggest that VPA and LiCl have a similar mode of action in D. 
discoideum. 
 
DAG levels in WT cells was then investigated following exposure to the anti-seizure 
compounds which the dgkA- cells were resistant.  The dgkA- cells were not tested in 
the presence of these compounds as there was low levels of DAG under control 
conditions which was abolished with VPA and LiCl treatment. In the presence of all 
compounds tested, statistically significant increases in DAG levels were identified 
compared with control conditions (P value 0.05) (Figure 7.13B). In the presence of 
the VPA structurally related compounds, DAG levels increased by approximately 11-
fold (to 1.91  0.45 ng per 5x106 cells) and 13-fold (to 2.17  0.22 ng per 5x106 cells) 
when exposed to VPD and PIA respectively. When treated with DA and OA, the 
main components of the MCT diet, DAG levels increased 10.6-fold (to 1.81  0.24 
ng per 5x106 cells) and 11-fold (to 1.88  0.51 ng per 5x106 cells) respectively. When 
treated with 4-EOA, a branch chain fatty acid, DAG levels 11-fold (to 1,90  0.13 ng 
per 5x106 cells). These results suggest that VPD, PIA, DA, OA and 4-EOA all have a 
similar mode of action by raising DAG levels in D. discoideum.  
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Figure 7.13. WT, dgkA- and dgkA-/+ analysis of DAG levels in response to anti-seizure 
compounds and a bipolar disorder treatment. (A) WT (black), dgkA- (blue) and dgkA-/+ (pink) 
DAG levels in the absence (control) of any treatment and in the presence of VPA (0.3 mM 
and 0.5 mM) and LiCl (8 mM) was increased in WT and dgkA-/+ cells in response to treatment, 
however, DAG levels were abolished in the dgkA- following treatment. (B) DAG levels in WT 
cells when exposed to VPD (6.5 mM, black squares), PIA (1.4 mM, black diamonds), DA (1.65 
mM, black and white lines), OA (0.22 mM, white bricks) and 4-EOA (0.5 mM, black and white 
vertical lines) increased significantly compared with control conditions. Data presented as 
mean (+/- SEM) n =4-7. Significant differences between WT and dgkA- are shown by a black 
star and between dgkA- and dgkA-/+ by a blue star using the Mann-Whitney test. P value: * P 
value = 0.05 and ** P value = 0.01. 
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7.5 Discussion 
VPA treatment has been shown to reduce D. discoideum phosphoinositide levels in 
both a time and dose dependent manner (Chang, et al., 2012). Therefore, proteins 
involved in regulating phosphoinositide synthesis and breakdown have previously 
been investigated for VPA resistance or sensitivity. It has been suggested that the 
target of VPA in this effect is unlikely to function within pathways for de novo 
inositol biosynthesis, PI3K activity, inositol recycling and de novo inositol production 
(Chang, et al., 2012; Frej, et al., 2016). Therefore, proteins within the PI salvage 
pathway have been studied. Within this chapter, DGKA, the enzyme responsible for 
the phosphorylation of DAG into PA has been investigated. This chapter has 
described the ablation of the encoding DGKA gene (Figures 7.2 and 7.3) and the re-
expression of DGKA in dgkA- cells (Figures 7.4 and 7.5). Both dgkA- and dgkA-/+ cells 
were phenotypically characterized in both the absence and presence of VPA, other 
anti-seizure compounds and the BD treatment LiCl (Figures 7.6- 7.13).  
 
DGKA was ablated from Ax2 D. discoideum cells using a dgkA knockout construct 
previously created using the pLPBLP vector (Faix, et al., 2004). Isogenic dgkA- cells 
were confirmed by RT-PCR and used for characterization in both the absence and 
presence of VPA. Ablation of DgkA is possible in D. discoideum as the gene has 
previously been ablated in D. discoideum JH10 cells (Abu-Elneel, Karchi and Ravid, 
1996). In this work, the authors believed they were ablating MHC-PKC, however, it 
was later found that the gene was in fact the single DgkA (De La Roche, et al., 
2002). Misinterpretation of the MHC-PKC was explained by the various DGK 
isoforms not being recognised as a kinase enzyme and from errors in the original 
DNA sequence at the time of cloning (De La Roche, et al., 2002). DGK has also been 
ablated in other organisms with one isoform, including yeast, suggesting that this 
protein is not essential for survival (Han, et al., 2008). The reason for the non-
essential nature of DGKA is that DAG can be converted into PE and PC via the 
Kennedy pathway and then reintroduced into the PI salvage pathway via the 
formation of PA from PC (Kennedy and Weiss, 1956; Gibellini and Smith, 2010). This 
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reaction bypasses the phosphorylation of DAG into PA via DGK within the PI salvage 
pathway. 
 
DGKA rescue cells (dgkA-/+) were also created where the gene was reintroduced 
into dgkA- cells. Characterization of dgkA-/+ cells initially involved Western blotting 
to ensure expression of GFP-DGKA. Fluorescence microscopy was conducted to 
determine the localization of GFP-DGKA. Consistent with previous work, GFP-DGKA 
was localized within the cytosol in vegetative cells and migrated to the cell cortex 
on cAMP stimulation where its enzyme activity is conducted (De La Roche, et al., 
2002). A similar effect to DGKA translocation from the cytosol to the plasma 
membrane has been shown for DGK- in rat arteries, where the enzyme migrates to 
the plasma membrane following noradrenaline stimulation (Walker, et al., 2001). In 
a transgenic mouse model, DGK- is activated by a Ras-nucleotide- releasing 
protein, resulting in enzyme translocation to the plasma membrane (Sanjuan, et al., 
2003). Future work could investigate the effect of VPA on DGKA localization to 
determine whether the drug inhibits DGKA movement from the cytosol to the 
plasma membrane.  
 
MHC localization was first investigated since the localization of this protein was 
disrupted in the dgkA- (JH10) cells (Abu-Elneel, Karchi and Ravid, 1996). MHC 
localization was investigated in both vegetative and starved dgkA- cells. Vegetative 
cells were fixed and stained with an MHC antibody, or dgkA- cells containing a 
plasmid driving expression of a GFP fluorescently tagged MHC were starved and 
pulsed with cAMP to enter the developmental phase. In agreement with previous 
work, MHC was localised to the cytosol as shown by punctate staining in vegetative 
dgkA- (Ax2) cells (Fukui, 1990; Abu-Elneel, Karchi and Ravid, 1996; Sabry, et al., 
1997; Heid, et al., 2004). In dgkA- (Ax2) starved cells, which had entered the 
developmental cycle, cytosolic MHC moved from the cytosol to the cell cortex, 
forming a dense cortical ring approximately 30 seconds post cAMP stimulation, 
consistent with the dgkA- (JH10) mutant (Abu-Elneel, Karchi and Ravid, 1996). No 
change in MHC localization was seen between WT (Ax2) and dgkA- (Ax2) cells 
during the vegetative phase, consistent with DgkA being expressed approximately 8 
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and 24 hours into the developmental cycle (Parikh, et al., 2010; Stajdohar, et al., 
2015). Dysregulation of MHC in dgkA- (Ax2) cells was of interest since the binding of 
cAMP to cell surface receptors initiates PIP2 hydrolysis into IP3 and DAG. DAG 
activates PKC (Kishimoto, et al., 1980; van Baal, et al., 2005) which initiates its 
movement to the site of stimulation. Meanwhile, IP3 initiates an influx of calcium to 
activate DGK (Hahn and Friedman, 1999), resulting in the translocation of the 
enzyme from the cytosol to the plasma membrane. PKC phosphorylates MHC 
(Dulyaninova, et al., 2007) to causes the disassembly of MHC from actin filaments, 
forming myosin light chains (Yumura and Fukui, 1985). The myosin light chains then 
translocate to the posterior end of the cell where they reassemble into actin-MHC 
by ATPase (Yumura and Fukui, 1985). The reaction ceases as DAG is converted into 
PA by DGK. The abnormal localization of MHC in dgkA- (Ax2) cells is, therefore, a 
result of enzyme loss as D. discoideum cells entering the developmental cycle are 
chemotactically competent through cAMP stimulation.    
 
Cell growth was then investigated in both the absence and presence of VPA. Both 
WT (Ax2) and dgkA- (Ax2) cells grew at a similar rate in the absence of VPA, 
consistent with that found in dgkA- (JH10) cells (Abu-Elneel, Karchi and Ravid, 
1996). In the presence of VPA, both cell lines had a dose-dependent reduction in 
cell number with increasing VPA concentration, suggesting DGKA is not the target 
of VPA during cell growth. This result is consistent with DgkA expression during the 
D. discoideum developmental cycle (Parikh, et al., 2010; Stajdohar, et al., 2015). 
DGKA was an enzyme of interest as DGK- (Ishisaka, et al., 2013), - (Leach, et al., 
2007) and - (Rodriguez de Turco, et al., 2001) have been linked to seizure activity 
in mice and DGK was found disrupted in a human epilepsy patient (Musto and 
Bazán, 2006). These studies have, therefore, shown a role of DGK isoforms in 
seizure generation. 
 
VPA sensitivity was then investigated during the initial stages of the D. discoideum 
developmental cycle, when the DgkA gene is highly expressed (Parikh, et al., 2010; 
Stajdohar, et al., 2015). In the absence of VPA, WT, dgkA- and dgkA-/+ cells had a 
similar behaviour in displacement, circularity, number of membrane protrusions 
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and motility. Acute VPA treatment of 0.3 mM upwards resulted in the inhibition of 
WT cell movement and rounding of the cells. In contrast, acute VPA treatment of 
0.3 mM and 0.5 mM on dgkA- cells resulted in similar values for displacement, 
membrane protrusions and motility compared with control conditions in the 
absence of VPA, where cells maintained their amoeboid shape. However, treatment 
of 0.7 mM VPA resulted in inhibition of cell displacement, membrane protrusions 
and circularity, which caused rounding of dgkA- cells. WT VPA sensitivity was 
restored in dgkA-/+ cells. The partial resistance of dgkA- cells to therapeutic VPA 
concentrations may be due to the drug targeting, or regulating, DGKA, causing 
enzyme inhibition. DGKA inhibition would result in the accumulation of DAG, which 
would upregulate the Kennedy pathway. Previous work using D. discoideum has 
shown components of the Kennedy pathway (PE and PC) are upregulated following 
approximately 30 minutes of VPA treatment (Elphick, et al., 2012). Both PE and PC 
are synthesised from DAG, as the mode of action of DGK is located at the branch 
point of the Kennedy pathway which utilises DAG for the synthesis of PE and PC 
(Kennedy and Weiss, 1956; Gibellini and Smith, 2010). Upregulation of the Kennedy 
pathway would enable the PI salvage pathway to bypass the formation of PA from 
DAG, allowing the PI salvage pathway to continue. Therefore, cells will continue 
movement as all PI salvage pathway molecules continue to be synthesized.   
 
DGKA was then further investigated as a target for VPA during fruiting body 
formation. Ablation of DgkA resulted in the development of fruiting bodies 
containing a spore head, stalk and basal disc, however, these fruiting bodies were 
smaller in size compared with WT (Ax2). Small sized fruiting bodies were also 
identified in dgkA- (JH10) cells, however, these fruiting bodies developed after 42-
44 hours with upward extensions protruding from the spore head (Abu-Elneel, 
Karchi and Ravid, 1996). In contrast, dgkA- (Ax2) fruiting bodies developed after 24 
hours with no protrusions from the spore head. On reintroduction of DgkA in   
dgkA-/+ (Ax2) cells, fruiting body size was restored back to that of WT (Ax2). This 
result suggests fruiting body size is dependent on DGKA. In D. discoideum cells the 
height of a fruiting body is determined by the number of cells within the 
aggregation stream. A typical fruiting body will contain 0.2-1.0x105 cells, whereas in 
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mutants which produce smaller fruiting bodies, such as the small aggregate 
formation protein mutant (sml-), only 5x103 cells are present (Brock and Gomer, 
1999). Vesicle aggregates are produced when PLC activation causes DAG synthesis 
at the plasma membrane in the bacteria Bacillus cereus (Villar, Alonso and Goñi, 
2000) and Listeria monocytogenes (Montes, et al., 2004). In a similar mechanism to 
sml-, dgkA- cells therefore contain less cells in the aggregation stream which form 
the fruiting body compared with WT as a result of PLC activation from cAMP, 
thereby resulting in smaller fruiting bodies.  
 
The effects of VPA were then investigated on dgkA- cell development. In the 
presence of 0.3 mM and 0.5 mM VPA, WT cells developed into fingers or mounds, 
whereas dgkA- cells continued to develop into mature fruiting bodies, resembling 
control conditions. In the presence of 1 mM VPA, dgkA- development was inhibited 
at the mound stage at 24 hours. VPA sensitivity was restored in dgkA-/+ cells, 
suggesting DGKA is a target for, or regulated by, VPA at therapeutic concentrations 
during D. discoideum development. Resistance of dgkA- cells to therapeutic VPA 
concentrations is of interest since epilepsy is associated with a reduction in 
dendritic spine formation, where DGK is responsible for both the promotion and 
maturation of dendritic spines (Hozumi, et al., 2009). In a mouse model, VPA has 
been shown to revert this by promoting dendritic spine formation (Yang, et al., 
2016), highlighting the neuroprotective effects of the drug during development.   
 
A range of anti-seizure compounds and the BD treatment LiCl were then 
investigated on fruiting body development. At concentrations where WT cells 
developed into mounds after 24 hours, dgkA- cells were resistant to VPD, PIA, DA, 
OA, 4-EOA and LiCl as they developed into mature fruiting bodies resembling 
control conditions. In the presence of the non- active compound 4-MHA, both WT 
and dgkA-cells developed into mounds. Resistance to these compounds was 
dependent on DGKA, demonstrated by WT sensitivity being restored in dgkA-/+ 
cells. These results suggest that the structurally related VPA compounds and the 
main MCT diet constituents, control seizures through a similar mechanism, by 
targeting or regulating, DGKA. Of interest was dgkA- cell resistance to the BD 
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treatment LiCl above the therapeutic concentration (0.6 mM-1 mM) (Singh, et al., 
2013). This result shows there is a conserved mechanism of action between both 
epilepsy and BD treatments, through DGKA, in D. discoideum. Previous work has 
implicated the inhibition of PKC signalling, which is controlled by DAG and reversed 
by DGK, in BD patients following LiCl (Wang and Friedman, 1989; Bitran, et al., 
1990) and VPA (Chen, et al., 1994) treatment. In conjunction with PKC inhibition, 
lithium treatment has been shown to result in the accumulation of DAG 
(Drummond and Raeburn, 1984; Brami, Leli and Hauser, 1993). Two DGK isoforms, 
DGK- and -  have been linked with BD, where a single nucleotide polymorphism 
in DGK had strong association with BD (Baum, et al., 2008). In addition, a 
significant increase in DGK was later found in post mortem brains of BD patients 
(Squassina, et al., 2009; Moya, et al., 2010). A DGK knockout mouse demonstrated 
lithium sensitive behaviours, such as reduced depression and anxiety, as well as 
hyperactivity which was lessoned with lithium treatment (Kakefuda, et al., 2010). 
This result highlights a strong association of DGK isoforms in BD development and 
treatment. 
 
Changes in DAG levels in the presence of all the compounds dgkA- cells were 
resistant to were then quantified using a DAG specific ELISA assay. In the absence of 
treatment, DAG levels in dgkA- cells was lower than that of WT and this was only 
partially rescued in dgkA-/+ cells. This reduction in DAG levels compared with WT is 
also seen in DGK knockout mice under control conditions and when seizures are 
stimulated with electroconvulsive shock (Rodriguez de Turco, et al., 2001). 
Treatment of VPA and LiCl resulted in an accumulation of DAG in WT cells, which 
was contrasted with dgkA- cells where there was little, or no, DAG detected. In 
dgkA-/+ cells, DAG levels were increased compared with control conditions following 
treatment of VPA and LiCl, however, DAG levels were not restored back to the WT 
concentration. Treatment of VPD, PIA, DA, OA and 4-EOA all resulted in a significant 
accumulation of DAG levels in WT cells compared with control, showing at the 
molecular level, both epilepsy and BD treatments work through a similar 
mechanism of action. VPA has previously been linked to reducing both inositol 
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phosphate and DAG signalling in C. elegans where it was thought VPA works 
through reducing inositol-1- phosphate and DAG synthesis (Tokuoka, Saiardi and 
Nurrish, 2008).   
7.6 Summary 
D. discoideum DGKA is not essential for cell survival and so a knockout approach 
was taken. To determine the resulting phenotype was due to ablation of the DGKA 
gene, a rescue cell line in which the gene was re-inserted into knockout cells was 
created, dgkA-/+. Expression of GFP-DGKA in dgkA-/+ cells was confirmed by Western 
blotting and protein localization. Localization studies showed GFP-DGKA within the 
cytosol. Since DgkA had been ablated in D. discoideum JH10 cells where MHC 
localization was investigated, this was also examined here. In the vegetative phase, 
MHC was localised to the cytosol in WT (Ax2) and dgkA- (Ax2) cells, however, in 
chemotactically competent cells stimulated with cAMP, MHC delocalized to the cell 
cortex, consistent with the previous findings. During cell growth, dgkA- cells showed 
dose-dependent reduction in cell number, consistent with WT cells. However, 
during acute cell behaviour and development, when the DgkA gene is expressed, 
dgkA- cells were resistant to VPA at 0.3 mM and 0.5 mM, spanning the therapeutic 
concentrations (0.3 mM- 0.6 mM) indicating a role for DGKA in the mechanism of 
action of VPA during development. The dgkA- cells were also resistant to other anti-
seizure compounds (VPD, PIA, DA, OA, 4-EOA) and the BD treatment LiCl during D. 
discoideum development at concentrations which blocked WT fruiting body 
formation. This result suggested a similar mechanism of action for treating both 
epilepsy and BD. At the molecular level, dgkA- cells had a reduction in DAG levels 
compared with WT cells, suggesting DAG, the substrate of DGKA, is being 
upregulated via another pathway, potentially the Kennedy pathway. Treatment of 
all anti-seizure compounds tested and LiCl resulted in an accumulation of DAG 
levels in WT cells, however, little to no DAG was detected in the presence of VPA 
and LiCl in dgkA- cells. On the reintroduction of DgkA into dgkA- cells, drug 
sensitivity during acute cell behaviour and development to all treatments tested 
was restored back to WT, suggesting the resistant phenotype to the compounds 
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investigated is due to ablation of DgkA. These results, therefore, suggest DGKA is a 
target for, or is regulated by, VPA, VPD, PIA, DA, OA, 4-EOA and LiCl in D. 
discoideum. This in turn suggests that both epilepsy and BD treatments work 
through a similar mechanism of action. 
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8. Conclusions  
8.1 Background 
A third of epilepsy and BD patients are resistant to medication that is currently 
available, when administered as monotherapy (a single drug) or as polytherapy (a 
combination of 2 or more compounds). This highlights a need for new drugs to be 
identified and made available to patients. One of the most effective and therefore 
highly prescribed AEDs is VPA (Haroon, et al., 2012). VPA, like many therapeutic 
treatments, has undesirable side effects, the most severe being hepatoxicity (liver 
damage) (Kesterson, Granneman and Machinist, 1984) and teratogenicity (defects 
in developing embryos) (Hauck and Nau, 1989). Despite these side effects, VPA 
continues to be used to control seizures in epilepsy patients. VPA is also used to 
treat mania in BD patients (Pope, et al., 1991) and is effective in controlling 
migraines (Hering and Kuritzky, 1992; Yurekli, et al., 2008). Currently, studies are 
also investigating VPA as a potential treatment option for cancer, with research 
being conducted using murine prostate cancer cells (Witt, et al., 2013),  
transformed hematopoietic progenitor cells, carcinoma cells, a rat model and 
leukemic blast cells from patients of myeloid leukaemia (Göttlicher, et al., 2001; 
Tang, et al., 2004). Due to the numerous diseases VPA is used to treat, many studies 
have focused on elucidating the molecular target of the drug. To date, the 
mechanism of action of VPA involves enhancing brain -amino butyrate levels 
(Godin, et al., 1969) and reducing or inhibiting voltage gated potassium, sodium and 
calcium channels (VanDongen, VanErp and Voskuyl, 1986; Kelly, Gross and 
Macdonald, 1990); NMDA excitation (Slater, Stelzer and Galvan, 1985; Holmes, et 
al., 1990; Zeise, Kasparow and Zieglgänsberger, 1991); histone deacetylase 
(Göttlicher, et al., 2001); inositol phosphate and phosphoinositide levels (Williams, 
et al., 2002; Eickholt, et al., 2005; Chang, et al., 2012; Chang, Walker and Williams, 
2014). In relation to phosphoinositide signalling, VPA causes a dose-dependent 
reduction of the molecule PIP2. This is achieved independently of PI3K activity, 
inositol recycling and de novo inositol biosynthesis (Chang, et al., 2012; Frej, et al., 
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2016), leaving the PI salvage pathway. This project has, therefore, been aimed at 
determining whether the molecular target of VPA is a component of the PI salvage 
pathway or reduces PIP2 levels through an interlinking pathway.  
8.2 Proteins Dismissed as VPA Targets 
In this thesis a total of 11 proteins in D. discoideum were investigated as potential 
targets of VPA (Table 8.1). These included all 5 PI3Ks, PTEN, PLC, LPIN2, CDSA, 
CDIPT and DGKA. Of these proteins, the 5 PI3Ks, PTEN, PLC, LPIN2 and CDSA were 
dismissed as VPA targets, as each of the knockout or overexpressing mutants 
demonstrated VPA sensitivity during acute cell behaviour, development and/or 
growth. In this work, VPA sensitivity of the 5 PI3K and PTEN null cells (pi3k1-5-/. 
pten-) has been identified, consistent with a previous study which showed a 
significant reduction in PIP and PIP2 levels when treated with VPA (Chang, et al., 
2012). Therefore, other VPA targets must be present in D. discoideum
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Cell Line Experiment 
Growth Acute Cell Behaviour Development ELISA 
pi3k1-5-/pten- - Resistant to 0.5 mM 
VPA. 
Sensitive to all compounds. - 
plc- - VPA sensitive. Sensitive to all compounds. - 
lpin2- - VPA sensitive. Sensitive to all compounds. - 
WT::RFP-cdsA VPA sensitive. - Sensitive to all compounds. - 
WT::RFP-cdipt Resistant to 
VPA up to 0.5 
mM. 
- Sensitive to VPD, DA, OA, 4-EOA, 2-MHA 
and LiCl. Resistant to 0.3 mM and 0.5 
mM VPA and 1.4 mM PIA. 
- 
dgkA- VPA sensitive. Resistant to VPA up to 
0.5 mM. 
Resistant to 0.3 mM and 0.5 mM VPA, 
VPD, PIA, DA, OA, 4-EOA and LiCl. 
Low levels of detectable DAG which was further 
reduced or abolished with treatment of 0.3 mM and 0.5 
mM VPA and 8 mM LiCl. 
dgkA-/+ - VPA sensitive. Sensitive to all compounds. DAG levels partially restored. DAG levels increased with 
treatment of 0.3 mM and 0.5 mM VPA and 8 mM LiCl. 
 
Table 8.1. Summary of results obtained within this thesis. Table summarizing the mutant strains investigated during this thesis and the results of each 
experiment conducted to determine sensitivity or resistance to each compound tested. Compounds tested were VPA (0.01 mM -2 mM), VPD (6.5 mM), PIA 
(1.4 mM), DA (1.65 mM), OA (0.22 mM), 4-EOA (0.5mM), 2-MHA (0.5mM) and LiCl (8 mM).
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8.3 Proteins Identified as Novel VPA Targets  
Two mutants within the PI salvage pathway were found to be resistant to 
VPA at therapeutic concentrations in this study. One of these mutants was 
overexpressed and the other ablated. The first strain resistant to VPA was 
CDIPT. CDIPT is the enzyme responsible for the formation of PI from CDP-
DAG and myo-inositol. CDIPT was an enzyme of interest as the enzyme 
product PI has been associated with seizure generation and progression 
through calcium signalling (Yoshida, et al., 1987; Alswied and Parekh, 
2015). CDIPT is vital in yeast (Nikawa, Kodaki and Yamashita, 1987), T. 
brucei (Martin and Smith, 2006) and Drosophilia (Wang and Montell, 2006) 
and may, therefore, be an essential protein in D. discoideum. CDIPT was 
characterized in both the absence and presence of VPA and a range of anti-
seizure. Unfortunately, RFP-CDIPT was mostly present within membrane 
bound vesicles in these cells, suggesting the majority of the overexpressed 
protein is inactive and so these cells maintain a tightly regulated pool of 
CDP-DAG (Lykidis, et al., 1997). Interestingly, the overexpressed and 
sequestered RFP-CDIPT may act to reduce the level of the endogenous 
protein within these membrane bound vesicles, thereby creating a CDIPT 
knockdown, which has been shown for drug-induced phospholipidosis 
(Yamamoto, et al., 1971; Seiler and Wassermann, 1975). Furthermore, 
overexpressed PI has previously been associated with inclusion body 
formation (Matsuzawa and Hostetler, 1980).  
 
WT::RFP-cdipt cells were resistant to therapeutic VPA concentrations 
during cell growth and development, suggesting the mechanism of VPA 
involves altering CDIPT activity. WT::RFP-cdipt cells were also resistant to 
PIA (1.4 mM), suggesting that the mechanisms of action of both VPA and 
PIA is likely to be regulated by CDIPT. However, it remains to be 
determined whether this resistant phenotype is through the small 
Chapter 8   Conclusions 
 219 
elevation of cytosolic RFP-CDIPT or through reduction of endogenous 
CDIPT levels in cells through sequestration.  
 
A second strain showing resistance to VPA contained disruption of the 
DgkA gene. DGKA is the enzyme responsible for the phosphorylation of 
DAG into PA. This enzyme was of interest as DAG levels are increased 
during seizures (Yoshida, et al., 1987) and VPA could work through 
inhibiting this increase. Similarly to WT cells, dgkA- cells had a dose-
dependent reduction in cell growth when exposed to increasing VPA 
concentrations. Investigations continued as D. discoideum DGKA is highly 
expressed 8 and 24 hours into the developmental phase (Parikh, et al., 
2010; Stajdohar, et al., 2015). Cells were stimulated to enter the 
developmental cycle where dgkA- cells were resistant to therapeutic VPA 
concentrations (0.3 mM and 0.5 mM) during both acute cell behaviour and 
development, suggesting DGKA is a potential target, or is regulated by, VPA 
in D. discoideum. This was confirmed by the creation of dgkA-/+ cells, where 
drug sensitivity was restored when treated with 0.3 mM and 0.5 mM VPA 
during both acute cell behaviour and development. These results confirm 
that DGKA is either a target, or is regulated by, VPA in D. discoideum.  
 
VPA targeting or regulating DGKA was further investigated by quantifying 
changes in molecular DAG levels in both the absence and presence of VPA 
in WT, dgkA- and dgkA-/+ cells. In the absence of VPA, DAG levels in dgkA- 
cells were lower than that of WT and only partially restored in dgkA-/+ cells. 
VPA treatment (0.3 mM and 0.5 mM) resulted in an increase in DAG levels 
in both WT and dgkA-/+ cells. This was contrasted in dgkA- cells, where 
there was a reduction of DAG levels compared with control conditions. This 
reduction of DAG levels following VPA treatment has been shown 
previously in C. elegans (Tokuoka, Saiardi and Nurrish, 2008).  
 
Other anti-seizure medications were also investigated on dgkA- cell 
development.  The dgkA- cells were resistant to VPD, PIA, DA, OA and 4-
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EOA and the BD treatment LiCl at concentrations which inhibited WT cell 
development. Sensitivity to these compounds was restored in dgkA-/+ cells, 
indicating DGKA is a target, or is regulated by, these compounds. To 
determine whether these compounds have a similar mode of action to 
VPA, DAG levels were quantified. The effects of LiCl (8 mM) on WT, dgkA- 
and dgkA-/+ cells on DAG levels was similar to that of VPA, where WT and 
dgkA-/+ cells had a rise in DAG levels, contrasted with no detectable DAG in 
the dgkA- cells. The rise in DAG levels in response to LiCl treatment is 
consistent with previous studies using pituitary tumour (Drummond and 
Raeburn, 1984) and mouse neuroblastoma-rat glioma (Brami, Leli and 
Hauser, 1991) cells and mouse (Sade, et al., 2016) and rat (Sherman, et al., 
1981) animal models. As DAG levels were not detectable on therapeutic 
VPA concentrations, nor LiCl treatment in dgkA- cells, only WT cells were 
treated with the remaining compounds. Like VPA and LiCl, all compounds 
tested (VPD, PIA, DA, OA and 4-EOA), resulted in a significant rise in DAG 
levels in WT cells. These results suggest that all of these compounds (LiCl, 
VPD, PIA, DA, OA and 4-EOA) have a similar mode of action in D. 
discoideum, by targeting or regulating DGKA. These compounds could, 
therefore, potentially be new AEDs which could replace VPA, as they have 
the same mechanism of action and have demonstrated anti-seizure effects 
(Williams, et al., 1999; Eickholt, et al., 2005; Williams, et al., 2002; Elphick, 
et al., 2012; Chang, et al., 2012; Chang, et al., 2013; Chang, Walker and 
Williams, 2014; Chang, et al., 2015; Chang, et al., 2016). 
8.4 Predicted Mechanism of Action of VPA 
Seizures are stimulated from an increase in calcium signalling, initiated 
from the release of IP3 from PIP2 hydrolysis (Paulus and Kennedy, 1960; 
Prottey and Hawthorne, 1967; Whatmore, et al., 1999). This results in a 
rise in DAG levels (Yoshida, et al., 1987) and reduction in PC (Corazzi, et al., 
1986), correlated with no change in PE levels (Marku, et al., 1987). The 
excess DAG is then converted into triglycerides (Yoshida, et al., 1987) and 
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free fatty acids (Bazán, 1970; Bazán and Rakowski, 1970; Bazán, Morelli de 
Liberti and Rodriguez de Turco, 1982; Rodriguez de Turco, Morelli de 
Liberti and Bazán, 1983) which are utilized during mitochondrial -
oxidation (Figure 8.1A). However, during VPA treatment, the rise in DAG 
levels (Drummond and Raeburn, 1984; Brami, Leli and Hauser, 1993) is 
associated with a rise in pERK activity (Ludtmann, Boeckeler and Williams, 
2011), PE, PC (Elphick, et al., 2012), CDP-DAG (Watson, Shipman and 
Godfrey, 1990; Stubbs Jr., et al., 1992;  Stubbs Jr. and Agranoff, 1993; Ju 
and Greenberg, 2003) and plasma and hepatic triglyceride levels (Seçkin, 
Başaran-Küçükgergin and Uysal, 1999) whilst inhibiting -oxidation (Coudé, 
et al., 1983; Kesterson, Granneman and Machinist, 1984; Granneman, et 
al., 1984) (Figure 8.1B).  
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Figure 8.1. Schematic comparing changes in cellular components during seizures 
and valproic acid treatment. Schematic comparing the changes in cellular 
components (A) during seizures and (B) valproic acid (VPA) treatment. The 
phosphatidylinositol salvage pathway components diacylglycerol levels (DAG), 
phosphatidic acid (PA), cytidine diphosphate- diacylglycerol (CDP-DAG), 
phosphatidylinositol (PI) and phosphatidylinositol-4,5-bisphosphate (PIP2). 
Components of the Kennedy pathway, phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC) and triacylglycerol (TAG) are converted into free fatty 
acids and used for -oxidation and protein kinase C (PKC) are also shown. 
Phosphorylated extracellular signal-regulated kinase (pERK) is regulated by PKC or 
is activated as a result of ER stress. Components which are increased during 
seizures or VPA treatment are shown in red and those reduced are shown in 
green. 
 
Taken with the results from this thesis, it can be hypothesised that the 
overexpression of CDIPT and inhibition or dysregulation of DGKA by VPA 
causes cellular changes to occur. Inhibition of DGKA would block the 
formation of PA through the PI salvage pathway. This effect is 
counteracted by the upregulation of the Kennedy pathway to ensure PA 
and therefore, PI, a regulator of the cell cycle (Deguchi, et al., 2002), are 
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synthesised (Figure 8.2). Increased calcium signalling and the accumulation 
of CDP-DAG would result in endoplasmic reticulum stress, which is known 
to activate pERK (Lumley, et al., 2017) independent of PKC (Wang and 
Friedman, 1989; Bitran, et al., 1990; Chen, et al., 1994). pERK reduces 
activity of the cell cycle (Brewer and Diehl, 2000) so to increases apoptosis 
and autophagy (Tallóczy, et al., 2002). This would be achieved by the 
binding of the Unc-51 autophagy activating kinase to CDIPT enriched 
subdomains of the endoplasmic reticulum to initiate PI synthesis from the 
excess CDP-DAG, via the overexpression of CDIPT. The excess PI could then 
be packaged into punctate autophagosomes (Nishimura, et al., 2017) as 
shown in WT::RFP-cdipt cells and in mammalian models of 
phospholipidosis (Yamamoto, et al., 1971; Seiler and Wassermann, 1975). 
Due to the packaging of PI into membrane bound vesicles for degradation, 
excess PI is limited, resulting in reduced synthesis of PIP2 and thereby 
preventing hydrolysis into IP3 and DAG. This in turn inhibits calcium release 
and seizure generation. DAG levels then fall as the molecule is synthesised 
at a reduced rate and that produced is utilized via the Kennedy pathway. 
This enables the cell cycle to continue to function, however, at a reduced 
rate. The role of pERK as a suppressor of cell proliferation whilst increasing 
apoptosis has been investigated in the development of cancer treatments. 
Targeting pERK for cancer treatment has been both successful, resulting in 
reduced tumour growth in HT29 colorectal carcinoma cells (Bi, et al., 2005) 
and mouse embryonic fibroblasts (Blais, et al., 2006) and unsuccessful, 
where tumour growth increased in human oesophageal and breast cell 
lines (Bobrovnikova-Marjon, et al., 2010). In cancer treatment, VPA may 
work in a similar way to the histone deacetylase inhibitor Vorinostat, which 
was approved for cutaneous T-cell lymphoma treatment in 2007 (Mann, et 
al., 2007), whose anti-tumour activity involves activating pERK (Kahali, et 
al., 2010).  
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Figure 8.2. Schematic of proposed mechanism of action of VPA. Schematic of the 
proposed mechanisms of action of VPA (shown in blue) whereby VPA inhibits 
diacylglycerol kinase (DGK) activity (red “T”), which results in a rise (red arrow) of 
diacylglycerol levels (DAG). The accumulation of DAG results in the upregulation 
of the Kennedy pathway where DAG is converted into phosphatidylethanolamine 
(PE) and then phosphatidylcholine (PC), or directly into PC from DAG. PC is then 
converted into phosphatidic acid (PA), restarting the phosphatidylinositol salvage 
pathway via the synthesis of cytidine diphosphate- diacylglycerol (CDP-DAG), 
phosphatidylinositol (PI) via CDP-DAG-inositol 3 phosphatidyltransferase (CDIPT) 
and phosphatidylinositol-4,5-bisphosphate (PIP2). 
 
This hypothesis of the mode of action of VPA is supported by many studies 
which have linked several DGK isoforms, DGK- (Ishisaka, et al., 2013), - 
(Leach, et al., 2007) and - (Rodriguez de Turco, et al., 2001; Musto and 
Bazán, 2006) with epilepsy. The results presented here also correlate with 
previous studies which associated epilepsy with a reduction in dendritic 
spine formation, a process regulated by DGK (Hozumi, et al., 2009) and 
reversed with VPA treatment in a mouse model (Yang, et al., 2016). This 
links the mechanism of disease progression and the therapeutic treatment 
counteracting this effect, through DGK. 
Another outcome from this study was that the mechanisms of action of the 
anti-seizure compounds VPD, PIA, DA, OA and 4-EOA and the BD treatment 
LiCl are also through targeting, or regulating, DGKA in D. discoideum. This is 
because other mutants of PI salvage pathway proteins were sensitive to 
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treatment. This was with the exception of WT::RFP-cdipt cells which were 
also resistant to 1.4 mM PIA. Of particular interest was dgkA- cell resistance 
to LiCl treatment during the development assay and the changes in DAG 
levels mimicking that of VPA treatment in WT, dgkA- and dgkA-/+ cells. 
These results suggest that both VPA and LiCl work through a similar target, 
DGKA, in D. discoideum. The similarity in the mechanism of action of both 
VPA and LiCl is supported in literature where DGK isoforms have been 
linked with BD (DGK- and -) (Baum, et al., 2008; Squassina, et al., 2009; 
Moya, et al., 2010; Kakefuda, et al., 2010) and epilepsy (DGK-,- and -) 
(Rodriguez de Turco, et al., 2001; Musto and Bazán, 2006; Leach, et al., 
2007; Ishisaka, et al., 2013). Both VPA and LiCl have also been found to 
inhibit PKC signalling. PKC is activated in BD patients by DAG from the 
hydrolysis of PIP2, with calcium being released by IP3 (Hahn and Friedman, 
1999), which is believed to be responsible for the different mood states 
(Dubovsky, et al., 1989) of BD patients. In support of the results presented 
in this thesis, LiCl treatment causes a rise in DAG levels in pituitary tumour 
cells (Drummond and Raeburn, 1984), rat brain slices (Wang and Friedman, 
1989), a human leukaemia cell line (Bitran, et al., 1990) and mouse 
neuroblastoma-rat glioma cells (Brami, Leli and Hauser, 1993). In 1984, 
Drummond and Raeburn proposed the mechanism for this increase in DAG 
was through LPIN2, with the excess DAG being redirected to PS or 
triacylglycerol biosynthesis. The data presented in this thesis builds upon 
this previous work as lpin2- cells were sensitive to VPA and LiCl treatment, 
thereby dismissing LPIN2 as a target of VPA and LiCl in D. discoideum. In 
addition, PS is synthesised via the CDP-DAG pathway which is regulated by 
the CDP-DAG pool (Paulus and Kennedy, 1960; Kiyasu, et al., 1963; Kanfer 
and Kennedy, 1964). CDS, the enzyme responsible for the synthesis of CDP-
DAG from PA, was also investigated as both VPA and LiCl treatment cause a 
rise in CDP-DAG levels in platelets (Watson, Shipman and Godfrey, 1990), 
human neutrophils (Stubbs, Jr., et al., 1992), human neuroblastoma 
(Stubbs, Jr. and Agranoff, 1993) and yeast (Ju and Greenberg, 2003) cells. It 
was suggested that the rise in CDP-DAG levels is a secondary effect 
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resulting from the increase in DAG (Stubbs, Jr., et al., 1992), however, the 
overexpressing WT::RFP-cdsA cells were sensitive to both VPA and LiCl 
treatment, suggesting this enzyme is not regulated by either drug. This 
overlap between the mechanisms of action of epilepsy and BD treatments 
is also supported by an African population study which showed relatives of 
epilepsy or BD patients have an approximate 13 % increased chance of 
developing the other disorder compared with individuals with no family 
history of either condition (Jidda, et al., 2010).  
8.5 Implications of These Findings 
The findings from this thesis have provided a step forward in elucidating 
the mechanism of action of VPA. By identifying DGKA and CDIPT as either 
novel targets, or enzymes regulated by VPA, new AEDs can be developed 
which inhibit DGK and/or overexpress CDIPT to ensure a similar potency to 
VPA. In addition to targeting a DGKA and CDIPT-related mechanism, new 
compounds can be designed which lack the teratogenic side effects of VPA 
by removing specific chemical structures (a free carboxyl group, - 
hydrogen atom and branching on carbon 2) (Nau, Hauck and Ehlers, 1991). 
Examples of new potential antiepileptic treatments which could replace 
VPA include those investigated in this thesis which have the same 
mechanisms of action as VPA- PIA, DA, OA and 4-EOA. Development of new 
AEDs may help the third of epilepsy patients resistant to currently available 
medication. 
 
These findings also highlight a common molecular mechanism between 
epilepsy and BD treatments. As both VPA and LiCl treatment causes a rise 
in DAG levels, which is abolished in dgkA- cells, AEDs and BD treatments 
whose mechanisms of action involves regulating DGK, could be used to 
treat both disorders. This, therefore, increases the range of medications 
available to patients of both diseases, benefitting the third of epilepsy and 
BD patients resistant to currently available medication.  
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To continue with this project this work would need to be translated into a 
mammalian model. Translation of these findings would determine whether 
single or multiple DGK isoform are being regulated by VPA. Both humans, 
mice and rats contain 10 DGK isoforms, of which type 2 DGKs contain 
pleckstrin homology domains which bind PI lipids and would therefore be 
likely targets of VPA.  
 
To overcome the unsuccessful attempts of creating CdsA and Cdipt ablated 
cell lines, a knockdown approach could be taken. A knockdown approach 
reduces the expression of essential genes and can be achieved by short 
hairpin RNA or by RNA interference (Friedrich, et al., 2015). RNA 
interference involves the transformation of small-double stranded 
interfering RNAs into cells which are complementary to the target 
messenger RNA. Gene silencing occurs as small-double stranded interfering 
RNAs are used by the RNA- induced silencing complex as a template to 
locate the target messenger RNA which is then cleaved by a ribonuclease. 
8.6 Summary 
This thesis has described the characterization of proteins in response to 
VPA within, and interlinking with, the PI salvage pathway, to help identify 
potential molecular targets of VPA in D. discoideum. From the results 
obtained, VPA has been shown to target DGKA and CDIPT, or regulate the 
signalling of these two proteins, as ablation of DgkA and overexpression of 
CDIPT results in reduced VPA sensitivity. In addition, a range of other anti-
seizure compounds, VPD, PIA, DA, OA and 4-EOA, also appear to function 
through DGKA. Interestingly, the BD treatment LiCl, also functions through 
DGKA. The effect of VPA and other compounds (VPD, PIA, DA, OA, 4-EOA 
and LiCl) through DGKA-dependent signalling is also validated at the 
molecular level where treatment resulted in a rise in DAG levels, 
dependent on the presence of DGKA. These results suggest that both VPA 
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and LiCl function through DGKA-related signalling, within the PI salvage 
pathway, highlighting a conserved mechanism of action of both epilepsy 
and BD treatments.  
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Primer Name Primer Sequence (5’-3’) Use 
Blasticidin cassette pLPBLP Forward AAAAGATAAAGCTGACCCGAAAG PCR Screening 
Blasticidin cassette pLPBLP Reverse TCAAATAATAATTAACCAACCCAAG PCR Screening 
CdsA Knockout 5’ pLPBLP Forward AATGGATCCGATTCGTCAAAAGATG Cloning 
CdsA Knockout 5’ pLPBLP Reverse ATACTGCAGCAGGATAATAGTTTGC Cloning 
CdsA Knockout 3’ pLPBLP Forward TATAAGCTTGGAATCATTACATTGTACTAG Cloning 
CdsA Knockout 3’ pLPBLP Reverse TTAGGTACCCAGTAATAGTACCAGTG Cloning  
CdsA Knockout 5’ Fragment Genomic Control Forward ATGAGGACAGATAACATTAG PCR Screening 
CdsA Knockout 5’ Fragment Genomic Control Reverse GTGATTAAGATTGGTTTAGC PCR Screening 
CdsA Knockout 5’ Fragment Vector Control Forward GATTCGTCAAAAGATGAAGAAACCAGTACA PCR Screening 
CdsA Knockout 3’ Fragment Genomic Control Forward CTAGAGATCCAGTATTCTTG PCR Screening 
CdsA Knockout 3’ Fragment Genomic Control Reverse GTAAACTCTATGGATTGTTTC PCR Screening 
CdsA Knockout 3’ Fragment Vector Control Reverse GTAAACTCTATGGATTGTTTC PCR Screening 
CdsA Overexpressing Primer Forward TGGGATCCATGAGGACAGATAAC Cloning  
CdsA Overexpressing Primer Reverse GCGGAATTCCTATGCAGTAATAG Cloning 
Cdipt Knockout 1 5’ pLPBLP Forward GCGGGATCCGTATTACGAAATTATTA Cloning 
Cdipt Knockout 1 5’ pLPBLP Reverse ATACTGCAGTGGCACATAAACGTGC Cloning 
Cdipt Knockout 1 3’ pLPBLP Forward ATACCATGGGAAGGTTTCTTCCTT Cloning 
Cdipt Knockout 1 3’ pLPBLP Reverse GCGGGTACCACTAGTGCATTA Cloning 
Cdipt Knockout 1 5’ Fragment Genomic Control Forward CATACATACACACCTACACCAATATATA PCR Screening 
Cdipt Knockout 1 5’ Fragment Genomic Control Reverse GGCACATAAACGTGCAA PCR Screening 
Cdipt Knockout 1 5’ Fragment Vector Control Forward CAAAAGTTTACACCTATGTACCAA PCR Screening 
Cdipt Knockout 1 3’ Fragment Genomic Control Forward GAAGGTTTCTTCCTTTTCTC PCR Screening 
Cdipt Knockout 1 3’ Fragment Genomic Control Reverse CCAGTGCACCCAATAAAATCTC PCR Screening 
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Cdipt Knockout 1 3’ Fragment Vector Control Reverse GATGACAACGCCTTTGAATAT PCR Screening 
Cdipt Knockout 2 5’ pLPBLP Forward TATGGATCCGTTTACACCTATGTACC Cloning 
Cdipt Knockout 2 5’ pLPBLP Reverse TTACTGCAGCATCTATCTGTAATCATATC Cloning 
Cdipt Knockout 2 3’ pLPBLP Forward ATAAAGCTTCAATTGCATTAATGGTAG Cloning 
Cdipt Knockout 2 3’ pLPBLP Reverse TATGGTACCATCATCAACAGCTTGG Cloning 
Cdipt Knockout 2 5’ Fragment Genomic Control Forward GTAGTATTACGAAATTATTATAATGG PCR Screening 
Cdipt Knockout 2 5’ Fragment Genomic Control Reverse GCTCCAAATTGTGAACC PCR Screening 
Cdipt Knockout 2 5’ Fragment Vector Control Forward GGATATTTCAGAGTTATTTTTGC PCR Screening 
Cdipt Knockout 2 3’ Fragment Genomic Control Forward GGTAGTATTATCACATTTCTATAAAG PCR Screening 
Cdipt Knockout 2 3’ Fragment Genomic Control Reverse CGTTTCTTTAGATGACCAAC PCR Screening 
Cdipt Knockout 2 3’ Fragment Vector Control Reverse GACTGACGATATCTAAGGTA PCR Screening 
Cdipt Overexpressing Primer Forward GCCGGATCCATGGCATTTTCAAAAG Cloning 
Cdipt Overexpressing Primer Reverse GCCGAATTCCTATTTTTTTAATTTTTGTTGG Cloning 
DgkA Knockout 5’ pLPBLP Forward ATAGGATCCGGGGTATTTGCACACAAG Cloning 
DgkA Knockout 5’ pLPBLP Reverse ATACTGCAGCCTTCAACCCAATGATG Cloning 
DgkA Knockout 3’ pLPBLP Forward GTACCATGGGTGGACTTATGGGGTG Cloning 
DgkA Knockout 3’ pLPBLP Reverse ATAAAGCTTGAGGTTGTGATTGAGGT Cloning 
DgkA Knockout 5’ Fragment Genomic Control Forward CTTTCTAACACACTCAATAAAATTC PCR Screening 
DgkA Knockout 5’ Fragment Genomic Control Reverse GCAATATATCTACATTCACTACAC PCR Screening 
DgkA Knockout 5’ Fragment Vector Control Forward GGGGTATTTGCACACAAGGATTTCAATG PCR Screening 
DgkA Knockout 3’ Fragment Genomic Control Forward GTGGACTTATGGGGTGC PCR Screening 
DgkA Knockout 3’ Fragment Genomic Control Reverse CGGTTCTGGTGATTGGGGTG PCR Screening 
DgkA Knockout 3’ Fragment Vector Control Reverse GAGGTTGTGATTGAGGTGG PCR Screening 
DgkA RT-PCR Forward  TGTATACATTGTATGGAACC RT-PCR 
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DgkA RT-PCR Reverse GGTATAGTTGATGGAACC RT-PCR 
Ig7 Forward  ACCTACAAGTCGATCAGAGAC  RT-PCR Control  
Ig7 Reverse CACCTCAGTCCTCTCGTAC RT-PCR Control 
 
Table S1. List of primer oligonucleotide sequences used for PCR amplification of DNA fragments for cloning and PCR screening protocols. The left column 
gives the names of the primer oligonucleotide sequences. The middle column states the DNA sequences which were used for the corresponding primers 
and the right column describes the procedure (cloning or PCR screening) which the corresponding oligonucleotide was used for.
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Organism Protein 
Name 
Accession 
Number 
Protein 
Length 
(aa) 
Identity 
(%) 
E-
value 
Dictyostelium discoideum 
(social amoeba) 
PikA P54673 1571 100 0 
Homo sapiens (human) 
Pik3ca P42336 1068 37 1e-161 
Pik3cb P42338 1070 35 3e-173 
Pik3cg P48736 1102 34 1e-151 
Pik3cd O00329 1044 35 2e-151 
Pik3r1 P27986 724 
No significant 
identity 
Pik3r2 O00459 728 
Pik3r3 Q92569 461 
Pik3r4 Q99570 1358 
Pik3r5 Q8WYR1 880 
Pik3r6 Q5UE93 754 
Pik3c2a O00443 1686 38 5e-135 
Pik3c2b O00750 1634 40 2e-131 
Pik3c2g O75747 1445 38 8e-108 
Pik3c3 Q8NEB9 887 32 6e-56 
Dictyostelium discoideum 
(social amoeba) 
PikB P54673 1571 100 0 
Homo sapiens (human) 
Pik3ca P42336 1068 37 6e-147 
Pik3cb P42338 1070 38 3e-147 
Pik3cg P48736 1102 43 5e-138 
Pik3cd O00329 1044 38 6e-146 
Pik3r1 P27986 724 
No significant 
identity  
 
Pik3r2 O00459 728 
Pik3r3 Q92569 461 
Pik3r4 Q99570 1358 
Pik3r5 Q8WYR1 880 
Pik3r6 Q5UE93 754 
Pik3c2a O00443 1686 34 7e-121 
Pik3c2b O00750 1634 35 2e-123 
Pik3c2g O75747 1445 37 4e-103 
Pik3c3 Q8NEB9 887 30 2e-51 
Dictyostelium discoideum 
(social amoeba) 
PikC P54673 1571 100 0 
Homo sapiens (human) 
Pik3ca P42336 1068 35 7e-129 
Pik3cb P42338 1070 37 1e-129 
Pik3cg P48736 1102 36 8e-131 
Pik3cd O00329 1044 33 2e-128 
Pik3r1 P27986 724 
No significant 
identity 
Pik3r2 O00459 728 
Pik3r3 Q92569 461 
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Pik3r4 Q99570 1358 
Pik3r5 Q8WYR1 880 
Pik3r6 Q5UE93 754 
Pik3c2a O00443 1686 34 6e-129 
Pik3c2b O00750 1634 36 5e-135 
Pik3c2g O75747 1445 36 3e-105 
Pik3c3 Q8NEB9 887 31 1e-52 
Dictyostelium discoideum 
(social amoeba) 
PikF P54673 1571 100 0 
Homo sapiens (human) 
Pik3ca P42336 1068 36 1e-139 
Pik3cb P42338 1070 39 2e-149 
Pik3cg P48736 1102 36 1e-131 
Pik3cd O00329 1044 37 1e-142 
Pik3r1 P27986 724 
No significant 
identity 
Pik3r2 O00459 728 
Pik3r3 Q92569 461 
Pik3r4 Q99570 1358 
Pik3r5 Q8WYR1 880 
Pik3r6 Q5UE93 754 
Pik3c2a O00443 1686 40 4e-127 
Pik3c2b O00750 1634 40 1e-136 
Pik3c2g O75747 1445 35 3e-104 
Pik3c3 Q8NEB9 887 31 4e-50 
Dictyostelium discoideum 
(social amoeba) 
PikG P54673 1571 100 0 
Homo sapiens (human) 
Pik3ca P42336 1068 40 1e-73 
Pik3cb P42338 1070 44 3e-75 
Pik3cg P48736 1102 40 2e-86 
Pik3cd O00329 1044 41 1e-78 
Pik3r1 P27986 724 
No significant 
identity 
Pik3r2 O00459 728 
Pik3r3 Q92569 461 
Pik3r4 Q99570 1358 
Pik3r5 Q8WYR1 880 
Pik3r6 Q5UE93 754 
Pik3c2a O00443 1686 42 7e-91 
Pik3c2b O00750 1634 42 6e-91 
Pik3c2g O75747 1445 48 2e-88 
Pik3c3 Q8NEB9 887 33 3e-46 
Dictyostelium discoideum 
(social amoeba) 
PTEN Q8T9S7 533 100 0 
Homo sapiens (human) PTEN P60484 403 51 9e-81 
 
Table S2.  D. discoideum and H. sapiens PI3K and PTEN protein homology search results 
identifying related proteins. The accession numbers of related proteins are given and the 
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name of the organism to which they relate. Protein length in number of amino acids are 
stated in addition to the percentage of identity relating to the D. discoideum protein. 
Statistical significance of a given pairwise alignment relating to the scoring system and size 
of the database used for comparison is shown by the E-value, with lower E-values 
indicating greater significance in homology. Results obtained using the NCBI protein-
protein BLAST database. 
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Organism Protein 
Name 
Accession 
Number 
Protein 
Length 
(aa) 
Identity 
(%) 
E-
value 
Dictyostelium discoideum 
(social amoeba) 
PLC Q02158 801 100 0 
Homo sapiens (human) 
PLC1 Q9NQ66 1216 34 2e-76 
PLC2 Q00722 1185 31 1e-66 
PLC3 Q01970 1234 31 6e-73 
PLC4 Q15147 1175 29 2e-72 
PLC1 P19174 1290 29 3e-48 
PLC2 P16885 1265 30 2e-47 
PLC1 P51178 756 30 3e-53 
PLC3 Q8N3E9 789 29 2e-105 
PLC4 Q9BRC7 762 32 3e-62 
PLC1 Q9P212 2302 45 3e-43 
PLC1 Q86YW0 608 29 2e-82 
 
Table S3.  D. discoideum and H. sapiens PLC protein homology search results identifying 
related proteins. The accession numbers of related proteins are given and the name of the 
organism to which they relate. Protein length in number of amino acids are stated in 
addition to the percentage of identity relating to the D. discoideum protein. Statistical 
significance of a given pairwise alignment relating to the scoring system and size of the 
database used for comparison is shown by the E-value, with lower E-values indicating 
greater significance in homology. Results obtained using the NCBI protein-protein BLAST 
database. 
 
 
 
 
 
 
 
 
 
 
 
  Supplementary Material 
 268 
 
Organism Protein 
Name 
Accession 
Number 
Protein 
Length 
(aa) 
Identity 
(%) 
E-
value 
Dictyostelium discoideum 
(social amoeba) 
LPIN2 XP_645519 1325 100 0 
Homo sapiens (human) 
LPIN1 Q14693 890 31 6e-75 
LPIN2 Q92539 896 33 4e-86 
LPIN3 Q9BQK8 851 30 2e-77 
 
Table S4.  D. discoideum and H. sapiens LPIN2 protein homology search results identifying 
related proteins. The accession numbers of related proteins are given and the name of the 
organism to which they relate. Protein length in number of amino acids are stated in 
addition to the percentage of identity relating to the D. discoideum protein. Statistical 
significance of a given pairwise alignment relating to the scoring system and size of the 
database used for comparison is shown by the E-value, with lower E-values indicating 
greater significance in homology. Results obtained using the NCBI protein-protein BLAST 
database. 
 
 
 
  Supplementary Material 
 269 
 
  Supplementary Material 
 270 
 
  Supplementary Material 
 271 
 
 
  Supplementary Material 
 272 
 
 
Figure S1. CDS full sequence alignment. Full sequence alignment of CDS proteins found in 
a range of organisms. The names of the species used for comparison in the alignment are 
shown to the left with the amino acid start position shown to the left of the sequence and 
the end amino acid residue number of each line shown to the right of the alignment. 
Identical amino acids to the D. discoideum protein are highlighted in blue. The multiple 
sequence alignment was produced using Clustal Omega and Multiple Align Show 
(bioinformatics.org).  
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Figure S2. CDIPT full sequence alignment. Full sequence alignment of CDIPT proteins found 
in a range of organisms. The names of the species used for comparison in the alignment are 
shown to the left with the amino acid start position shown to the left of the sequence and 
the end amino acid residue number of each line shown to the right of the alignment. 
Identical amino acids to the D. discoideum protein are highlighted in blue. The multiple 
sequence alignment was produced using Clustal Omega and Multiple Align Show 
(bioinformatics.org).  
 
 
 
 
 
